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ABSTRACT

Abdominal aortic aneurysms (AAAs) are typically fusiform (symmetric) dilations
of the aortic wall most commonly arising below the renal arteries. The progression is
typically associated with an activated smooth muscle cell (SMC) phenotype, diminished
density of mature medial elastic fibers, and an elevated presence of matrix-degrading
enzymes (e.g., matrix-metalloproteases; MMPs), which may ultimately lead to vessel
rupture. Currently, no surgical or non-surgical methods are available to regress AAAs
via regeneration of new elastin matrices to regain normal vessel contour, particularly due
to the inherently poor elastin synthesis by adult vascular cells and absence of methods to
stimulate the same. Previously, the lab showed that extracellular matrix-derived factors
based on hyaluronan oligomers (HA-o) and growth factors (TGF-β1) stimulate elastin
regeneration by healthy vascular cells. Yet, the utility of these factors for matrix synthesis
by AAA-derived SMCs has not been determined. Thus, the objective of this study was to
assess the efficacy of these factors on AAA-derived SMCs (peri-adventitial CaCl2
(aRASMCs) and intralumenal elastase-perfusion AAA models (EaRASMCs)) and further
compare their responses to human AAA SMCs (aHASMCs). In addition, we assessed
how the pre-existing elastic matrix content/quality influenced elastogenic inductability of
SMCs. Finally, we evaluated a mode of factor delivery in vitro using a factor-loaded
Extracel-HP™ hydrogel coating on Aeos™ ePTFE grafts.
We generated rat abdominal aortic expansions (~45% and 120% increases in
diameter for CaCl2 exposure and elastase perfusion, respectively) that had characteristics
typical of human AAAs, such as medial elastic matrix disruption, medial thinning, and
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calcification (CaCl2 only) as identified histologically and with scanning electron
microscopy, and increased elastolytic MMP activity as quantified by zymography.
Primary cells derived from these expansions had similarities to human AAA-derived
SMCs in terms of decreased contractile activity (decreased α-actin, SM-22, caldesmon,
and calponin expression) enhanced proliferation (2.5-fold and 2.8-fold greater aRASMC
and EaRASMC counts), and reduced elastogenic capacity relative to healthy RASMCs.
Also, there was significant differential gene expression of EaRASMC relative to
RASMCs, supporting our hypothesis that the AAA-derived cells maintain altered gene
expression in vitro.
Concurrent delivery of HA-o and TGF-β within our tested doses (0, 2, 20 µg/ml
HA-o and 0, 1, 5, 10 ng/ml TGF-yielded a decrease in aRASMC and EaRASMC
proliferation and an increase in their tropoelastin (1.5-fold for aRASMC and 1.9-fold for
EaRASMC) and matrix elastin production (2.2-fold for aRASMC and 1.5-fold for
EaRASMC) relative to their respective aneurysmal controls. Factors attenuated
elastolytic MMP-2 activity in aRASMCs; interestingly, no significant decrease was seen
in aHASMC cultures, yet an overall decrease in MMP and TIMP expression was seen
with factor supplementation. In support of these findings, differential gene expression
(e.g., MMP-12, TIMP-3) with supplementation of HA-o and TGF-was observed, yet
further assessment of functional gene groups is necessary.

Overall, we believe the

elastase perfusion-injury model of AAAs may be suitable as a surrogate in the context of
elastin regeneration within advanced human AAAs, yet a shortcoming is the unparalleled
increases in elastin production by aHASMCs in response to factor supplementation (5-
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fold increase in tropoelastin, 8.5-fold increase in matrix elastin relative to aHASMC
controls).
Observations from our in vitro elastase-injury studies illustrated the ability of cell
layers to self-repair and regenerate elastic matrices following their proteolytic damage is
limited, particularly when elastic matrix injury is severe. Our results also provide
evidence that HA-o and TGF-β factors together can elastogenically stimulate RASMCs in
elastin-degraded cultures to restore both elastic matrix amounts and elastic fiber
deposition to levels of accumulation observed in healthy cultures. Doses of the
elastogenic factors must be enhanced and optimized based on the severity of elastic
matrix damage.
In our preliminary in vitro assessment of factor-loaded Extracel-HP™ hydrogel
coatings on Aeos™ ePTFE grafts we achieved sustained TGF-β delivery over weeks,
which is promising. In future work, our delivery approach could be applied to
endovascular delivery in vivo at the site of AAA for elastin regeneration, elimination of
endoleak, inhibition of AAA growth, and possibly even AAA regression.
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CHAPTER ONE
INTRODUCTION

1.1 Background
Aneurysms are localized dilations of elastic arteries, typically caused by disease
or weakening of the vessel wall. They may be associated with atherosclerosis and
vascular hypertension, or may result from vessel wall architectural changes, trauma,
infection, enzymatic degradation, or as a result of inherited conditions (e.g., Marfan
syndrome). The ultimate outcomes of aneurysm progression may be local vessel wall
dissection (tear) and fatal rupture. Aneurysms are classified by shape, structure, and
location. Abdominal aortic aneurysms (AAAs) are the most common, occur between the
renal and iliac bifurcations and are typically associated with atherosclerosis and
inflammation. AAAs can grow until catastrophic rupture and cause hemorrhage and
embolisms, leading to shock and stroke 1. Most AAAs are asymptomatic and detected
incidentally during clinical investigation for other conditions (e.g., ultrasound or X-ray).
Although it is difficult to estimate their prevalence, it is estimated that AAAs are present
in 1.3–12.7% of the adult population (depending on the age group studied and greatly
increasing over the age of 70 years) 2. Current, clinical AAA treatment methods are
primarily surgical, and include open repair, wherein the weakened aortic segment is
replaced with a sutured synthetic mesh graft, and endovascular repair, wherein a woven
graft mounted on a self-expanding stent is deployed at the site of AAA 3. Despite their
relative merits and demerits, short and long-term cardiac/pulmonary complications and
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other surgical and graft-associated complications cause survival rates to drop drastically
within 10 years post-surgery 4. Alternative AAA treatment methodologies are thus
warranted.
Within AAAs, vascular elastic matrices are severely disrupted. These elastic
matrices contain fiber bundles that provide blood vessels the compliance to absorb and
transmit hemodynamic forces to maintain blood pressure and mechano-transduce smooth
muscle cell (SMC) behavior through binding to cell surface elastin-laminin receptors to
regulate cell activity, particularly during vascular morphogenesis and disease. Congenital
or acquired malformation or degradation of vascular elastin, such as in AAAs, can
severely compromise vascular homeostasis and therefore must be preserved, replaced, or
regenerated as a priority.
Elastin preservative strategies aim to maintain matrix stability by inhibiting
proteolytic enzyme production or activity. Pharmacologic agents, matrix metalloprotease
(MMP) and other protease inhibitors, as well as transcription factor regulators, can
attenuate matrix degradation to slow AAA progression, but do not encourage their
regression. In the case of severely degraded vascular matrix in which the structural
stability of the vessel is lost, replacement strategies are considered. Natural or synthetic
matrices that resemble the size, architecture and mechanical properties of the native ECM
are harvested or fabricated. Matrix replacement strategies include replacing lost,
degraded, or malformed tissues using autologous, allogenic, xenogeneic, or polymer/
synthetic grafts.

2

Tissue engineering (also known as regenerative medicine), which is defined as
restoring, maintaining, or enhancing tissue and organ function, is an emerging
multidisciplinary field involving biology, medicine, and engineering that is likely to
revolutionize medicine. It has been proposed as a promising alternative to the
stabilization and replacement strategies discussed. The foundation of tissue engineering
for therapeutic applications is the ability to exploit living cells in a variety of ways using
biomaterial, biomolecule, and mechanical stimuli to repair and/or regenerate tissue. The
major goal for vascular tissue engineering is maintenance of viable and self-renewing
vessel components5.
Matrix engineering is an area of expertise within vascular tissue engineering that
incorporates the broad goals of bioengineering and the specific goals of tissue
engineering to restore, maintain, and improve defective, damage, or injured extracellular
matrix (ECM) tissue, which is crucial to improving vascular health and function. Elastin,
as discussed above, is vital to vascular homeostasis, but has proven to be exceptionally
challenging to regenerate or restore; therefore, there are specific bioengineering efforts
being made to address the challenges of vascular elastin matrix engineering. Our
approach seeks to utilize biological factors to stimulate endogenous cells to regenerate
elastic matrix in AAA environments in order to restore vascular homeostasis. The
significance of this approach lies in its potential to overcome the poor elastogenic
potential of adult cells that deters any regenerative effort.
The biological factors we are utilizing for elastogenic stimulation of AAA-derived
vascular SMCs are the glycosaminoglycan, hyaluronan (HA), and the growth factor,
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transforming growth factor β1 (TGF-β). HA has been chosen due to its potential to
enhance the synthesis and organization of fibrillin microfibrils, the scaffold for elastic
fiber deposition 6. Specifically, HA‟s intimate binding of the proteoglycan, versican 7, has
been suggested to play an indirect role in elastogenesis by further interacting with
microfibrillar proteins (fibulin-1, 2) and elastin-associated proteins to form structures
important for elastic fiber assembly

7-10

. Evidently, HA brings together soluble

tropoelastin monomers, to facilitate LOX-mediated crosslinking into matrix elastin

11-12

,

and stabilizes elastin fibers against degradation by proteases 10-12.
TGF-β has been chosen in combination with HA because recent studies have
shown benefits of TGF-β in matrix regeneration and vessel wall re-building in AAAs.
Specifically, paracrine secretion of TGF-β by endovascularly seeded SMCs in rat AAAs
decreased proteolysis by reducing MMP expression and up-regulating (tissue inhibitors
of MMPs) TIMP-1, 2, and 3 mRNA expression, increased matrix production (by various
cell types (SMCs and fibroblasts), and enhanced production of lysyl oxidase, critical for
collagen and elastin crosslinking and fiber organization in situ

13

. Gene therapy

techniques have also been used to over-express TGF-β within already formed AAAs.
Results paralleled those above and also qualitatively showed improved elastin
stabilization, and endoluminal reconstruction, evidenced by generation of a collagen- and
elastic-fiber-rich intimal lamina

14

. Thus, we hypothesize TGF-β and HA availability

may be useful to trigger matrix regeneration by aneurysmal SMCs and possibly regress
AAAs. This will be studied in the present dissertation work.

4

Numerous animal models exist for the study of AAAs, which recapitulate features
of the human disease

15-16

. Human AAAs may result from an inflammatory response

caused by an insult to the vessel wall (i.e. atherosclerosis involving calcified lipid
deposits) or congenital abnormalities (i.e. Marfan Syndrome involving defect in fibrillin1) and may include medial degradation, inflammation, thrombus formation, and rupture.
Animal models most commonly implemented are those that have been genetically
modified or chemically induced to form AAAs. The genetic approaches include
engineered and spontaneous mutations that generate defects in ECM maturation,
increased degradation of elastin and collagen, irregular cholesterol homeostasis, and
enhanced production of angiotensin II (AngII) 17. AAA induction via chemical injury can
be accomplished by the intraluminal infusion of elastase, peri-adventitial exposure of
calcium chloride (CaCl2), and subcutaneous infusion of AngII 17. For the purpose of our
studies of inflammation-induced AAAs, peri-adventitial CaCl2 and elastase intraluminal
perfusion are relevant and well characterized rodent models. Peri-adventitial CaCl2
exposure results in a localized insult to the vessel wall, which induces inflammatory cell
infiltration leading to high MMP levels and chronic elastin degradation, and calcification
resulting in time-dependent aorta expansion (e.g., 4 weeks yields ~45% aortic diameter
increase)

15-16, 18-19

. With this model, this caustic agent increases inflammatory cell

infiltration and the subsequent release of matrix degrading proteases, mimicks that of
human AAA pathology. Whereas with elastase perfusion, there is a combined effect from
the increased pressure on the vessel wall and the enzymatic attack that play a role in
aortal expansion. Enzymatically, elastase penetrates the vessel wall from the intima to the
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media (the increased pressure allows for passage readily through the intima) and degrades
the elastic matrix 20. The matrix degradation products then incite inflammatory response
and further matrix degradation.

Elastase diffusion through the intima is extremely

effective and yields more dramatic aneurysms. This results in a larger diameter and more
elastic matrix degradation in a shorter time frame (e.g., 12 hours yields ~30% and 2.5
days yields 300% aorta diameter increase

21

) than the CaCl2 exposure model. Here

increased pressure and elastase are the primary causes of elastic matrix degradation,
although secondary degradation and vessel expansion occurs due to MMP overexpression by late-stage recruitment of inflammatory cells. There are advantages and
disadvantages to each of these models and both involve a complex sequence of
biochemical and cellular events that can provide insight into this interesting pathological
outcome and treatments thereof. Our study results will help ascertain the validity of
studying aneurysmal SMCs from both models as a surrogate cell type for AAA-derived
human SMCs in the context of stimulating elastin regeneration, and for developing stand
alone or combination therapies with existing surgical or pharmacological approaches to
regenerate elastic matrices within AAAs.

1.2 Study objectives and aims
The objectives of this project are designed based upon the background
information presented and preliminary data collected by the lab. Previously, the lab
showed that extracellular matrix-derived factors based on hyaluronan oligomers (HA-o)
22-23

and growth factors (TGF-β1) 24-25 stimulate elastin regeneration by healthy rat aortic
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smooth muscle cells (RASMCs). HA-o and TGF-β1 together, which we term elastogenic
factors, synergistically attenuated SMC proliferation and dramatically increased elastin
synthesis, matrix yield, fiber formation, and maturation/stability. Despite these benefits,
the utility of these factors for matrix synthesis by AAA SMCs has not been determined.
Thus, our objective is to assess the efficacy of these factors on AAA-derived SMCs.
Since cell phenotype can be influenced by the specific means of AAA induction, we will
compare elastogenic inductability of these cells using two different AAA induction
models and further compare their responses to human AAA SMCs. In addition, we will
assess how the pre-existing elastic matrix content/quality influences elastogenic
inductability of SMCs. Finally, we will evaluate a mode of delivery that can be
incorporated into current treatment approaches. In order to achieve these goals, we
propose the following specific aims.

Specific Aim 1: Compare phenotype and elastogenic inductability of cultured SMCs
biopsied from human AAAs (aHASMCs) and induced rat AAAs (aRASMCs).
(A) Demonstrate that cultured aHASMCs and aRASMCs (derived from peri-adventitial
exposure of CalCl2 and elastase perfusion) are reliable models of the diseased cells
in vivo.
(B) Compare the elastogenic potential of SMC cultures established from (a) healthy
aortae (for both human and rat) and (b) human AAAs and the above models of
AAA induction in rats.
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(C) Evaluate dose-specific matrix synthesis responses of the above cultured aRASMC
and aHASMC populations to elastogenic factors (HA-o and TGF-β1).

Specific Aim 2: Ascertain the impact of pre-existing elastic matrix disruption on
phenotype and basal/induced elastic matrix (a) repair and (b) regeneration by vascular
SMCs.

Specific Aim 3: Develop a hydrogel-coated graft system for delivery of elastogenic
factors.
(A) Fabricate a hydrogel system incorporating elastogenic factors.
(B) Assess the hydrolytic stability and factor release from the hydrogel when bound to
graft material (ePTFE).

1.3 Project significance and innovation
Aim 1 of this study will identify the AAA induction model, of the two evaluated,
that most closely mimics the pathology of inflammation-induced human AAAs. This
model will then serve as the injury model of choice for further in vitro studies aimed at in
situ regenerative elastic matrix repair by AAA-derived SMCs and isolating the impact of
pre-existing elastic matrix quality on basal and induced elastogenic response of activated
SMCs in cell culture models of matrix injury. To support these future studies, this aim
will seek to provide evidence that (a) aneurysmal SMCs can be elastogenically
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stimulated, (b) identify a working range of effective elastogenic factor doses, that may
serve as a basis for model-independent prediction of in vivo delivery doses, and (c)
demonstrate that clinical translation of this elastogenic induction approach is feasible.
The benefits of the cell culture approach over studies aimed at elastogenic induction of
cells within intact aneurysms is that we will able to de-couple behavioral responses of
cells, including matrix synthesis, from the influence of their ECM, and thus more reliably
compare cell type-specific differences in these responses.
Different from aim 1, the 2-D cell culture model of proteolytic injury in aim 2 will
provide a simple, yet controlled matrix environment that will allow us to isolate the
impact of pre-existing matrix content/ quality on basal and induced elastic matrix
regeneration by activated SMCs, in the absence of influencing in vivo parameters such as
inflammatory cells and thrombi. The outcomes will signify a first step towards predicting
if and how basal and induced elastic matrix repair and new elastic matrix regeneration by
activated vascular SMCs depends on their location within AAAs, which exhibit sitespecific differences in ECM content and quality, with more severe, generalized
proteolysis occurring at the rupture (i.e., proximal) site and milder, predominantly
elastolytic injury occurring at distal sites. The elastogenic induction outcomes will
correlate the therapeutic dose of elastogenic factors to the extent of proteolytic injury, and
will therefore signify a need to deliver a gradient of elastogenic factors across the length
of aneurysm rather than a single delivery dose, as will be predicted from in vitro dose
guidelines established in aim 1.
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Finally, aim 3 will provide preliminary data toward developing a strategy for
localized delivery of elastogenic factors within intact AAAs, and demonstrate the
feasibility of sustained release of these factors. These studies will serve as the basis for
more involved studies in the future, directed at delivery of our therapeutic, elastogenic
factors for in situ elastic matrix regenerative repair within AAAs, optimistically leading
to AAA regression.

1.4 Organization of dissertation
In chapter 2, a comprehensive overview of the ultrastructure, composition, and
distribution of the vascular matrix, elastin distribution, composition, structure, and
function, abnormalities of vascular matrix elastin, and current strategies for restoration of
vascular elastin homeostasis is presented.
Chapters 3, 4, and 5 detail the effect of TGF-β1 and HA-o on elastogenic potential
of SMC cultures established from (a) healthy aortae (for both human and rat) and (b)
human AAAs and two different models of AAA induction in rats (i.e., peri-adventitial
exposure of CalCl2 and elastase perfusion). The benefits of exogenous delivery of these
factors to elastin production, stabilization, crosslinking, and maturation by aneurysmal
SMCs will be elaborated upon. Also, we will discuss the efficacy of these models as
surrogate models for human AAA-derived SMC elastic matrix regeneration.
Chapter 6 details the impact of pre-existing elastic matrix disruption on phenotype
and basal/induced elastic matrix (a) repair and (b) regeneration by vascular SMCs.
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Chapter 7 describes a hydrogel-coated graft system for delivery of elastogenic
factors. The hyaluronan-based hydrogel system incorporating elastogenic factors is
assessed for hydrolytic stability and factor release when bound to graft material (ePTFE).
Chapter 8 outlines the overall conclusions derived from this project and identifies
future directions for short and long-term progress.
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CHAPTER TWO
BACKGROUND

2.1 Ultrastructure, composition, and distribution of the vascular matrix
The vasculature is composed of cells and their surrounding matrix. The
extracellular matrix (ECM) is a complex network of polysaccharides and proteins
secreted by cells that provides support and anchorage for cells and regulates intercellular
communication. Elastin is an ECM protein that crucially maintains structural
configurations of vascular tissues and regulates cell-signaling pathways involved in
morphogenesis, injury response, and inflammation. Specifically, elastin matrices contain
closely arranged fiber bundles (lamellae) that provide vessels the compliance necessary
to absorb and transmit forces and also provide biochemical and bio-mechanical signals
that regulate cell proliferation and matrix synthesis. Elastin also mechano-transduces
smooth muscle cell (SMC) behavior, particularly during vascular morphogenesis and
disease. Vascular elastic matrices can be damaged by injury or disease, or when
congenitally malformed or absent, and the failure to reinstate healthy elastic matrices can
severely compromise vessel homeostasis.

2.1.1 Ultrastructure of an elastic blood vessel
To understand the role of elastin in vascular homeostasis, vascular ultrastructure
must first be addressed. Blood vessels are composed of three layers (tunics). Each tunic is
an organization of cells and ECM that serves specific functions within the vessel walls.
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Moving outward from the lumen, these layers are the tunica intima, tunica media, and
tunica adventitia. Figure 2.1 is a schematic of the vessel tunics.
The tunica intima forms the intermost layer of a blood vessel. It consists of axially
oriented endothelial cells, a thin sub-endothelial layer of areolar tissue, and a basement
membrane of connective tissue. The endothelial cells excrete molecules, such as nitric
oxide, that inhibit platelet activation and thrombus formation. The basement membrane is
comprised of collagen type IV, laminin, entactin, and proteoglycans (heparin sulfate) and
is formed by the association of the basal lamina and reticular lamina. The basal lamina
(collagen IV) and reticular lamina (collagen III and ground substances) act as a molecular
exchange barrier between the endothelial layer and underlying mass of connective tissue,
influence cell polarity, proliferation, and differentiation, and metabolism 26.
The tunica media is the location of the majority of vascular elastin. It is bound by
the internal (IEL) and external elastic laminae (EEL). The IEL separates the intima and
media (arteries only). The EEL separates the adventitia and the media. This tunic is
composed of SMCs and elastin arranged in concentric alternating bundles (lamellae). The
elastic lamellae are surrounded by sheaths of collagen I, III, V fibers. The SMCs are
responsible for the synthesis of the elastin molecules that compose elastic fibers, which
organize into lamellae and regulate blood flow by constricting and dilating the vessel
with varying hemodynamic stresses 27.
The tunica adventitia is the outermost layer of the vessel and consists of a
collagenous ECM and fibroblasts. This fibrous, collagen I-rich layer prevents vessel
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over-expansion due to luminal blood pressure. The adventitia is also responsible for
anchoring the blood vessel to surrounding tissue 28.

Figure 2.1 Schematic of vessel anatomy 29.

2.1.2 Composition, distribution & structure of the vascular matrix
The vascular matrix structure is dependent upon the vessel function. Major,
conducting (elastic) arteries have thick walls and contain large amounts of elastin, which
allows them to expand and contract to maintain blood pressure. Smaller, distributing
arteries are more rigid and contain a greater quantity of collagen. Venules and veins have
thinner walls and much less connective tissue than arteries because they encounter much
lower pressures. Capillaries contain an endothelial layer and basement membrane, which
allows rapid diffusion of molecules.
The vascular matrix is composed of fibers (collagen, elastin, and reticulin),
glycoproteins (fibronectin and laminin), and amorphous ground substance (proteoglycans
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and glycosaminoglycans). Table 2.1 identifies the composition of a typical elastic artery,
the aorta, which is further discussed below.

Collagen
5-15 %

Elastin
7-15 %

Glycosaminoglycans Water
0.2-2.5 %
70-75 %

Table 2.1 Compositional makeup of a mammalian aorta (dry w/w % of composition) 30.

Collagen is an abundant protein of blood vessels and is primarily responsible for
providing support and tensile strength. It has a helix of 3α-polypeptide chains containing
glycine, proline, and hydroxyproline and is classified in three groups based on helix size.
Group I (collagen type I, III, and V) participates in fiber formation. Types I and III are
the predominant types of collagen in the vasculature. They form fibers by lateral
aggregation and undergo lysyl oxidase mediated crosslinking. Type V is associated with
types I and III and regulates collagen fiber formation, as well as connects the basement
membrane to underlying extracellular matrix (ECM). Group II (types IV, VI, and VII)
does not participate in fiber formation. Type IV contains helical interruptions that yield a
greatly flexible molecule, which contributes usefully to the fluid structure of the
endothelial basement membrane allowing selective passage of molecules through from
the lumen to the underlying connective tissue. Type VI is microfibrillar collagen
distributed in the aorta only and is thought to mediate the interaction of collagen fibers
and cells. In addition to its structural role, collagen is also believed to be involved in
promoting cell differentiation and attachment.
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In cardiovascular tissues, elastin contributes up to 50% of the tissue dry weight 31.
Within these vessels, particularly, those that may be classified as elastic or conducting
(e.g., aorta, carotid, subclavian, common iliac arteries), elastin is organized as fibers and
lamellae that form rings, circumferentially organized around the vessel lumen. These
elastic lamellae alternate rings of SMCs to form the tunica media of the arterial wall. The
structure and function of elastin is discussed further below.
Glycoproteins, such as fibronectin and laminin, are not as abundant as collagen
and elastin in the vascular matrix, but are vital to vascular homeostasis. They are
biomolecules composed of a protein and a carbohydrate. Fibronectin is a high molecular
weight glycoprotein that binds to receptor proteins spanning the cell membrane
(integrins) and to the ECM. It can also specifically bind to other molecules such as
collagen and fibrin.

It has a role in matrix deposition and coagulation, as well as

functions in the activation and migration of inflammatory cells

32

. Laminin is associated

with type IV collagen networks. It also binds to cell membranes through integrin
receptors and other plasma membrane molecules. Through these interactions, laminin
contributes to cell attachment, differentiation, cell phenotype, and movement.
Proteoglycans (PGs) and glycosaminoglycans (GAGs) constitute the amorphous
ground substance surrounding cells of the vasculature. PGs are complex macromolecules
that contain a core protein to which at least one GAG chain is covalently bound. They are
closely associated with collagen and elastic fibers in the ECM, which suggests
interactions between them

33

. GAGs (e.g., hyaluronan, chondroitin sulfate, dermatan

sulfate, heparin sulfate, and keratin sulfate) are long unbranched polysaccharides
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consisting of a repeating disaccharide unit. This unit consists of an N-acetyl-hexosamine
and hexuronic acid, either or both of which may be sulfated. The availability of sulfate
groups and carboxylate groups on their uronic acid residues yields these molecules a very
high density of negative charge. These polysaccharides bind water to become highly
hydrated gel-like structures that resist compressive forces while permitting rapid
diffusion of nutrients, metabolites, and hormones between blood and tissue.

2.2 Elastin distribution, composition, structure, and function
Elastin is a major extracellular matrix (ECM) protein present in dynamic
connective tissues such as skin, lungs, ligaments, and arteries
tissues, elastin contributes up to 50% of the tissue dry weight

31

34

. In cardiovascular

. Within these vessels,

particularly those that may be classified as elastic or conducting (e.g., aorta, carotid,
subclavian, and common iliac arteries), elastin is organized as fibers and sheets (lamellae)
that form rings, which are circumferentially organized around the vessel lumen. These
elastic lamellae alternate with rings of smooth muscle cells (SMCs) to form the tunica
media of the arterial wall.

2.2.1 Chemical composition of elastin
A single gene on the human chromosome 7q11.23 codes for elastin

35

. Elastin is

produced as a hydrophobic protein containing a highly conserved amino acid sequence
(VGVAPG), rich in proline (10%) and glycine (33%), and contains additional amino
acids such as OH-proline (1%), alanin, valine, and leucine (40-50%) 36. It is secreted as a
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soluble monomer, tropoelastin, which has a secondary structure characterized by
alternating hydrophobic (β-sheet) and hydrophilic (α-chain) regions encoded by separate
exons 37. The secondary structure of elastin consists of 10% α-helices, 40% β-sheets, and
50% undefined conformations

38

. Figure 2.2 illustrates the alpha and beta domains

conserved among many proteins, including elastin. The hydrophilic regions are alanineand lysine-rich, while the hydrophobic domains are rich in proline, valine, and glycine 39.
Lysyl oxidase (LOX), a copper-dependent enzyme,

36

crosslinks targeting domains

40-41

of the α-helical regions, via desmosine and isodesmosine linkages38, to yield a
crosslinked insoluble, yet flexible matrix protein.
Alpha helix

Twisted beta sheet - saddle

Beta barrel

Figure 2.2 Secondary structures of protein: alpha & beta domains 42.

2.2.2 Elastin ultrastructure
Elastin may be ultrastructurally organized into individual and networked fibers
(e.g., loose fibers and loose or compact meshes)

43

or inter-woven, non-fibrillar matrix

structures (e.g., continuous sheets, fenestrated sheets)

43

. Figure 2.3 includes scanning

electron micrographs of some of the various elastin structures. The fibrillar structures

18

contribute to the elasticity of the tissues that contain them, allowing them to
characteristically recoil, when distending forces are removed.

Figure 2.3 Scanning electron micrographs illustrating the variability in ultrastructural
organization of elastin 43.

Elastic fibers (~200-900 nm diameter) are major insoluble ECM assemblies
deposited during early development in elastic connective tissues. They are composed of a
central core of cross linked, amorphous elastin surrounded by microfibrils 34 (Figure 2.4).
The microfibrils are composed of a number of different glycoproteins, predominately
fibrillin, which are essential both to maintain the integrity of the fibers and the ability of
cells to interact and respond to them. Microfibrils are typically 10 nm in diameter with an
average periodicity of 57 nm

44

. They form linear bundles and are deposited as pre-

scaffolds onto which soluble tropoelastin monomers then coalesce and are crosslinked.
During the elastin deposition process, the microfibrils are displaced to the periphery of
the growing elastin fibers, and typically appear electron-dense, as opposed to the electron
lucent amorphous elastin.
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Figure 2.4 Scanning electron micrographs of elastic fibers 45.

2.2.3 Biochemical roles of elastin
In addition to rendering tissues elastic, vascular matrix elastin also regulates
vascular cell behavior

28, 46

. Correlative studies have demonstrated large changes in the

composition and distribution of extracellular matrix (ECM) components during tissue
development, cell differentiation, and in response to growth factor, hormone, and
cytokines

47

. Modulation of a variety of cellular functions, including secretory activities

and gene transcription, occurs via interaction with the ECM. The ECM also serves as a
reservoir for growth factors and cytokines

28

. Therefore, ECM proteins, such as elastin,

may influence cell development, survival (anchorage-dependent), proliferation,
phenotype, migration, differentiation, and function 48.
Elastin affects cell-fate. Some cell types are dependent upon anchorage to the
surrounding ECM for survival. Anchoring junctions, such as adherens junctions and
hemidesmosomes formed by integrin transmembrane proteins, mechanically attach cells
and their cytoskeletons to the ECM

49

. Therefore, the presence or absence of elastin

may influence cell viability. The phenotype (the appearance and behavior of cells) also
depend upon the ECM. For example, in pathologic conditions, elastin may be
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fragmented and the fragments may encourage SMCs to change from a contractile to a
synthetic phenotype. Additionally, cell locomotion is affected by ECM components,
including elastin, and requires an initial polarization of the cell to promote migration in a
particular direction. Cell movement is in response to chemical and physical cues in the
cell environment. Therefore, the physical properties of elastin influence cell movement,
specifically inflammatory cells in scenarios of disease. These cell-fate processes will be
discussed further below with regard to elastin and its interaction with the elastin binding
protein.
Under healthy conditions, vascular SMCs in the tunica media are quiescent and
embedded in a network of elastin-rich ECM that acts as a barrier to SMC migration50.
During elastogenesis, the elastin binding protein (EBP), present on the extracellular
domain of SMC membranes, binds the soluble elastin precursor, tropoelastin
Tropoelastin influences chemotaxis
Ca2+

53

52

, and promotes cell adhesion

51

.

, stimulates vasodilation53, regulates intracellular
54

. Mature elastin also has numerous effects on

vascular SMCs including inducing actin stress fiber orientation, inhibiting SMC
proliferation, and regulating cell migration 55. In disease states, wherein elastin has been
broken down, the binding of elastin peptides (the soluble products of elastin
degradation) via the elastin receptor (EBP and two other integral membrane proteins), G
protein-coupled receptors (GPCR), or other integrins
proteins and opening of calcium channels

55

55

results in activation of G

. The Rho signaling cascade can be

stimulated by elastin and is mediated by GPCRs, the largest family of transmembrane
receptors 56-57. Karnik et al. have proposed a molecular mechanism for vascular SMCs in
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which elastin activates a G-protein-coupled pathway, inhibits adenylate cyclase, reduces
cAMP levels 58, and stimulates Rho induced actin polymerization 57.
Under pathologic conditions, such as in atherosclerosis (Figure 2.5) and within
AAAs, elastin breaks down to generate elastin peptides at an accelerated rate. These
elastin degradation products up-regulate SMC proliferation and activate phagocytic cells
55

. Elastin peptides are released and through their interaction with receptors present on the

surface of fibroblasts, phagocytes, lymphocytes, SMCs, and endothelial cells (ECs) elicit
a variety of biologic effects such as matrix-metalloprotease (MMP) over-expression,
greater Ca2+ influx, enhanced vasorelaxation and chemotactic activity. In atherosclerotic
and neointimal lesions, SMCs thus migrate from the tunica media through the internal
elastin lamina to the intima. Protease release by these SMCs is responsible for further
elastin destruction in the arterial wall. Elastin is similarly enzymatically degraded by
MMPs in aneurismal vessels, specifically MMP-2 and MMP-9 released by activated
SMCs and infiltrated leukocytes, which leads to formation of floppy, de-elastized
vascular segments, susceptible to rupture

50

. The degradation of elastin is the result of a

proteolytic cascade that involves the cooperation of several degradative enzyme types
such as serine proteases, matrix metalloproteinases, and cysteine proteases 59. These may
be present in latent forms under healthy physiologic conditions, yet become activated
following vessel wall injury.
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.

A

B

Figure 2.5 Schematics to describe SMC response to a vessel injury (A) and
atherosclerotic plaque development (B) 60-61.

2.2.4 Contribution of elastin to vascular mechanics
The mechanical properties of blood vessels stem from their microstructural wall
components, such as collagen and elastin fibers and smooth muscle cells (SMCs)

50

.

Together with collagen, elastin gives vessels the ability to receive and transmit blood at
high pressures without bursting. Pressure of flowing blood and wall shear stress that a
vessel encounters critically impact these mechanical properties. Collagen limits the
distensibility of vascular tissue and prevents tear caused by excessive stretching. Axial
elastin fibers in intimal and adventitial layers and circumferential medial fibers help
distribute stresses during vessel contraction and relaxation

62

. The elastic lamellae

provide elasticity that arteries need to absorb hemodynamic stress during systole and
release this energy in the form of sustained blood pressure during diastole. Figure 2.6
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illustrates the contribution of elastin and collagen to vascular mechanics. The average
tensile strength of the adult human aorta typically ranges from 800 to 1000 kPa 63.

Figure 2.6 Stress-stretch ratio curve for a blood vessel 64.

Elastin content and organization affect vascular mechanics. Passive stiffness of
the aortic wall is determined by the individual stiffness, content, and microstructure of
elastin at low stresses, of collagen at high stresses, and of both elastin and collagen at
physiologic stresses

65

. Additionally, elastin organization plays an important role in

arterial ageing and the development of atherosclerosis. Elastic lamellae grow increasingly
fragmented and fibrotic with age66, which can be seen in Figure 2.7, and in a similar
manner elastin disruption occurs in the development of atherosclerotic plaque, both of
which result in arterial stiffening, though for different reasons

67

. In arterial plaques,

elastin breakdown generates soluble peptides that interact with cells. There is an
increased Ca2+ influx, which causes calcification and wall stiffening.
The bulk, as well as nano-scale mechanical properties of ECM/ scaffolds, have
been shown to influence cell behavior. For example, studies have led researchers to
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believe matrix organization (fibrils) provide topographical and/ or mechanical features
that are important determinants of cell phenotype

68

. Cells interact with elastin through

the elastin binding protein (EBP), which binds the tropoelastin51. Mechano-transduction
between elastin and SMCs occurs and transforms mechanical forces created by the ECM
into intracellular chemical signals. Intracellular signaling modulates a variety of cellular
functions including cell phenotype, secretory activities, and gene transcription28.

Figure 2.7 SEM micrographs of elastin matrix deposition (1-3), then fragmentation with
age (4-5), within vascular tissues. Developmental induction of elastin synthesis increases
7 to 14-fold between 17 and 19 weeks of gestation. (1,2) Fetal elastic tissue contains thin
strands of amorphous elastin associated with bundles of 10-20 nm wide microfibrils; (3a)
At 0 years, elastic fibers are thicker, contain a more defined core of amorphous elastin
surrounded by discontinuous microfibril coat; (3B) At 10 years the diameter of elastic
fibers has increased to final size (40-300 nm) by deposition of amorphous elastin; (3C) At
16 years, fibers contain amorphous elastin with longitudinal strips of electron-dense
25

materials; few microfibrils; (3D) At 40 years, electron-dense materials accumulate within
elastic fibers; (4,5) At 70+ years, electron-dense material disappears leaving „holes‟ and
there is appearance of isolated fibers containing interwoven filaments, not amorphous
elastin 69.

2.3 Mechanisms of elastin synthesis, maturation, and breakdown
Vascular elastin matrix deposition occurs extracellularly in a process directed by
vascular SMCs. Figure 2.8 illustrates the mechanism of elastic fiber assembly.
Tropoelastin, the elastin precursor, is secreted from these cells, then crosslinked. The
tropoelastin first moves through the extracellular space and interacts with glycoprotein
microfibrils, which guide it to become appropriately aligned for crosslinking70. This
assembly process is mediated at the cell-surface by an elastin-binding complex. The
complex consists of two membrane proteins (55 and 61 kD), which form a link between
the extracellular compartment and the cytoskeleton, and the elastin binding protein
(EBP), a 67 kD protein, which binds the hydrophobic VGVAPG sequence in elastin, the
cell membrane, and galactosugars. Binding of the galactosugars to the EBP lowers its
affinity for both tropoelastin and for the cell-binding site, resulting in the release of
bound tropoelastin and the dissociation of the EBP from the cell membrane. This release
of the tropoelastin caused by the galactosugar-containing microfibrillar glycoproteins
allows for congregation and crosslinking of the elastin precursor 70. The initial step in the
crosslinking reaction is the formation of the -aldehyde, through the oxidation of lysine
amino acid groups by lysyl oxidase (LOX )

71
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. Microfibrils serve as a scaffold template

for elastin deposition and organization into fibers; therefore, an abnormality of galactosecontaining microfibrils (e.g., glycoproteins, galactolipids, and glycosaminoglycans) may
impair elastin assembly

70

. If alignment and LOX-mediated crosslinking occur

appropriately, elastin molecules are then connected by formation of desmosine (Des) and
isodesmosine (IDes) linkages between adjacent elastin molecules. These types of
crosslinks, specific to elastin, allow the matrix to stretch and recoil as a unit.

Figure 2.8 Schematic of mechanism of elastin fiber assembly 70.

2.3.1 Growth factor modulation of elastin synthesis
Prior studies have shown that elastin matrix synthesis is regulated by numerous
biochemical factors that may be broadly classified as elastin synthesis inhibitors (e.g.,
absorbic acid 72, basic fibroblast growth factor (FGF) 73, cyclic AMP 74, monensin 75, and
natural aging
77

76

), and elastin synthesis stimulators (e.g., cyclic GMP

74

, fetal calf serum

, insulin-like growth factor 1 (IGF-1) 78, transforming growth factor β1 (TGF β) 79, and

mechanical stretch/cyclic distention)

80

. Table 2.2 shows the effects of these factors on
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transcription level and biosynthesis of elastin. Additionally, recent studies have
implicated the ECM proteoglycan, versican, in mediating increase in cellular tropoelastin
production, as well as in encouraging elastic fiber formation 81-82.
Factor

Effects
Transcription levels

Biosynthesis
Inhibitors
Absorbic acid72
FGF73
Cyclic AMP74
Monensin75
Aging76

-

?
-

+
+
+
+
+

?
+
+
+
?

Stimulators
74

Cyclic GMP
Fetal calf serum77
IGF-178
TGF-β79
Mechanical stretch/cyclic distention80

Table 2.2 Effects of various factors on elastin biosynthesis and transcription levels.

2.3.2 Impact of GAGs on elastin synthesis and organization
Other

than

those

listed

above,

certain

ECM

molecules

such

as

glycosaminoglycans (GAGs) may have elastogenic qualities as well. GAGs contain
repeating disaccharide units consisting of uronic acid and hexosamine components (e.g.,
glucuronic acid and n-acetyl-d-glucosamine in hyaluronan (HA)). Previous studies
describe close association between several GAG types (e.g., HA, heparin sulfate) and
linked proteoglycans (e.g., versican), and elastin in pulmonary
dermal

69, 90

83

, vascular

84-89

, and

tissues. While some GAGs (e.g., dermatan and chondroitin sulfates) inhibit

elastic fiber formation 6, 70, 91, others such as HA, facilitate the synthesis and organization
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of microfibrils (fibrillin), a precursor for elastic fiber deposition 6. HA has been suggested
to play an indirect role in elastogenesis through its intimate binding of versican 7, which
in turn interacts with microfibrillar proteins (fibulin-1, 2) and elastin-associated proteins
to form higher-order macromolecular structures important for elastic fiber assembly

7-10

.

Evidently, some highly anionic GAGs (e.g., HA) coacervate soluble tropoelastin, to
facilitate LOX-mediated crosslinking into an insoluble matrix

85, 86

, and stabilize elastin

fibers against degradation by elastase 10-12. Additional details regarding HA and its effects
on elastin synthesis and organization can be found in Section 2.6.4.4.1.

2.3.3 Physiologic turnover of elastin
As seen in Figure 2.8, physiological turnover of elastin is very slow. In healthy
tissues, very little remodeling of elastin fibers occurs in adulthood. The half life of
vascular elastin is thus lengthy (approximately 70 years)

92

and minimal turnover occurs

in healthy tissues. However, elastin degradation is greatly accelerated under certain
pathological conditions. Physiological and pathological vascular remodeling occurs in
response to a variety of stimuli including mechanical injury or disease induced
inflammation. The primary ECM receptors mediating ECM remodeling are integrins,
which act as mechano-transducers, transforming mechanical forces created by the ECM
into chemical signals. Direct integrin signaling and indirect integrin modulation of
intercellular signaling pathways regulate matrix remodeling and control subsequent cell
behavior and tissue organization

93

. Excessive matrix remodeling occurs in diseased

states and is thought to be the primary cause of the most prevalent vascular pathologies of
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arteries, including atherosclerosis and restenosis

94

. In acquired vascular inflammatory

diseases (e.g. atherosclerosis and aneurysms) it can be caused by the release of powerful
elastinolytic

proteases

released

by

inflammatory

cells

or

bacteria,

matrix-

metalloproteases (MMPs), or cysteine proteases. Additionally, degradation could be due
to genetic vascular abnormalities, such as those pertaining to elastin or fibrillin, or those
in the gene coding for the in the naturally present elastase inhibitor 1-antitrypsin 95.

2.3.4 Role of MMPs in elastin turnover
Matrix-metalloproteases (MMPs) are the enzymes typically involved in elastin
turnover. Vascular smooth muscle cells (SMCs) release numerous MMPs that are capable
of digesting individual components of the ECM

94

and are normally regulated by tissue

inhibitors of metalloproteases (TIMPs). They are important in maintaining the vessel by
breaking down matrix while new is being synthesized. Degradation of the matrix scaffold
by MMPs enables cell movement and general tissue reorganization, yet also contributes
to cardiovascular pathologic processes

96-97

. MMPs may be chronically over-expressed

and insufficiently regulated by TIMPs in pathologically afflicted blood vessels, leading to
accelerated elastin breakdown and subsequent loss of biochemical and structural
homeostasis of the vessel.

2.4 Abnormalities of vascular matrix elastin
Abnormalities of vascular matrix elastin may be genetic and/or congenital, or may
be an outcome of acquired vascular diseases. Most commonly, elastin is disrupted as an
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outcome of non-inherited, vascular proliferative diseases such as arthrosclerosis and
restenosis, or due to direct mechanical injury to blood vessels. During injury induced
inflammation, macrophage-derived proteases degrade the vascular elastin matrix,
disrupting elastin-smooth muscle cell (SMC) signaling pathways, causing SMCs to
switch to an activated, synthetic phenotype. Similarly, abdominal aneurysms develop
when elastin is progressively degraded by matrix-metalloproteases (MMPs), enzymes
that are involved in normal elastin turnover in healthy vessels, but are pathologically or
genetically overproduced. Less frequently, genetic disorders can cause aberrations in
structure or even the formation of vascular matrix elastin. In either of these cases,
vascular elastin synthesis, structure, and stability may be variably and adversely affected
to elicit the common downstream effects of SMC hyper-proliferation and medial
thickening, and to further result in decreased arterial compliance and pathogenesis of
hypertension.

2.4.1 Genetic abnormalities of vascular matrix
Genetic abnormalities of connective tissue matrix structures, specifically elastin,
affect cardiovascular tissues. These can be categorized into those that impact the elastin
gene (ELN), and those that target the fibrillin or fibulin genes. Elastogenesis is regulated
by the presence of the 67-kD elastin binding protein (EBP), which is encoded by the
elastin gene. Congenital defects in the ELN gene can cause impaired deposition of
insoluble elastin and accumulation of smaller elastin peptides, which transduces
intercellular communication resulting in hyper-proliferation
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98

. Additionally, genetic

abnormalities affecting the fibrillin and fibulin genes impair elastin organization.
Impaired elastogensis or elastin organization can lead to the development of potentially
fatal connective tissue abnormalities.
William-Beuren syndrome (WBS) affects the elastin gene on chromosome 7q11.
It is present at birth and is estimated to occur in 1 per 7,500 deliveries

99

. Peripheral

arterial stenoses and hypertension result and may be caused by the deletion of 1 allele of
the elastin gene 100. As a result of this deletion, people with WBS are missing one copy of
the ELN gene, reducing the production of elastin in half, which disrupts the normal
structure of elastic fibers. Affected patients have abnormally thick, distensible arterial
walls, which is likely due to the abnormal elastic fiber assembly and SMC dedifferentiation leading to hypertrophy

98

. WBS is often associated with supravalvular

aortic stenosis.
Supravalvular aortic stenosis (SVAS) also affects the elastin gene on chromosome
7q11. It is caused by point mutations, translocations, and/ or deletions in the ELN gene
and affects 1 in 13,000 live births and shows extreme clinical variability

98

. Most ELN

mutations in SVAS result in premature termination codons, some of which have also
been shown to cause decay of mRNA products

101

. The condition is characterized by

abnormally structured elastin in the arterial walls leading to increased proliferation of
SMCs and formation of intimal lesions. It results in an increase in elastolytic activity and
narrowing of the arterial tree.
Marfan syndrome (MFS) is caused by mutations in a gene on the chromosome
15q21.1 encoding fibrillin-1, a major constituent of extracellular microfibrils. The
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prevalence of the disorder is 1-3 per 10,000 with an incidence of 25% new mutations

102

.

This mutation results in elastin fiber abnormalities primarily in the medial layer of aortic
wall. Early fragmentation, poor and disorganized deposition of elastic fibers, loss of
elastin content, and accumulation of amorphous elastin result

103

. Secondary to fibrillin

abnormalities are impaired SMC-elastin fiber interactions, which have been shown to be
mediated by fibrillin-1 microfibrillar components. As discussed previously, such
impaired interactions enhance local cellular release and activity of MMPs, serine
proteases, or cysteine proteases, or conversely induce a local deficiency of protease
inhibitors, including tissue inhibitor of MMPs, -antitrypsin, or cystatin C

104

,

exacerbating loss of elastic matrix homeostasis.
There are additional genetic factors that contribute to elastic matrix abnormalities.
For example, fibulin, a 6-member protein family, is hypothesized to function as an
intermolecular bridge that stabilizes the organization of extracellular matrix structures.
Reduced expression of fibulin-4 leads to aneurysm formation, dissection of the aortic
wall and cardiac abnormalities

105

. The lack of fibulin-4 leads to disrupted elastogenesis

leading to the development of elastic fibers that contain irregular elastin aggregates and
diminished desmosine crosslinks 106.

2.4.2 Acquired elastin disorders
In addition to genetic abnormalities that adversely impact the vascular matrix,
there are acquired inflammatory and vascular cell proliferative pathologies, such as
atherosclerosis and restenosis that lead to exaggerated remodeling and synthesis with the
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ultimate outcomes of severe vessel occlusion. Vascular proliferative disorders share
common features including the disruption of elastic fibers and the accumulation of
vascular SMCs within the intima due to a disturbance of homeostatic cues. Elastin
regulates vascular homeostasis by signaling vascular SMCs through defined pathways to
localize around the elastic fibers in organized lamellar units and remain in a quiescent,
contractile state. The disruption of elastin by inflammation, or direct mechanical injury
can interrupt cell–matrix signaling and directly activate the SMCs. Degradation of elastin
by macrophages, T cells, and their proteases during inflammatory disease of vessels, act
in conjunction with the numerous cytokines and growth factors activated during vascular
injury to incite SMCs to de-differentiate, proliferate, migrate towards the vascular intima,
exhuberantly deposit a disorganized matrix prone to calcification, and ultimately form a
plaque that occludes the vessel lumen. Elastic matrices have additionally been implicated
as a negative regulator of SMC activity within the arterial wall and are therefore
important contributors to the pathogenesis of occlusive vascular disease, not simply an
outcome of inflammation and vascular occlusion. Therefore, preventing elastic matrix
degradation following vascular injury or restoring the lost/ degraded vascular elastic
matrix is essential for restoration of vascular homeostasis 60.

2.4.3 Abdominal aortic aneurysms (AAAs)
Aneurysms are progressive, localized dilations of elastic arteries (Figure 2.9)
caused by pathological weakening of the vessel wall that may have final outcomes of
dissections (tears) and fatal rupture. They occur secondary to atherosclerosis, vascular
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hypertension, as a result of vessel wall architectural changes, trauma, infection, chronic
enzymatic degradation, and certain inherited conditions (e.g., Marfan Syndrome). In
relatively less-inflammatory environments, abdominal aortic aneurysms (AAAs) develop
from a diminished quantity of elastic fibers, accumulation of proteoglycans, and loss of
SMCs

107

. More commonly, they occur in concurrence with calcified lipid deposits or

atherosclerotic plaques in the abdominal aortic wall, wherein lymphocytes and
macrophages infiltrate and cause matrix proteolysis leading to AAA formation 17.

Figure 2.9 (A) The anatomical position of an AAA. (B) Computed tomography (CT) of
the progression of an AAA 108.

Current, clinical AAA treatment methods are primarily surgical, and include open
aneurysm

repair, wherein the weakened aortic segment is replaced with a sutured

synthetic mesh graft, and endovascular repair, wherein a woven graft mounted on a selfexpanding stent is deployed at the site of AAA

3

(Figure 2.10). Despite their relative

merits and demerits, long-term cardiac/ pulmonary complications and other surgical and
graft-associated complications cause survival rates to drop drastically within 10 years
post-surgery 109.

35

Figure 2.10 Current surgical treatment methods for AAA repair. (A) Open repair; (B)
endovascular repair.

There is great variability in the extracellular matrix of AAAs due to numerous
influencing parameters such as AAA initiating cause, size and location, proximity to site
of injury, stage in development, inflammatory cell involvement, thrombus formation, and
tendency to rupture. For instance, proximal to the site of maximal diameter expansion
AAAs exhibit great loss of both elastin and collagen, while distal to the site of maximal
diameter expansion AAAs exhibit rapid loss of elastin with minimal net collagen loss,
which is attributed to the differential load the vessel experiences at the proximal and
distal sites. Also, AAAs exhibit an expression/ activity gradient of proteolytic MMPs 1,
2, 9, and 12 with the greatest concentration at the site of rupture

110

. MMP expression is

also increased in thrombus-free AAAs relative to those involving thrombus formation 111.
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Additionally, the infiltration of leukocytes has been shown to accompany increased
matrix destruction and AAA growth112.

2.5 Approaches to restoring elastin homeostasis
Vascular elastic matrices contain fiber bundles that provide blood vessels the
compliance to absorb and transmit hemodynamic forces to maintain blood pressure.
Elastin also mechano-transduces smooth muscle cell (SMC) behavior through binding to
cell surface elastin-laminin receptors to regulate cell activity, particularly during vascular
morphogenesis and disease. Therefore, congenital or acquired malformation or
degradation of vascular elastin can severely compromise vascular homeostasis and
therefore must be preserved, replaced, or regenerated as a priority.

2.5.1 Elastin stabilization
Elastin preservative strategies aim to maintain matrix stability by inhibiting
proteolytic enzyme production or activity. Pharmacologic agents, MMPs and other
protease inhibitors, as well as transcription factor regulators, can attenuate matrix
degradation to slow AAA progression, but do not encourage their regression. These
approaches are further discussed below.
Pharmacologic inhibition of MMPs 2 and 9 (over-expressed within AAAs by
SMCs, fibroblasts, and recruited inflammatory cells) using non-antibiotic tetracyclines
(e.g., doxycycline) have been shown to inhibit AAA formation in rats

113

. Also, in a

small, randomized patient study, no aneurysm growth has been noted after 12 months in
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patients treated with doxycycline

114

. These promising results have resulted in MMP

inhibition with doxycycline to proceed toward larger clinical trials to inhibit AAA
expansion.
Within AAAs, a marked imbalance in amounts and total activities of MMPs and
endogenous tissue inhibitors of MMPs (TIMPs) has been noted. Therefore, exogenous
TIMP delivery is being investigated as a means of arresting AAA growth. MMP
inhibition may inhibit plaque-stabilizing mechanisms, such as SMC growth, while
conversely retarding ECM destruction and subsequent vessel rupture. The development
of selective MMP inhibitors, that do not have inhibitory effects on SMC function, may be
useful therapies to prevent plaque rupture 115.
Protease inhibitors bind to elastase enzymes to prevent unrestricted and
potentially harmful effects of proteases on elastin matrices. The most common group of
protease inhibitors that protect tissues from protease attack, and subsequent matrix
degradation are serine proteinase inhibitors. Loss or absence of these elastase inhibitors
due to inherited genetic defects (e.g., anti-trypsin deficiency) can lead to elastin
degradation. Exogenous delivery of alternative elastase inhibitors, or transfection of
vascular SMCs with genes (e.g., -1 antitrypsin gene) can help regulate in vivo
production of these elastase inhibitors and inhibit elastin degradation 116.
Transcription factors regulate formation of RNA that codes for assembly of
proteins in the cell cytoplasm. Transcription factors can be selectively activated or
deactivated.

In the vascular context, inflammation is specifically regulated by

transcription factors that can up-regulate MMP synthesis and release, which causes
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degradation of matrix components. Therefore, inhibition of such transcription factors is
an approach to treat matrix degradation 117.
Chemical stabilization of vascular elastin is a novel approach to limit elastin
degradation. Specifically, Isenburg et al. has shown pentagalloyl glucose (PGG), a
polyphenolic tannin produced from tannic acid, decreases elastin loss and preserves
integrity of elastic lamellae

118

. In a rat model of CaCl2 –induced AAA, PGG has been

shown to inhibit elastin degeneration, limit aneurysm expansion, and hinder AAA
development without increasing inflammation, calcification, and MMP activity

118

. This

is a promising technique to preserve vascular elastin.
Despite the promise of these techniques, active regression of AAAs is limited or
non-existent due to lack of new elastin regeneration and existing matrix disruption.
Emerging studies in the field have sought to address this problem.

2.5.2 Elastin replacement strategies
In the case of severely degraded vascular matrix in which the structural stability
of the vessel is lost, replacement strategies are considered. Natural or synthetic matrices
that resemble the size, architecture and mechanical properties of the native ECM are
harvested or fabricated. Characteristics of an ideal blood vessel substitute include: strong,
compliant, kink restistant, good suture retention, non-toxic, non-immunogenic, low
thrombogenicity, biocompatible, readily available, and low processing or manufacturing
costs 5. Matrix replacement strategies include replacing lost, degraded, or malformed
tissues using autologous, allogenic, xenogeneic, or polymer/ synthetic grafts.
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Autologous grafts (e.g., greater saphenous vein or internal mammary artery) are
the most viable clinical option for replacement of a vessel, but are limited by a lack of
quality and availability. The major benefit of using autologous grafts is no immune
response. Many patients simply do not have enough appropriate blood vessels for use as
grafts. Typically, the blood vessels are diseased or the blood vessels were used in a
previous surgery

119-120

. In such cases, allogenic, xenogenic, or synthetic graft materials

are implemented.
Allogenic tissue grafts are an attractive substitute for replacing vessel segments
due to identical structural makeup, mechanical properties and size-matches. They may be
sourced from vessels from deceased fetuses, cadavers, and umbilical cords121. Allogenic
tissue may produce an immune response from the recipient and graft rejection may occur.
Therefore, lifelong immuno-suppression is required to ensure allograft survival. More
recently, techniques have been developed to extract immunoreactive epitopes and
globular proteins from allograft tissues prior to transplantation to facilitate host tissuetransplant integration 121.
Xenogenic (e.g., bovine or porcine) materials present problems of end-stage organ
failure, different lifespan of recipient and donor, disease transmission, and permanent
alteration to the genetic code. The biggest challenge for xenografted tissue is immune
rejection due to cross-species transplants being more likely to produce host-graft
reactions than same-species transplants. Processing of xenografts (e.g., SDS treatment)
to remove immunoreactive molecules and cells is the most commonly utilized method to
avoid immune rejection. Yet, this process is thought to compromise the structural
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integrity of the resulting acellular matrix composed of elastin and collagen. Compliance
mismatch, elastic degradation, and mechanical stiffening are resulting problems

122

.

Additionally, due to the lack of endothelium of decellularized grafts, they are
thrombogenic. To overcome this problem researchers have done autologous vascular cell
seeding of the luminal surface establishing a confluent monolayer of cells 123.
Synthetic polymers provide an alternative to natural polymers for vessel
replacement.

Dacron

(polyethylene

terepthalate,

PET),

Teflon

(expanded

polytetrafluoroethylene, ePTFE), and polyurethanes (PUs) are typical, readily available
synthetic conduits

124

. Problems associated with synthetic polymer grafts are early post-

operative thrombosis, long-term intimal hyperplasia and graft infections. Material
properties of the grafts greatly influence the resulting problems. Dacron has a tensile
strength of 170-180 MPa 124, which is much greater than that of the aorta (800-1000 kPa)
63

. These properties contribute to its resistance to biodegradation, but also reduce its

compliance. Dacron is produced in either woven or knitted forms. Woven grafts are
stronger with smaller pores while knitted grafts have larger pores that promote greater
tissue ingrowth and are more compliant. This porous nature also increases its
susceptibility to the infiltration of hyperplasic medial SMCs and formation of a neointima
consisting of a fibrin, macrophages, and connective tissue. Dacron has been shown to
remain intact for more than 10 years, yet its most common failure mode is dilation 124.
Teflon is highly crystalline and has a tensile strength of 14 MPa, which is slightly
greater than that of a native human aorta (800-1000 kPa)

63, 124

. It has an electronegative

surface that inhibits protein adsorption and thrombus formation improving its stability. In
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addition, its porous structure provides favorable cellular reaction. Inflammatory response
and formation of a neointima, similar to that which occurs with Dacron, occurs with
implantation of Teflon 124.
PU has shown significant applicability as a vascular graft. The porosity and
therefore the radial compliance of the graft can be regulated

125

. The material has hard

domains dispersed within a soft segment matrix. The hard segment accounts for the
strength and rigidity, while the soft segment provides flexibility. Depending on the ratio
of the hard and soft segments, tensile strengths range between 20 MPa and 90 MPa,
which is slightly greater than that of a native human aorta (800-1000 kPa)

126

. PU has a

viscoelastic and compliant nature, which is essential for blood and tissue compatibility.
PUs have also shown thromboresistance, rapid ingrowth of living tissue and minimal
anastomotic hyperplasia

127

. The major problem associated with PU is the degradation of

the soft segments. To overcome this problem, PUs with poly(carbonate) soft segments
have been developed which are more stable 128.

2.5.3 Elastin regenerative strategies
Tissue engineering (and its in vivo counterpart, regenerative medicine), defined as
restoring, maintaining, or enhancing tissue and organ function, is an emerging
multidisciplinary field involving biology, medicine, and engineering that is likely to
revolutionize medicine. It has been proposed as a promising alternative to the
stabilization and replacement strategies discussed. The foundation of tissue engineering
for therapeutic applications is the ability to exploit living cells in a variety of ways using
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biomaterial, biomolecule, and mechanical stimuli to repair and/or regenerate tissue. The
major goal for vascular tissue engineering is maintenance of viable and self-renewing
vessel components 5. Ideally, engineered tissues should provide nutrient transport,
mechanical stability, coordination of multi-cellular processes, and a cellular
microenvironment that promotes phenotypic stability. 129
Thus far, scientists have not created a viable vascular graft that possesses the
necessary complex mechanical properties and mimics the biological function of a native
artery, specifically elastin, but much progress has been made. Table 2.3 illustrates the
progress of vascular tissue engineering conduit technology and some major contributors
from 1906 to present. The table is not comprehensive, but illustrates the field‟s
continuing advancement in biomaterials, cell sources, and mechanical stimuli.
Reference

Year Graft material

Cell seeding

Additional
manipulation

Carrel130

1906

Goyanes131

1906

Gross132
Sparks133

1948
1968

Dardik134

1975

Herring135
Weinberg &
Bell3
Niklason et
al.136
Banguneid et
al. 137

1978
1986

+/- Dacron

EC seeding
Bovine SMCs & ECs

1999

PGA mesh

Bovine SMCs &ECs

Cyclical stretch

2000

Dacron scaffold

Porcine SMCs & ECs

Shear stress
preconditioning

Homologous &
heterogeneous
canine grafts
First autologous
vein transplant
Arterial allograph
Dacronsupplemented
autologous
fibrous tubes
Human umbilical
cord vein
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Vaz et al.138

2005

PLA/PCL

Xu et al.139

2007

PGA unwoven
fiber scaffold

Guillemette
et al.140

2010

Mouse fibroblasts &
human venous
myofibroblasts (HVS)
Canine carotid artery
SMCs
Human fibroblasts &
endothelial cells

Pulsatile stimuli

Table 2.3 History of tissue engineered blood vessels.

2.6 Matrix engineering
Matrix engineering is an area of expertise within tissue engineering that
incorporates the broad goals of bioengineering and the specific goals of tissue
engineering to restore, maintain, and improve defective, damage, or injured ECM tissue,
which is crucial to improving health and function. The elastic matrix, though vital to
vascular homeostasis, has proven to be exceptionally challenging to regenerate or restore.
Therefore, there are specific bioengineering efforts being made to address the challenges
of vascular elastin matrix engineering. The following sections will discuss the successful
approaches that have been explored and the challenges that still exist.

2.6.1 In vitro tissue engineering approaches
In vitro approaches are those that are completely conducted in a controlled
environment outside the body, typically in a petri dish. These approaches are important
for preliminary investigation as a proof of concept for elastic matrix engineering
techniques, but further investigation in vivo is necessary to verify the effectiveness of a
specific technique. They allow for control over individual parameters, which permits the
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investigation of the effects of specific elastogenic stimuli. Additionally, they minimize
the number of animals sacrificed for experimentation and give a starting point for
appropriate exposure doses of factors.
An example of an in vitro tissue engineering approach for increasing elastin
matrix is the work conducted by Kim and Mooney

141

. They tested poly(L-lactic acid)-

bonded polyglycolide fiber-based scaffolds and type I collagen sponges under cyclic
strain conditions. They found tissues engineered with type I collagen sponges subject to
cyclic strain had greater elastin than control tissues, and the SMCs in these tissues
exhibited a contractile phenotype. In contrast, SMCs in control tissues exhibited more of
a synthetic phenotype. These studies indicate that a natural scaffold material and a
mechanical stimuli are elastogenic

141

. Many other research groups have conducted in

vitro studies to up-regulate elastin production in vascular cell and tissue culture systems.
It is a necessary starting point prior to in situ and in vivo elastin regeneration and repair.

2.6.2 In situ elastin regeneration and repair
Although a great deal of experimentation has been performed in vitro, in vivo
studies are needed to better understand the technique or therapeutic approach being tested
in physiologic conditions. An important intermediate between in vitro and in vivo is in
situ experimentation. In situ investigation compensates for some of the limitations of in
vitro while still allowing for greater control of the test environment.
Ex vivo vascular models are those in which elastic vessels are explanted from a
subject, and then cultured in a controlled environment. This is more representative of a
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physiologic environment than that of explanted cells growing in an in vitro culture
system. The native cells and ECM structure are intact. The effects of elastogenic stimuli
can be investigated on the vessel as a whole. This is extremely important in studies
focusing on aneurysm repair as outlined below.
In situ sustained delivery of factors is more challenging than that of in vitro
studies in which the therapeutic stimuli can be directly incorporated into culture media
and the exposure dose of the agent to the cells is known throughout the culture period. In
in situ and in vivo models the complex environment may decrease the exposure of the
cells and ECM to the therapeutic agent, so more direct, controlled delivery is necessary.
Systemic injection, peri-adventitial injection, delivery via catheterization or osmotic
pump, and stent graft delivery are some options currently under investigation.

2.6.3. Animal models for matrix engineering
There are numerous considerations for selection of animal models for vascular
tissue engineering including: size match, hemodynamics, blood reactivity, calcification
potential,

endothelialization

potential,

pharmacokinetics

(drug

metabolism),

developmental pattern, life span, ethical consideration, and cost. A list of animal models
currently utilized for cardiovascular tissue engineering is included in Table 2.4 below. A
few examples of the research use for each animal model, as well as the advantages and
disadvantages of each, are listed.
The rat model of aortic aneurysms is well-established. This model involves a
localized injury to arterial tissue, which induces chronic elastin degradation that leads to
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increased MMP levels, and eventually causes vessel expansion similar to that that occurs
in human aneurysm formation

142-143

. Adult rat vascular SMCs additionally poorly repair

disrupted vascular elastin matrices in situ, in a similar manner to that of human vascular
SMCs. Therefore, regenerative outcomes in rats may imply a similar response in humans.
Animal
Model

Advantages

Disadvantages

Examples of Research Use

Primate

Anatomical size & lifespan
similar to human

Ethical concerns,
cost

Porcine

Similar anatomy &
physiology to humans

Ovine/
Caprine

Large size, easy
access to the carotid artery,
adult animals do not grow

Uncooperative
without full general
anesthetic, capable
of rapid growth,
cost
Cost

Demonstrate chronic EC &
SMC growth on graft
materials
Test durability & functionality
of various TE conduits &
small intestinal submucosa
(SIS) as a growing venous
graft
Evaluate a tissue-engineered
vascular constructs, animal of
choice for assessment of
cardiac valves (sheep)
Test a vascular prostheses in
long-term in vivo studies

Canine

Convenient size, ready supply,
lack of rapid growth, easy to
work with
Convenience of anatomical
Size, lower cost

Ethical concerns,
cost

Cheap, easy to
anaesthetize & work with,
vascular healing mechanisms
parallel that in humans, yet
highly accelerated
Cheap, easy to
anaesthetize

Small size presents
quite a technical
challenge

Smaller size of the
vasculature

Rabbit

Rat

Mouse

Even greater
technical difficulty

Assess in vivo vascular
engineering in the reduction
of atherosclerosis postangioplasty, test vascular graft
materials
Compare graft patency, study
vascular pathogenesis, injury
response, remodeling, & test
therapies for preserving
existing vascular matrices
Too small for vascular use
typically

Table 2.4 Animal models used for vascular tissue engineering 144.

2.6.3.1 Animal models for study of AAA
Numerous animal models exist for the study of AAAs, which recapitulate features
of the human disease

15-16

. Human AAAs may result from an inflammatory response

47

caused by an insult to the vessel wall (i.e. atherosclerosis involving calcified lipid
deposits) or congenital abnormalities (i.e. Marfan Syndrome involving defect in fibrillin1, an elastin associating microfibril) and may include medial degradation, inflammation,
thrombus formation, and rupture. Animal models most commonly implemented are those
that have been genetically modified or chemically induced to form AAAs. The genetic
approaches are engineered and spontaneous mutations including defects in ECM
maturation, increased degradation of elastin and collagen, irregular cholesterol
homeostasis, and enhanced production of angiotensin

17

. The chemical approaches

include intraluminal infusion of elastase, peri-adventitial exposure of calcium chloride
(CaCl2), and subcutaneous infusion of AngII 17.
For the purpose of our studies of inflammation-induced AAAs, peri-adventitial
CaCl2 injury and elastase perfusion of rodent aortae are relevant and well characterized
models. Peri-adventitial CaCl2 exposure results in a localized insult to the vessel wall,
which induces inflammatory cell infiltration leading to high MMP levels and chronic
elastin degradation and calcification resulting in time-dependent aorta expansion

15-16, 18

.

With this model, this caustic agent increases inflammatory cell infiltration and the
subsequent release of matrix degrading proteases, mimicking that of human AAA
pathology. Whereas with elastase perfusion, elastase penetrates the vessel wall from the
intima to the media and enzymatically degrades the elastic matrix

20

. The matrix

degradation products then incite inflammatory response and further matrix degradation.
Elastase diffusion through the intima is extremely effective and yields more dramatic
aneurysms. This results in greater diameter expansions and more elastic matrix

48

degradation in a shorter time frame (e.g., 12 hours yields ~30% and 2.5 days yields 300%
aorta diameter increase

21

). Here, elastase is the primary cause of elastic matrix

degradation, although secondary degradation and vessel expansion occurs due to MMP
over-expression by late-stage recruitment of inflammatory cells. There are advantages
and disadvantages to each of these models and they both involve a complex sequence of
biochemical and cellular events that can provide insight into this interesting pathological
outcome and treatments thereof. A notable advantage of peri-advential treatment is the
easy access to arterial segments, minimal mechanical damage to the arterial wall or direct
injury of the vascular endothelium or elastic lamellae, and no systemic or metabolic
changes to blood profile or blood pressure.

2.6.4 Parameters influencing matrix engineering outcomes
There are numerous parameters influencing the outcomes of vascular matrix
engineering techniques including whether the approach is acellular or cellular. In the case
of cellular approaches, cell source, cell signaling, biomaterial selection, mechanical
conditioning, and growth factors influence the success of the strategy greatly. These
parameters are discussed further below.
Acellular approaches utilize biologic scaffold materials that provide a
regenerative tissue matrix, but do not incorporate cells. The biologic scaffold serves as a
mechanical reinforcement for the soft tissues and provides an area for parenchymal cell
ingrowth after implantation. Biologic scaffold materials are discussed in detail below.
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Incorporating cells in a natural or synthetic scaffold is another method being
thoroughly investigated for vascular matrix engineering. Numerous cell sources are being
considered including embryonic stem cells, adult progenitor and stem cells, vascular
endothelial cells, and vascular smooth muscle cells. The cell donor can be the recipient
(autologous), a different animal of the same species (allogenic), or a different species all
together (xenogenic). Cell based therapies have promise as a regenerative strategy, but
continued expansion of biological and biomaterial knowledge is necessary to bring cellbased therapies forward. Key topics being addressed are how cells assemble the
architecture of vascular tissues and what signals guide the molecular assembly.
There are issues that must be kept in mind for cellular approaches, specifically in
clinical studies. First, the manpower, cost, and time associated with harvesting cells,
allowing them to proliferate in vitro for weeks, then implanting them in the recipient, is
large. Second, there is variability that will exist between patients; remodeling that will
take place within a body can be extremely different, depending on the individual. Also,
the therapy, in whatever form it takes, must overcome the disease state of the individual
(e.g., pathophysiological conditions) 145. Finally, if the cells are not autologous, there is a
key issue of immunogenicity 145.
The following sections discuss the many parameters that influence cellular
approaches to vascular elastic matrix engineering including: cell sources, cell signaling,
biomaterials, mechanical stimuli, growth factors, and matrix/substrate impact. Successful
results of approaches that take these parameters into account in their experimental design
are discussed.
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2.6.4.1 Cell sources
The use of autologous cells eliminates the issues involved in immune acceptance,
but has a large time constraint; they cannot be used in emergency scenarios because they
do not have off-the-shelf availability. Autologous cells must be harvested, propagated for
a number of weeks to acquire adequate cell numbers, and returned to the donor. Off-theshelf availability is important because it will make the clinical treatment or therapy
available to the wide population of patients in need145. Alternatively, the use of allogeneic
and xenogenic cells does provide for off-the-shelf availability; however, these cells
require a strategy for immune acceptance. Further issues involve cell isolation and
procurement, expansion, differentiation, and movement to specific sites. The cell lineage
is important as well. Vascular smooth muscle cells (SMCs) are commonly used for
vascular elastin matrix engineering because of the native role of SMCs in elastin
synthesis as discussed previously. Primary cell lines are typically used to encourage
matrix production similar to in vivo.
The goal of cell-based tissue engineering is to encourage tissue regeneration,
regardless of the cell source or lineage. Cells sense soluble factors and their physical
environment including growth factors, cell- substrate (matrix) interactions, and cell-cell
interactions. The key to regenerative medicine is to deliver the correct signals at the right
place and at the ideal time

145

. The ability of cells to perceive and correctly respond to

their microenvironment is the basis of tissue repair and homeostasis and thus is vital to
vascular elastin matrix engineering.
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Cells receive information from their environment through receptors, which are
proteins present on the extracellular membrane. Receptor ligands activate or, in some
cases, inhibit the receptors, which may be hormones, neurotransmitters, cytokines, or
growth factors. The ligand-receptor interactions are fundamental to cell signaling. In
some cases, receptor activation is directly caused by ligand-receptor binding, whereas in
other cases, the activated receptor must first interact with other proteins inside the cell
before the ultimate physiological effect of the ligand on the cell's behavior is produced.
Often, the behavior of a chain of several interacting cell proteins is altered following
receptor activation (signal transduction pathway). Cell biology advancements in cell
signaling pathways will greatly aid bioengineers in designing cell-based therapies.

2.6.4.2 Biomaterials selection
If the key to success of cell-based regenerative medicine approaches are the
signals that are delivered, then “smart” instructive biomaterials 145 are of vital importance
to a successful tissue engineering approach. These can be biologic or synthetic and have
instructive influence on cells due to their chemistry, architecture, and scale of surface
features. Material surface modification or controlled release of biologically active
materials could provide the necessary signals or cues to facilitate cell-mediated tissue
regeneration.
Biologic

scaffold

materials

include

collagen,

elastin,

fibrin,

and

glycosaminoglycans (GAGs). The most popular biopolymer in vascular engineering is
collagen I since it is the most abundant protein in the human body and a major
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component in the ECM wall, making it a natural cell substrate. Bovine collagen I has
been approved by the Food and Drug Administration (FDA)

146

. Scaffolds can be

constructed in the form of a hydrogel within a hollow cylindrical mold and the mild
fabrication conditions allow direct

cellularization by cell

entrapment. Also,

electrospinning techniques can be implemented to obtain scaffolds with controlled
characteristics (e.g., fiber size, porosity). Additionally, pure tubular elastin and pure
collagen scaffolds prepared from porcine carotid arteries have been investigated

147-148

.

Elastin stabilization by tannic acid (TA), a polyphenol capable of protecting elastin from
enzymatic degradation, in conjunction with glutaraldehyde (Glut) treatment has been
shown to increase the stability of fixed aorta against elastin digestion by 15-fold and
decrease calcification in the rat subdermal model by 66%

149

. Biologic scaffolds are a

promising matrix engineering scaffold material.
The most commonly used synthetic degradable polymers are polyglycolic acid
(PGA), poly-L-lactic acid (PLLA), poly-D,L-lactic-co-glycolic acid, and polyurethanes.
PGA and PLLA and its copolymers are biodegradable. Synthetic scaffolds have the
advantages of industrial-scale replication and controllable biochemical and mechanical
qualities including degradation products, degradation time, compliance, tensile strength,
and size. Alteration of the polymers is common. For example, PGA, the most common
synthetic scaffold, is copolymerized to improve its long-term mechanical stability with
other degradable polymers such as poly-L-lactic acid (PLLA)
151

, poly-4-hydroxybutyrate

152

150

, polyhydroxyalkanoate

, polycaprolactone-co-polylactic acid

glycol 154.
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153

and polyethylene

Hybrid vascular grafts have also been created by combination of natural and
synthetic polymers. For example, hybrid vascular prostheses have been developed using
SMCs and collagen reinforced with a knitted, segmented polyester mesh. The grafts have
been successfully seeded with endothelial cells and exhibit similar compliance to native
tissue under pulsatile flow conditions

155

. Table 2.5 illustrates various scaffold materials

and cell type combinations that have been published. The list is not comprehensive, but it
illustrates some of the major advancements over the last 20 years.
Author

Scaffold

Cells

Weinberg & Bell,
19863
L‟Heureux et al.,
1993156

Collagen

Bovine aortic
SMCs
Human umbilical
cord vein SMCs
& ECs
Canine jugular
SMCs & ECs
Human umbilical
vein SMCs &
ECs, human
dermal fibroblasts
Ovine carotid
SMCs, ECs, &
fibroblasts
Bovine aortic
SMCs & ECs
Canine femoral
vein SMCs &
fibroblasts
Human umbilical
cord cells &
human dermal
fibroblasts
Canine autologous
endothelial cells
& smooth muscle
cell

Hiral et al.,
1994157
L‟Heureux et al.,
1998158

Type I &
III
collagen
Type I
collagen
None

Shum-Tim et al.,
1999151

PGAPHA

Nicklason et al.,
1999136
Watanabe et al.,
2001153

PGA

Hoestrup et al.,
2002152

PGAP4HB

Yang et al,
2009159

Allogenic
acellular
carotid
artery
matrix

PGACL/LA

Mechanical
properties
Poor

Implantation
site
Not tested

Poor

Not tested

Poor

Canine posterior
vena cava
Canine femoral
artery

65% at 6
months
50% at 7
days

Good

Ovine infrarenal
aorta

100% at 5
months

Good

Bovine
saphenous artery
Canine inferior
vena cava

100% at 4
weeks
100% at
13 months

Good

Canine femoral
artery

50% at 7
days

Good

Canine carotid
artery

100% at 6
months

Good

Moderate

Patency

Table 2.5 Development and success of various vascular tissue engineered constructs 160.
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Whether investigating natural or synthetic scaffold materials, cellularization is
necessary and can be accomplished by cell infiltration or cell seeding techniques

141

. The

scaffold initially acts as a mechanical support until infiltrating cells are able to produce a
significant amount of ECM to maintain the mechanical stability. For synthetic,
biodegradable scaffolds, the polymer resorption and tissue infiltration should occur at the
same rate. Cellular interaction with the scaffold can be accomplished by incorporating
adhesion ligands or growth factors to these constructs such as RGD peptides

161

, heparin

binding sites 162, and transforming growth factor- beta (TGF-β) 163.

2.6.4.3 Mechanical Conditioning
Mechanical conditioning is another consideration for tissue engineering vascular
grafts. Blood vessels experience shear stress, luminal pressure, radial stretch, and
longitudinal stretch. Table 2.6 outlines shear stress and cyclic strain and their effects on
vascular cells. These forces act independently and synergistically to control the behavior
of vascular tissues 160, 164-165. Bioreactors have been designed to imitate these mechanical
stresses and have been found to increase matrix production and cell and fiber alignment.

2.6.4.4 Growth factors and other biomolecules
As discussed previously in Section 2.3.1, studies have shown that elastic matrix
synthesis is regulated by numerous biochemical factors that may be broadly classified as
elastin synthesis stimulators (e.g., cyclic GMP74, fetal calf serum77, insulin-like growth
factor 1 (IGF-1)78, and transforming growth factor β1 (TGF β)79. Also, studies have
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implicated the ECM proteoglycan versican in mediating increase in cellular tropoelastin
production, as well as in encourage elastic fiber formation 81-82. These growth factors can
be added to the scaffold materials to promote desirable cellular activities. For instance,
TGF β1 has been shown to increase lysyl oxidase enzyme activity and mRNA in rat
aortic SMCs

166

. Also, IGF-1 has been shown to regulate transcription of the elastin

gene78 and stimulate elastin synthesis by bovine pulmonary arterial SMCs 167.
Shear stress mediated EC response
Response
Effect
Morphology
Alignment & elongation
Actin stress fiber
Formation & alignment
DNA synthesis
Stimulated (if turbulent)
Apoptosis
↓
G proteins
Acivation
Tissue plasminogen factor
↑

Endothelin 1
VCAM-1
ICAM-1
Nitric oxide
pH

↓
↓
↑
↑
↓

Tissue
plasminogen
activator
Endothelin 1
VCAM-1

No change

Nitric oxide

↑

↓

Platelet derived
No change
growth factor
Cyclic strain mediated SMC
response

Shear stress mediated SMC response
Morphology
Proliferation
Tissue plasminogen
activator
Nitric oxide
pH

Cyclic strain mediated EC response
Response
Effect

No alignment
↓
↑
↑
↓

Proliferation

↑

Platelet derived
growth factor
MMP 1

↑
↓

Table 2.6 Mechanical forces and their effects on difference vascular cell types 168.
Recent studies have shown benefits of transforming growth factor- β1 (TGF-β) in
matrix regeneration and vessel wall re-building in AAAs. Paracrine secretion of TGF-β
56

by endovascularly seeded SMCs in rat AAAs decreased proteolysis by reducing MMP
expression and up-regulating TIMP-1, 2, and 3 mRNA expression, increased matrix
production (primarily collagen) by various cell types (SMCs, fibroblasts), and enhanced
production of lysyl oxidase, critical for collagen and elastin crosslinking and fiber
organization in situ

13

. Gene therapy techniques have also been used to over-express

TGF-β within already formed AAAs.

Results paralleled those above and also

qualitatively showed improved elastin stabilization, and endoluminal reconstruction,
evidenced by generation of a collagen- and elastin-fiber-rich intimal lamina

14

. Thus,

TGF-β over-expression/availability may be useful to trigger matrix regeneration and
AAA regression. It is important to note that these outcomes are specific to abdominal
AAAs, which differ in cause, etiology, and pathology from thoracic AAs (TAAs). In
TAAs, TGF-β over-expression is thought to be a pathological factor. Thus, TAAs are
treated successfully with TGF- β inhibitors (e.g., losartan) 169.

2.6.4.4.1 Glycosaminoglycans as elastogenic factors
Glycosaminoglycans (GAGs) are negatively charged polysaccharides containing
repeating disaccharides containing uronic acid and hexosamines. Variable elastogenic
effects have been shown by different GAGs, both inhibition (e.g., dermatan and
chondroitin sulfates) of elastic fiber formation

6, 70, 91

and facilitation (e.g., hyaluronan;

HA) of the synthesis and organization of fibrillin microfibrils, the scaffold for elastic
fiber deposition 6. In tissues, GAGs are closely associated with proteoglycans (e.g.,
versican)

69, 83-90

. Specifically, HA‟s intimate binding of versican7 has been suggested to
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play an indirect role in elastogenesis by further interacting with microfibrillar proteins
(fibulin-1, 2) and elastin-associated proteins to form structures important for elastic fiber
assembly 7-10. Evidently, HA brings together soluble tropoelastin monomers, to facilitate
LOX-mediated crosslinking into matrix elastin85, 86, and stabilizes elastin fibers against
degradation by proteases 10-12. Additional details on HA are below.
Originally named hyaluronic acid due to its naturally glassy state and high uronic
acid content, hyaluronan (encompassing the acid and salt forms) is a GAG synthesized as
a large, negatively charged, unbranched polymer, which is composed of repeating
disaccharides of glucuronic acid and N-acetylglucosamine

170

(Figure 2.11) that provides

compressive strength, lubrication, and hydration within the ECM and regulates cell
adhesion and motility and mediates cell proliferation and differentiation171-172. It is
synthesized as an unmodified polysaccharide by transmembrane enzymes, hyaluronan
synthases (HAS1, HAS2 and HAS3) 173, and has extraordinary biophysical properties that
contribute to extracellular matrix structure and interstitial homeostasis. It also influences
cell behavior by binding to cell surface receptors (e.g., CD44 and RHAMM) or through
attachment to a hyaluronan synthase across the plasma membrane

174-175

. It has been

shown in studies of embryonic development, tissue regeneration, and healing that
proliferating and migrating cells are in an environment highly enriched in hyaluronan 174.
In disease processes, such as atherosclerosis and restenosis, altered hyaluronan-cell
interactions causing aberrant cell behavior have also been shown

176

. There is yet to be a

detailed mechanistic understanding of hyaluronan and its influences cell behavior, yet
transduction of signals between hyaluronan and CD44 and RHAMM are of under
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rigorous investigation

177

. Interestingly, RHAMM gene expression has been shown to be

markedly elevated when cells are exposed to TGF-β and there is evidence indicating
growth factor regulation of RHAMM gene expression at least in part involves a
posttranscriptional mechanism 178.

Figure 2.11 Structure of hyaluronan disaccharide unit 179.

HA is known to be involved in many fundamental physiological and pathological
processes (morphogenesis, embryonic development, tissue stability, cell proliferation,
remodeling, migration, differentiation, angiogenesis, and wound healing), yet the
functions appear to be molecular weight dependant. High molecular weight HA
(HMWHA) binds cells and extracellular hyaladherins (proteins capable of binding to
HA) to maintain the structural stability and integrity of tissues with few stimulatory
effects on cells. In contrast, low molecular weight HA, or HA oligomers (HA-o) interact
with cellular receptors resulting in a multitude of cell signaling cascades. In addition, the
large strands of HMWHA are capable of blocking biomolecules from stimulating the cell
while LMWHA allows these biomolecules to influence cells (Figure 2.12).
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HA-o (0.75–10 kDa) are capable of binding to cell surface receptors in a monovalent
manner, therefore communicating directly with cells and influencing their metabolic
functions. This results in the stimulation of specific cell signaling cascades. An example of
such a signaling cascade results in an up-regulation of ECM production and is of interest to
our group. It has been shown, SMCs cultured in the presence of HA-o, have highly upregulated production of ECM, specifically elastin

45

. Recently our group has shown, in the

presence of exogenously supplemented HA-o, there is an increased production of
tropoelastin, desmosine, and crosslinked elastin. In addition, the elastic fibers are laterally
aggregated and larger than those produced by SMCs cultured with HA of higher MW. These
findings encourage further study into the utility of HA-o for elastic matrix tissue engineering
180-181

.

Figure 2.12 Interactions of high MW HA (A) and HA-o (B) with cells 182.
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2.6.4.5 Matrix/ substrate
Cell phenotype and matrix synthesis are affected by the substrate in which they
are grown upon or within. The chemical composition of the substrate, as well as its
geometric properties, plays a role. For example, 2-D substrate monolayers and 3-D
substrates may promote different or exaggerated cell responses. There is evidence that 3D, ECM-based scaffolds are superior to 3-D synthetic scaffolds or 2-D monolayer cell
cultures in their efforts to simulate the chemical and physical environment of tissues
183-184

150,

. Cells within a natural 3-D scaffold exist in a more natural environment in which

they contact other cells and ECM and interact with cell adhesion molecules, growth
factors, and mechanical stimuli similarly to that of native tissues. Integrin-ECM
interactions and cell phenotype are also preserved

150

. Cell phenotype and matrix

synthesis can be greatly affected by the substrate; therefore, selection of scaffold that
facilitates elastogenesis in vivo is important.

2.7 Challenges to elastin matrix regeneration and repair
Tissue engineering elastic matrices to mimic that of healthy vasculature is a
critical challenge. The ability to regulate the amount, quality, ultrastructure and higher
scale organization of the elastin matrix are significant problems. Providing cells suitable
biomechanical and biochemical cues may alleviate these problems, but further
investigation is needed to create an effective tissue engineering approach that replicates
healthy elastin matrix structure.

61

2.7.1 Tropoelastin production
Tropoelastin production is the initial step for producing stable, organized matrix
elastin. As discussed previously, vascular elastin matrix deposition occurs extracellularly
in a process directed by vascular SMCs. First, tropoelastin, the elastin precursor, is
secreted from these cells. The tropoelastin then moves through the extracellular space and
interacts with glycoprotein microfibrils, which guide it to become appropriately aligned
for crosslinking

70

. Numerous studies have shown, adult SMCs do not inherently

regenerate elastin 185-186, therefore stimulation of tropoelastin production is necessary.

2.7.2 Matrix elastin yield
After the tropoelastin is appropriately aligned on the cell membrane, it is released
and crosslinked. The initial step in the crosslinking reaction is mediated by lysyl oxidase
(LOX) 71. Microfibrils serve as a scaffold template for elastin deposition and organization
into fibers; therefore, an abnormality of galactose-containing microfibrils (e.g.,
glycoproteins, galactolipids, and glycosaminoglycans) may impair elastin assembly 70. If
alignment and LOX crosslinking occurs appropriately, elastin molecules are then
connected by formation of desmosine (Des) and isodesmosine (IDes) linkages between
adjacent elastin molecules. Obtaining healthy quantities of crosslinked matrix elastin is a
major goal of vascular elastic matrix engineering.
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2.7.3 Organization of elastin matrix
Matrix elastin content and organization affects vascular biochemistry and
mechanics. For example, studies have led researchers to believe matrix organization
(fibrils) provide topographical and/ or mechanical features that are important
determinants of cell phenotype

68

and ECM production. Cells interact with elastin

through the elastin binding protein (EBP), which binds the tropoelastin

51

. Intracellular

signaling modulates a variety of cellular functions including cell phenotype, secretory
activities, and gene transcription

28

. Therefore, elastic matrix organization into a native,

healthy structure (lamellae) is vital.

2.7.4 Matrix stability
Vascular matrix stability is necessary and is disrupted in many pathologic
vascular conditions. Excessive matrix remodeling occurs in diseased states and is thought
to be the primary cause of the most prevalent vascular pathologies of arteries, including
atherosclerosis and restenosis

94

. In acquired vascular inflammatory diseases (e.g.

atherosclerosis and aneurysms) it can be caused by the release of powerful elastinolytic
proteases released by inflammatory cells or bacteria, matrixmetalloproteinases (MMPs),
or cysteine proteases. Additionally, degradation could be due to genetic vascular
abnormalities, such as those pertaining to elastin or fibrillin, or those in the gene coding
for the in the naturally present elastase inhibitor 1-antitrypsin

95

. Therefore, a vascular

matrix that does not stimulate these elastolytic proteases is necessary and should be
considered as a priority in matrix engineering approaches.
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2.7.5 Delivery of elastogenic factors
In situ sustained delivery of factors is more challenging than that of in vitro
studies in which the therapeutic stimuli can be directly incorporated into culture media
and the exposure dose of the agent to the cells is known throughout the culture period. In
in situ and in vivo models the complex environment may decrease the exposure of the
cells and ECM to the therapeutic agent, so more direct, controlled delivery is necessary.
Systemic injection, peri-adventitial injection, delivery via catheterization and osmotic
pump, and graft delivery are described below.
Sytstemic injection is a method of putting liquid into the body with syringe and
hollow needle, which is pierced through the dermis, then forced into the body. The effect
is not typically local to the area in which the injection is administered. It is systemic.
Therefore, if a therapeutic agent is meant for only a small region of the body (e.g.,
aneurysm site) alternative methods of specific delivery to the target are necessary. Periadventitial injection of factors directly into the adventitia of the vessel is a technique used
to obtain targeted delivery of therapeutics. The agent distributes both longitudinally and
circumferentially at the same rate and penetrates from the adventitia to the intima within
1-2 hours after the delivery 187.
Controlled delivery can be achieved via subdermal osmotic pumps. Osmotic
pumps are miniature, infusion pumps for the continuous dosing of laboratory in situ and
in vivo models. They provide a convenient and reliable method for controlled agent
delivery and typically require no external connections or researcher intervention during
the delivery period. They eliminate the need for frequent animal handling and repetitive
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injection schedules and have proven valuable in predictably sustaining compounds at
therapeutic levels, avoiding potentially toxic or misleading side effects, and ensuring
accurate exposure doses. An assortment of sizes, flow rates and durations is available to
meet a variety of research needs. Osmostic pumps can be used to deliver a variety of
agents. For example, Meyer et al. used the Alzet mini osmotic pump subdermally in the
thoracic region of a rabbit model to deliver an agent continuously and locally to the
carotid artery

188

. The study investigated how the expression of inducible nitric oxide

synthase (iNOS) affected intimal thickening.
Graft delivery is a mode of factor delivery that expands upon the current clinical
endovascular aneurysm repair (EVAR). Factors are incorporated in or coated on a stent
graft that is endovascularly introduced into the vessel; this facilitates slow, localized
release of the factors. Kajimoto et al. demonstrated the release of basic fibroblast growth
factor (bFGF) from a gelatin hydrogel sheet, which was coated on a stent graft

189

. This

biodegradable and biocompatible material was coated on an ePTFE graft that covered a
stainless steel stent. This delivery system was introduced in the canine thoracic aortic
aneurysm model with endoleaks and the ePTFE graft diameter (outer) was doubled to
10% to 20% larger than those of both the proximal and distal landing zones (measured in
preoperative aortography) upon delivery with a balloon catheter. They showed locally
and persistently delivery of bFGF 189. This is a promising mode of delivery.
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CHAPTER THREE
ELASTOGENIC INDUCTIBILITY OF EARLY-STAGE RAT ABDOMINAL AORTIC
ANEURYSM-DERIVED SMCS
3.1 Introduction
In past work, our lab identified and optimized extracellular matrix-derived
biomolecules based on hyaluronan (HA) fragments
IGF-1)

24-25

22-23

and growth factors (TGF-β1,

, for stimulating elastin regeneration by healthy vascular cells. Specifically,

our lab showed that a combination of HA oligomers (HA-o; 4-6 mer; MW ~ 756-1221
Da; 0.2 g/mL) and TGF-β1 (1 ng/mL), referred as elastogenic factors, synergistically
attenuated vascular SMC proliferation and dramatically increased elastin synthesis,
matrix assembly, maturation, and stability. Despite their benefits to elastin synthesis by
healthy adult SMCs, it is yet unknown if these factors will suppress pro-calcific and
elastolytic activities of diseased vascular cells, such as those within AAA segments, and
enable synthesis and assembly of new elastic matrices.
To ascertain this, in this study, we adopted an established abdominal aorta injury
protocol involving application of calcium chloride to induce an expansion/ aneurysm
within rats over 4-weeks

190

.

We then investigated the standalone and combined

elastogenic benefits of TGF- and HA-o factors on SMCs isolated and cultured from
these expanded aortae (aRASMCs), in an in vitro culture model.
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3.2 Materials and methods

3.2.1 Induced aortal injury by calcium chloride application
All animal studies were approved by the IACUC at Clemson University. Adult
Sprague-Dawley rats (300-350 g in weight) were procured and acclimatized for one-week
before surgery. The rats were placed under general anesthesia (2-4% isoflurane) and the
infrarenal abdominal aorta exposed surgically. The aortae were treated using a protocol
adopted by various groups

190-191

(Figure 3.1), wherein sterile cotton gauze presoaked

with 0.5 mol/L CaCl2 was placed on the aorta for 15 min. Sufficient care was taken not
to expose other organs to this caustic treatment. Following treatment, the abdominal
cavity was thoroughly washed with sterile saline to remove the residual CaCl2. The
cavity was then closed, subcutaneously sutured and stapled, and the rats were allowed to
recover. After 28 days in rehabilitation, the animals were humanely euthanized by CO2
asphyxiation. The abdominal aorta was excised and processed for SMCs isolation. The
abdominal aortae were photographed before surgery and after 28 days to compare the
changes in aortic diameter.

Detailed histological/ biochemical analysis of these

expansions was not performed, as prior work by Vyavahare et al.

190, 192

rigorously

characterized the aneurysms induced by this method.

3.2.2 Isolation and culture of aRASMCs
The isolated aortae (n = 3) were opened lengthwise and the intima was scraped
gently with a scalpel blade. The medial layer dissected from the underlying adventia was
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chopped into ~ 0.5 mm-long sections, and washed twice with warm PBS. The resulting
tissue slices were pooled, enzymatically degraded in DMEM-F12 (Invitrogen, Grand
Island, NY) containing 125 U/mg collagenase and 3 U/mg elastase for 30 min at 37C,
centrifuged at 400 g for 5 min, and cultured in T-75 flasks with DMEM-F12 containing
10% fetal bovine serum over 15 days. Aneurysmal rat aortic SMCs (aRASMCs) derived
by outgrowth from these tissue explants were cultured over 2 weeks, and the cells
passaged when confluence was attained. Passage 2 SMCs were then seeded onto 6-well
tissue culture plates (area = 10 cm2) at a seeding density of 2 × 105 cells/well and cultured
in DMEM-F12 medium containing 10% FBS and 1% Penstrep. The total volume of
medium added per well was 5 mL.

Figure 3.1 Procedural diagram of CaCl2 injury to rat abdominal aortae.
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HA-o mixtures supplemented to aRASMC cultures were prepared in-house by
digestion of long-chain HA (MW: 2×106 Da; Genzyme Biosurgery, Cambridge, MA)
with testicular hyaluronidase (Sigma Aldrich, USA), as previously reported23.

The

mixtures contained 75 ± 15% w/w of HA 4-mers (henceforth referred to HA-o), with 6mers and 8-mers forming the balance. The experimental groups were aneurysmal SMCs
cultured with no-additives (controls), and aneurysmal cells cultured with supplements of
HA-o alone, TGF- alone, or TGF-β and HA-o together. TGF- (PeproTech Inc., Rocky
Hill, NJ) was added at a final concentration of 1 ng/mL, while oligomers were added at a
final dose of 0.2 μg/mL. Medium aliquots were replaced twice weekly, and spent media
from each well was pooled and stored at -20 oC. At 21 days, these pooled aliquots from
each well and their corresponding cell layers were biochemically assayed.

3.2.3 DNA assay for cell proliferation
The DNA content of cell layers was quantified at 1 and 21 days of culture to
assess the proliferation of SMCs over the culture period.

Briefly, cell layers were

detached with 0.25% v/v trypsin-EDTA (Invitrogen), pelleted by centrifugation, resuspended in NaCl/ Pi buffer, and assayed using a fluorometric assay193, with the cell
density calculated on the basis of an estimated 6 pg DNA/ cell193.

3.2.4 Hydroxy-proline assay for collagen
A hydroxy-proline assay was used to estimate the collagen content within test and
control cell layers, and in the supernatant medium fraction. As described earlier22, the
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cell layers were homogenized in distilled water after 21-days of culture, pelleted by
centrifugation (10000 g, 10 min) and digested with 1 mL of 0.1 N NaOH (1 h, 98ºC).
The digestate was then centrifuged to isolate a mass of insoluble, crosslinked elastin. The
supernatant containing solubilized collagen and uncrosslinked matrix elastin was
neutralized with an equal volume of 12 N HCl, and divided into two equal volumetric
halves. One half-volume was hydrolyzed at 110°C for 16 h, and dried in a constant
stream of N2 gas overnight and 20 μL aliquots of the reconstituted residue were assayed
for hydroxy-proline content. The total and matrix collagen amounts were then calculated
on the basis of the 13.2% hydroxy-proline content of collagen, and normalized to DNA
content of corresponding cell layers.

3.2.5 Fastin assay for elastin
The amounts of matrix elastin (alkali-soluble and insoluble fractions) and soluble
tropoelastin (in pooled spent medium) were quantified using a Fastin assay (Accurate
Scientific Corp, Westbury, NY), according to manufacturer‟s recommendations. Since
the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was first reduced
to a soluble form by digesting with 0.25 N oxalic acid (1 h, 95°C), and filtering the
pooled digestate in microcentrifuge tubes fitted with low molecular weight cut-off
membranes (10 kDa). The insufficiently crosslinked, soluble elastin fraction retained in
the oxalic acid-free fraction and in the water-reconstituted hydrolysate (from the collagen
assay above) were also quantified using the Fastin assay. Spent fractions of media
pooled at bi-weekly intervals over the 3-week culture period were lyophilized and
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processed for tropoelastin using the Fastin assay. The measured elastin amounts were
normalized to corresponding DNA amounts to provide a reliable basis of comparison
between samples.

3.2.6 Von Kossa staining
After 21 days of culture, aRASMCs were incubated with 1% silver nitrate
solution and placed under UV light for 20 min. After several changes of distilled water,
the unreacted silver was removed with 5% sodium thiosulfate for 5 min, and the cells
were rinsed. The slides were counterstained with hematoxylin. The presence of black
stain confirmed the presence of calcium phosphate deposits.

3.2.7 Desmosine assay for elastin crosslinks
The desmosine crosslink densities within elastin matrices were quantified using
ELISA to determine if any of the provided factors enhanced elastin crosslinking
efficiency 22. The 3-week old cell layers were digested with collagenase (12 h, 37ºC) and
elastase (12 h, 37ºC), the digestates acid-hydrolyzed (6 N HCl, 110ºC, 16 h), and
desmosine content in the reconstituted dried residue determined by ELISA, and compared
to corresponding trends in insoluble matrix elastin.

3.2.8 Lysyl oxidase (LOX) enzyme activity
Spent culture medium pooled over 21 days of culture were assayed for LOX
activity using a flurometric assay (Amplex® Red Assay, Molecular Probes, Eugene, OR)
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based on measurement of H2O2 released when LOX oxidatively deaminates alkyl
monoamines and diamines194. The fluorescence intensities were recorded with excitation
and emission wavelengths at 560 and 590 nm, respectively.

3.2.9 Elastase assay
Elastase activity in the cell cultures was assayed using an EnzChek® Elastase
Assay kit (Molecular Probes, Eugene, OR). Briefly, 50 L of supernatant was mixed
with 50 L of diluted bovine neck ligament elastin, incubated for 30 min incubation at
37ºC, and the fluorescence intensity measured at 485 nm excitation and 510 nm emission
wavelengths. One unit of elastase was defined as the amount of porcine pancreatic
elastase required to solubilize 1 mg of elastin at pH 8.8 and 37ºC.

3.2.10 Western blot analysis for LOX
Western blot analysis was performed to semi-quantitatively assess LOX protein
synthesis, as described earlier25. Briefly, the spent medium from cultures pooled over the
21 day period were lyophilized, assayed for protein content using a DC protein assay kit
(Bio Rad Laboratories, Hercules, CA), to further optimize sample volumes for SDS
PAGE/ western blot. Protein bands were detected with primary rabbit anti-rat polyclonal
antibodies to the 31 kDa active LOX protein (Santa Cruz Biotechnology, Santa Cruz,
CA), and visualized in a Chemi-Imager IS 4400 system (Alpha Innotech, CA).
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3.2.11 Gel zymography for MMP activity
MMP-2, 9 activity was detected in the culture medium by gelatin zymography
methods described elsewhere195. Briefly, aliquots of culture medium were assayed for
protein content using the BCA assay, and all lanes were loaded in triplicate with 15 μg of
protein from each extract alongside with prestained molecular weight standards (Bio Rad
Laboratories). After development and staining, densities of MMP-2 and 9 bands on a
dark background of stained gelatin were measured using Gel Pro Analysis software
(Media Cybernetics, Bethesda, MD), and reported as relative density units (RDU).

3.2.12 Immunoflourescence detection of elastin, fibrillin and LOX
Immunofluorescence techniques were used to confirm the presence of elastin
within the cultured cell layers. aRASMCs were cultured in 4-well sterile chamber slides
under identical conditions at an initial seeding density of 5  103 cells/ well. At 21 days,
the cell layers were fixed with 4 % v/v paraformaldehyde for 10 min, and labeled with a
monoclonal antibody against rat SMC -actin (Abcam Inc, Cambridge, MA; 1:200
dilution; 30 min, 25°C). Elastin and fibrillin were detected with polyclonal antibodies
(Elastin Products Company) as well as LOX (Santa Cruz Biotech) visualized with a
Rhodamine-conjugated donkey anti-rabbit IgG secondary antibody (Abcam Inc.). Cell
nuclei were visualized with the nuclear stain 4, 6-diamino-2--phenylindole
dihydrochloride (DAPI) contained in the mounting medium (Vectashield; Vector Labs,
Burlingame, CA).
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3.2.13 Matrix ultrastructure
Transmission electron microscopy (TEM) was used to characterize the
ultrastructure of matrix elastin. aRASMC layers at 21 days of culture in the absence of
any supplements (controls) and in the presence of TGF- and HA-o factors were fixed
with 2.5% v/v glutaraldehyde, post-fixed in 1% v/v osmium tetroxide (1 h), dehydrated in
graded ethanol, embedded in Epon 812 resin, sectioned, placed on copper grids, stained
with uranyl acetate and lead citrate, and visualized on a Hitachi H7600T TEM.

3.2.14 Statistical analysis
Since experimental data (n = 3/case) was determined to exhibit a near Gaussian
distribution, they were analyzed using Student‟s t-test, assuming unequal variance.
Statistical significance was deemed for p < 0.05. Asterisks in figures denote statistical
significance (p < 0.05) for each group compared with controls (cells in medium alone).

3.3 Results

3.3.1 Aneurysm progression and SMC phenotype
Figures 3.2A and B show representative rat abdominal aortae before and 28 days
after CaCl2 injury. It was observed that an ~45% local increase in aortic diameter was
attained over this period, agreeing with prior observations. Images pre and post-treatment
confirmed increased size of CaCl2 injured aortae relative to those treated with NaCl
(treatment controls). Hematoxylin and eosin and Verhoeff–Van Gieson‟s staining
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indicated that CaCl2 injury caused extensive breakdown of medial elastin, visible as
gaping holes in the elastic lamellae (see arrows); these outcomes were confirmed via IF
labeling of medial elastin (green), which appeared intact in NaCl-treated aortae, but again
exhibited holes within CaCl2-treated aortae (Figure 3.3). As shown in Figures 3.4A and
B, aRASMCs outgrowing from aneurysmal aortic explants initially appeared rounded,
then more spindle-shaped, and thereafter somewhat more spread attaining 50%
confluence by 15 days. In contrast, SMCs isolated from healthy rat aortae exhibited more
spread morphology on day 7 after seeding (Figure 3.4C). The SMC phenotype was
confirmed by staining for SMC α- actin (Figure 3.4D).

Figure 3.2 Representative images of abdominal rat aortae before calcium chloride
(CaCl2) treatment (A) and 28 days post-injury (B), when significant elastin degradation
was observed. The aortae showed a local diameter increase of ~45%.
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Figure 3.3 Histological analysis of rat aortae are shown 28 days post-treatment with
0.5M CaCl2 and 0.5M NaCl (treatment control).The solutions were applied for 15 min,
postadventitially. Hematoxylin and eosin–stained sections of l2-treated aortae showed
extensive breakdown of elastic lamellar structures (see arrows) in the tunica media layer,
in contrast to those within NaCl-treated aortae, which remained intact. These results were
confirmed by comparison of elastin (black structures) within Verhoeff- Van Gieson–
stained sections, and using immunofluorescence (note holes in green fluorescing elastic
lamellae). Von Kossa staining revealed presence of calcific deposits within aortae treated
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with CaCl2, but not NaCl, confirming the induction of an abnormal, disease-like
microenvironment in the former case.

Figure 3.4 Significant rounding of the smooth muscle cells isolated from the aneurysmal
segment (aRASMCs) was observed on day 1 (A) and more spindle-shaped by day 7 (B).
SMCs isolated from healthy aortae showed more spread morphology on day 7 of seeding
(C). The cells were stained with SMC-a actin to confirm the SMC phenotype (D).

3.3.2 aRASMC proliferation and matrix synthesis
Figure 3.5A shows the proliferation ratios of passage 2 aRASMCs cultured in the
presence of TGF- alone, HA-o alone, or both.

Non-additive control aRASMCs

proliferated 2.5 ± 0.32– fold over 21 days. Addition of TGF- to SMC cultures had no
effect on these proliferation ratios (0.97 ± 0.08– fold at 21 days vs. controls; p = 0.56).
However, HA-o supplemented alone or together with TGF- suppressed cell
proliferation ratios significantly, relative to non-additive control aRASMCs (0.81 ± 0.1
and 0.66 ± 0.15 –fold respectively; p = 0.002 and 0.0001).
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Figure 3.5 (A) Proliferation ratios of aRASMC cultures supplemented with HA-o alone,
TGF-β alone, or factors together. Data shown represent mean ± SD of DNA content of
cell layers after 21 days of culture, normalized to initial seeding density, and further
normalized to aRASMC control cultures that received no additives (n = 3/ case). (B)
Effects of HA-o alone, TGF-β alone, and factors together, on total collagen synthesis by
aRASMCs. Data shown (mean ± SD) are normalized to cellular DNA content at 21 days
of culture and represented as fold change in protein production relative to aRASMCs
controls (n = 3/ case). p < 0.05 represents significant differences from controls (*).

When HA-o or TGF- alone were provided to SMCs, significant increase in
collagen synthesis (1.4 ± 0.07 and 1.33 ± 0.05–fold, respectively; Figure 3.5B) was
observed, relative to control cultures (p = 0.008 and 0.005, respectively). Addition of
both the factors furthered collagen synthesis to 1.78 ± 0.18–fold relative to controls (p =
0.008).
As shown in Figure 3.6A, addition of HA-o alone or together with TGF-
promoted tropoelastin synthesis by 1.17 ± 0.02–fold and 1.47 ± 0.05–fold, respectively,
relative to non-additive controls (p = 0.007 and 0.0001 vs. controls, respectively).
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However, addition of TGF- alone had no effect on tropoelastin synthesis (0.94 ± 0.02fold; p = 0.13). Interestingly, collagen and tropoelastin synthesis (779 ± 62 ng/ng DNA
and 3516 ± 149 ng/ng DNA, respectively) observed within additive-free aRASMC
cultures were much lower than that we previously measured within healthy RASMC
cultures of similar passage (22509 ± 668 ng/ng of DNA and 39070 ± 8707 ng/ng DNA,
respectively) 24.
As explained earlier, elastin protein incorporated into the extracellular matrix was
measured as a sum of two individual fractions, i.e., a highly cross-linked, alkali-insoluble
elastin (which represents structural elastin), and an alkali-soluble fraction. As shown in
Figure 3.6B and C, the trends in matrix elastin protein production mirrored those
observed for tropoelastin synthesis under identical conditions. Addition of 0.2 g/mL of
HA-o to aRASMC cultures increased soluble and insoluble matrix elastin synthesis by
1.5 ± 0.11 and 1.23 ± 0.09–fold respectively, relative to that measured in control
aRASMC cultures (157 ± 26 ng/ng DNA and 216 ± 54 ng/ng DNA; p = 0.017 and 0.031,
respectively). However, addition of TGF- (1 ng/mL) alone had no effect on basal
matrix elastin synthesis levels (soluble elastin: p = 0.56, insoluble elastin: p = 0.54). On
the other hand, HA-o and TGF- factors together increased production of soluble and
insoluble matrix elastin fractions by 1.78 ± 0.29 and 1.56 ± 0.34–fold, respectively,
relative to controls (p = 0.014 and 0.026, respectively). Overall, relative to controls, the
total elastin output (sum of tropoelastin and matrix elastin fractions) increased by 1.19 ±
0.03, 0.96 ± 0.03 and 1.49 ± 0.06–fold, respectively, upon addition of HA-oalone, TGF alone, or both the factors together, respectively (Figure 3.6D).
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Figure 3.6 Effects of HA-o alone, TGF-b alone, and both factors together, on
tropoelastin (A), alkali-soluble (B), crosslinked matrix elastin (C), and total elastin (D)
produced by aneurysmal SMCs. Data shown (mean ± SD) are normalized to cellular
DNA content at 21 days of culture and represented as fold change in protein production
relative to aneurysmal controls (n = 3/ case). p < 0.05 represents significant differences
from controls (*).
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3.3.3 LOX protein expression and functional activity
Figure 3.7A compares outcomes of western blot analysis of LOX protein
expression with trends in biochemical quantification of matrix elastin. LOX protein
expression increased significantly in cultures supplemented with TGF- alone or together
with HA-o (1.59 ± 0.05 and 1.72 ± 0.04–fold, relative to controls; p < 0.001 in both the
cases). However, addition of HA-o alone promoted only 1.03 ± 0.14–fold increase in
LOX protein expression relative to controls (p = 0.73). In all the cases, no significant
differences in the cellular LOX activities were observed, relative to non-additive controls
(data not shown).

Figure 3.7 (A) Sodiumdodecyl sulfate (SDS) polyacrylamide gel electrophoresis/
Western blot analysis of tropoelastin and lysyl oxidase (LOX) proteins within the pooled
medium of aRASMC cultures at the end of 21 days. Data shown represent mean ± SD of
three repeats/ case and are shown normalized to controls. (B) Desmosine amounts
measured in test cell layers were normalized to corresponding DNA amounts (ng/ ng),
and further a similar ratio obtained for the healthy nonadditive controls. Comparable
trends were observed for the desmosine/ DNA density and respective insoluble matrix
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elastin/ DNA for selected cases. *Represents significance of differences in values relative
to cultures of healthy additive-free cells, deemed for a p < 0.05.
As shown in Figure 3.7B, aRASMCs, alone or in the presence of HA-o, did not
show any significant increase in desmosine synthesis (0.78 ± 0.01 and 0.92 ± 0.08-fold)
relative to healthy SMC layers (11.85 ± 0.37 pg desmosine/ ng DNA), while TGF-
alone or together with HA-o enhanced the desmosine synthesis by 1.07 ± 0.07–fold and
1.21 ± 0.03–fold, respectively (p = 0.06 and p < 0.001 vs. healthy RASMCs controls).

3.3.4 Activity of proteolytic enzymes
As shown in Figures 3.8A and B, gel zymography analysis revealed that the
MMPs-2 and 9 activity was significantly higher within non-additive aRASMC cultures
relative to healthy cell cultures (1.67 ± 0.16 and 2.07 ± 0.35–fold, respectively; p = 0.03
and 0.01), confirming their activated/ diseased phenotype. Addition of either HA-o or
TGF- alone to aRASMCs did not alter their basal MMP activity levels. However, in the
presence of both HA-o and TGF-, production of MMPs-2 and 9 was marginally lower
than those in aRASMC control cultures (p = 0.08 and 0.03), and not different than those
in healthy SMC cultures (p = 0.67 and 0.71). Similarly, as shown in Figure 3.8C,
elastase activity within additive-free aRASMC cultures was 1.19 ± 0.09–fold higher than
those in healthy SMC cultures (0.23 ± 0.02 U/mL; p = 0.04). Addition of HA-o or TGF supplements to aRASMC cultures also increased elastase activity by 1.29 ± 0.08 and
1.39 ± 0.18–fold, respectively, (p = 0.015 and 0.03), relative to healthy SMC cultures,
though these values are not significantly different from those in control aRASMC
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cultures.

In the presence of both the factors, elastase activity however was almost

identical to additive-free aRASMC cultures (1.01 ± 0.06–fold vs. aRASMC non-additive
cultures; p = 0.82).
Figure 3.8C shows the images of Von Kossa stained aRASMC cultures.
Untreated aRASMC cultures (panel D) exhibited multiple large calcific deposits (black);
supplementing cultures with TGF- alone (panel F) did not alter patterns of matrix
calcification, while addition of HA-o (panel E) appeared to decrease the density of these
deposits. However, the presence of both the factors significantly suppressed formation of
calcific deposits (panel G), though complete inhibition was not observed.

Figure 3.8 Gel zymography analysis revealed the activity of MMP-2 (A) and MMP-9 (B)
within aRASMC cultures treated with or without factors. Data were shown normalized to
the respective values observed in healthy non-additive treatment controls (n = 3/case).
(C) Elastase enzyme activity within aRASMC cultures treated with HA-o alone, TGF-b
alone or together with HA-o. Data are shown normalized to the corresponding values in
healthy non-additive cultures (n = 3/ case). Von Kossa staining images of untreated
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aRASMC cell layers (D) or those treated with TGF-b alone (E), HA-o alone (F), or
factors together (G), and healthy RASMC layers (H). Significant calcific deposits were
evident in control cultures and those treated with TGF-β alone or HA-o alone, while
cultures that received factors together showed a decrease in the calcific mineralization,
almost to levels exhibited in healthy SMC layers. *Indicates significance of differences
relative to healthy, additive-free control cell cultures, deemed for p < 0.05.

3.3.5 Immunodetection of elastin, fibrillin, and LOX in cell layers
Figure 3.9 shows immunofluorescence micrographs of cell layers stained for
elastin, fibrillin, and LOX after aRASMC culture for 21 days with HA-o alone, TGF-
alone or both the factors together.

Non-additive aRASMC cultures and negative

immunolabeling controls (untreated with primary antibodies) are also shown for
comparison. While featureless amorphous elastin deposits were seen in non-additive
aRASMC cultures and TGF--treated cultures, more organized fibrous elastin were
visible in cell layers cultured with either HA-o alone, or together with TGF-.
Fluorescence intensity of elastin matrices within cell layers supplemented with both
TGF- and HA-o was much greater than in the absence of the factors, or either of the
factors alone. Fluorescence intensity due to fibrillin microfibrils was similarly greater in
cultures supplemented with HA-o alone, or together with TGF-, compared to nonadditive aRASMC cultures or those cultured with TGF- alone. The fibrillin appeared
organized into honey-comb-like structures in cultures treated with factors alone or
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together, than in non-additive control cultures. However, in all cases, LOX was rather
faintly expressed and was sparsely distributed.

Figure 3.9 Immunodetection of elastin, fibrillin, and LOX within control aRASMC and
factor supplemented aRASMC layers after 21 days of culture. For each labeled protein,
images of each of the treatment control (no additives) and supplemented layers were
collected under identical image capture settings and were identically brightness/ contrast
enhanced. An average of 15 random locations were imaged on each of the three replicate
cell layers/ case/ set. An increase in matrix elastin, fibrillin, and LOX is evident in
aRASMC cultures that received both TGF-b and HA-o, relative to non-additive
aRASMC cultures (treatment controls). Cultures that received TGF-b alone or HA-o
alone showed relatively less intense fluorescence relative to cultures receiving both
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factors. Lack of fluorescence in cultures untreated with primary antibodies (negative
immunofluorescence controls) confirms lack of nonspecific binding of the fluorophoreconjugated secondary antibody.

3.3.6 Ultrastructure of matrix elastin
Figure 3.10 shows representative transmission electron micrographs of 21-day
cell layers of aRASMCs cultured in absence and presence of elastogenic factors. Similar
to that previously observed in healthy control RASMC cultures

24

, non-additive

aRASMCs also deposited aggregating clumps of amorphous elastin protein that were
overall sparse and rather localized within the cell layers (panels A, B). When TGF-1
and HA-o together were provided to these cultures, mature elastin fiber formation was
favored, with the matrix containing numerous fully-formed bundles (100-200 nm
diameter) of aggregating fibrils (panels C, D). Fibrillin (immunogold particle-stained)
appeared as darkly stained nodules, and was located at the periphery of aggregating
elastin fiber bundles, signifying normal elastic fiber assembly.

Figure 3.10 Representative transmission electron micrographs of 21-day-old aRASMC
layers cultured additive-free aRASMCs layers (treatment control; (A) 50000 X; (B)
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100000 X) and those cultured with both TGF-β and HA-o ((C) 50000 X; (D) 100000 X).
Aggregating amorphous elastin clumps leading to the formation of elastin fibers can be
clearly seen in aneurysmal cell cultures treated with the factors (C, D), while aRASMC
cultures that received no additives (A, B) showed amorphous elastin deposits with sparse
fiber formation. In all cultures, immunogold labeling showed presence of fibrillin
microfibrils (black dots), indicative of normal mechanisms of elastic matrix assembly.

3.4 Discussion
The long-term goal of this project is to develop technologies to enhance elastic
matrix regeneration within AAAs, to stabilize and even possibly regress their growth,
thus eliminating the need for surgical intervention.

This is specifically challenging

because elastin turnover is slow, and minimal remodeling of elastin fibers occurs in
adults 196. Our elastogenic factors are novel in stimulating elastin regeneration and repair
in vitro, which raises the possibility that they may also have a future in vivo role as a
stand alone or combination therapy for AAAs.
Rats, which we have chosen to investigate as a model for elastic matrix
regeneration, are widely used to study AAAs 197-198. Among the several models available
to induce AAAs are genetic manipulation (deficiencies in LOX, TIMP-1, LDL-receptor,
etc) and surgical/chemical induction (intraluminal elastase infusion and peri-adventitial
injury with CaCl2) 191, 199. In particular, peri-adventitial injury of the abdominal aorta with
CaCl2 has been shown to induce several characteristics of human AAAs, such as medial
layer disruption, inflammation, matrix calcification, thrombus formation18, and enhanced
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MMP activity at the site of application 190, 192 associated with significant and progressive
local aortic dilation within 4 weeks200. Since cells isolated from diseased and healthy
tissues can be propagated in culture, limitations to tissue procurement do not restrict
rigorous evaluation of parameters that influence cell phenotype and matrix regenerative
potential in each case; further, the standalone effects of each of these parameters on the
outcome of interest can be isolated. However, conditions of culture do not mimic the
arterial conditions of cyclic stress, pressure, and interaction with circulating blood, nor
with any paracrine effects of neighboring tissues, including the intima or adventitia.
However, although a 2-D cell culture model may not replicate the physiologic 3-D matrix
microenvironment, it is nevertheless valuable to study biochemical regulation of cell
phenotype by supplemented biomolecules.
Though the CaCl2-injury-derived rat aortic SMCs (aRASMCs) isolated from our
rat aortal expansions expressed smooth muscle -actin confirming a SMC-phenotype, a
significant number amongst them exhibited decreased volume/ spreading especially in the
first 10-days after seeding, which was different from the spread morphology observed in
healthy RASMC cultures.

Such differences in phenotype between healthy and

aneurysmal vascular SMCs have also been reported by others

201

. In general, these

aRASMCs generated greater amounts of MMPs and elastases than did healthy control
RASMCs, and promoted deposition of a greater number of calcific deposits than in
healthy RASMC cultures, suggesting an activated phenotype.

Interestingly, the

aRASMCs proliferated more slowly than healthy RASMCs 24 over the 21 day period (33
± 4 % of healthy RASMCs; p < 0.001), produced far less tropoelastin (9 ± 0.3 % of
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healthy RASMCs; p < 0.001), collagen (3.4 ± 0.5 % of healthy SMCs; p < 0.001) and
matrix elastin (11 ± 2 % of healthy RASMCs; p < 0.001) than did healthy control
RASMCs24. These results were supported by a significant decrease in the production of
elastin crosslinking proteins (LOX and desmosine), as gauged from our biochemical
analysis, and a visible decrease in elastin matrix density within these cultures relative to
healthy RASMC controls

24

. Overall, these observations point to the activated state of

these isolated „aneurysmal‟ aRASMCs when cultured in vitro.
In our recent studies exploring the elastogenic benefits of HA-o (0.2 g/mL) to
elastin synthesis by RASMCs

24

, we found tropoelastin synthesis to be modestly

enhanced (48.5 ± 23%), while elastin yield was increased multi-fold (2.57 ± 0.3-fold vs.
non-additive healthy RASMC cultures), though matrix elastin synthesis on a per cell
basis remained unchanged. In this study, addition of HA-o alone (0.2 g/mL) suppressed
aRASMC proliferation, promoted tropoelastin and insoluble matrix elastin synthesis (~
1.2–fold), and increased collagen and soluble matrix elastin synthesis (~ 1.5-fold).
However, the elastin matrix yield remained similar to that in non-additive aRASMC
cultures (10.8 ± 0.8 vs. 9.6 ± 2.1 %), which might be due to the lack of any significant,
parallel increase in desmosine and LOX protein content within these cultures.
Interestingly, the production of the MMPs-2 and 9 and the levels of elastase activity and
matrix calcification in these cultures remained similar to that within additive-free
(control) aRASMC cultures, and significantly higher than that within additive-free
healthy RASMC cultures. In contrast to factor benefits of deposition of a fibrillar rather
than amorphous elastin matrix deposition by healthy RASMCs
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23

, HA-o alone provided

no particular advantage to the quality of elastin matrix deposited by aRASMCs, since the
elastin matrix was still largely non-fibrillar (not shown).

These results lead us to

speculate that much higher doses of HA-o may be necessary to stimulate aRASMCs to
enhance elastogenesis and elastin fiber deposition, in a similar manner as that of healthy
RASMCs, which respond HA-o at low doses (0.2 g/mL).
Though in a previous study, we found TGF-1 ng/mL) to significantly
suppress healthy SMC proliferation and increase synthesis of matrix elastin (~2.5-fold)
and collagen (~1.3-fold) 24, the same dose of TGF- had no effect on aRASMC cultures,
except for collagen synthesis (~ 1.3-fold). Also, TGF- had no impact on elastin yield
within aRASMC cultures (11.2 ± 1.8% vs. 9.6 ± 2.1% in additive-free aRASMC; p =
0.72), although the same dose of TGF- enhanced elastin matrix yield in healthy
RASMC cultures.

The lack of elastogenic impact of TGF- on aRASMCs when

provided at doses optimized for healthy RASMCs, similar to that with HA-o, suggests
attenuated sensitivity of aRASMCs to these factors and thus the necessity to likely
increase and re-optimize doses of these factors to up-regulate elastogenesis by these
diseased cell types. Nevertheless, attenuated TGF--induced elastic matrix effects on
aRASMC cultures also appear to directly correlate with increases in production of
MMPs-2 and 9 and elastase activity, and greater distribution of non-fibrillar elastin,
suggesting higher elastolytic activity within these cultures. Thus, the presence of either
HA-o or TGF- alone could be inciting increased elastolytic activity within aRASMC
cultures to rapidly generate soluble elastin peptides, and thereby discouraging
accumulation of crosslinked matrix elastin.
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When aRASMCs were exposed to both TGF- and HA-o factors, their impact
on aRASMCs differed from that on healthy RASMCs.

The factors suppressed

proliferation of aRASMCs, though not as severely as they did healthy SMCs

24

. The

suppression in proliferation of aRASMCs has vital implications in deterring hyperproliferation of these activated cell types when factors are delivered to an intact AAA
site. Again, in both aRASMC and RASMC cultures, the factors enhanced tropo- and
matrix elastin synthesis and that of collagen matrix, although the level of increase in
aRASMC cultures was far less compared to the healthy RASMC cultures. Previously,
we showed that the factors improved elastin matrix yields in healthy RASMC cultures,
quite possibly by increasing LOX protein synthesis and desmosine content

24

. Based on

these outcomes, we expected similar improvements in elastin matrix yields within
aRASMCs cultures that received these factors, which was not the case (10.7 ± 2.1% yield
with factors vs. 9.6 ± 2.1% for additive-free aRASMC cultures) despite measured
increases in production of the elastin crosslinking enzyme, LOX, and desmosine.
Relative to healthy RASMC cultures, the lack of net increase in matrix yield may not be
due to the lack of factor-derived benefits of recruitment and crosslinking of tropoelastin
precursors, but rather due to innately enhanced elastolytic activity within aRASMCs
cultures.

Regardless, on a positive note, these elastogenic factors reduced matrix

calcification and MMP activity by aRASMCs, results that were not observed when either
of these factors alone was provided to the aRASMCs.
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3.5 Conclusions
1. Calcium chloride-treatment was successful in inducing expansions in the abdominal
aorta of a rat within 4 weeks (~45% diameter increase). The model yielded medial
layer disruption, inflammation, matrix calcification, and enhanced MMP activity.

2. aRASMCs isolated from the medial portion of the expansions had SMC phenotype,
yet they exhibited significant rounding within the first few days of culture and an
increase released MMP-2 and 9 activity, relative to healthy RASMCs.

3.

Compared to healthy RASMCs, aRASMCs proliferated less and produced less
collagen, tropoelastin, and matrix elastin. The protein synthesis within aRASMC
cultures was not up-regulated by adding either HA-o or TGF-β alone.

4. Relative to control aRASMC cultures, concurrent delivery of the factors resulted in
slight suppression of proliferation, significant increases of LOX, desmosine, collagen,
tropo- and matrix elastin production by aRASMCs, and reduced calcification and
MMP activity, which was not achieved by the presence of either factor alone.

5.

The factors significantly promoted crosslinking and deposition of matrix elastin, as
evident from immunofluorescence and ultrastructural analysis, yet optimization of the
factor doses is necessary to maximize the elastogenic inductibility of aRASMCs.
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CHAPTER FOUR
EVALUATION OF ELASTIC MATRIX REGENERATION BY EARLY-STAGE RAT
ANEURYSM-DERIVED SMCS AS A SURROGATE FOR HUMAN AAA SMCS

4.1 Introduction
In chapter three, we observed that the elastogenic factors provided at doses
optimized for healthy cells (2 μg/ml HA-o and 1 ng/ml TGF-β) were effective in
stimulating elastogenesis by SMCs derived from CaCl2-induced rat AAAs (aRASMCs)
19

. This study provided preliminary evidence that such SMCs continue to exhibit a

diseased/ activated phenotype in culture and that they can be elastogenically stimulated,
though factor doses must be re-optimized (likely increased) separately for diseased cell
types since induced elastic matrix amounts were still an order of magnitude lower than
that by healthy RASMCs. This is addressed in the present study.
While demonstration of the therapeutic efficacy of biomolecular factors in
animal models of disease must necessarily precede testing in human subjects, it is vital to
ascertain that outcomes with the surrogate model/ cell type parallel outcomes in humans.
In this study, we thus compare dose-specific elastogenic effects of HA-o and TGF-β in
cultures of SMCs, isolated from CaCl2-induced rat AAAs and SMCs isolated from a
biopsied atherosclerotic human AAA tissue (aHASMCs). The study results will help
ascertain the validity of studying aRASMCs from CaCl2-injured aortae as a surrogate for
aHASMCs in the context of stimulating elastin regeneration, and for developing stand
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alone or combination therapies with existing surgical or pharmacological approaches to
regenerate elastic matrices within AAAs.

4.2 Materials and methods

4.2.1 Aortal injury by peri-adventitial application of CaCl2
All animal studies were approved by the IACUC at the Medical University of SC.
Adult Sprague-Dawley rats (250-300 g in weight) were procured and acclimatized for
one-week before surgery. The rats were placed under general anesthesia (2-3% v/v
isoflurane) and the infrarenal abdominal aortae exposed surgically. The aortae were
treated using a protocol adopted by various groups

190-191

, wherein sterile cotton gauze

pre-soaked with 0.5 mol/L CaCl2 was placed peri-adventitially on the aorta for 15 min.
Sufficient care was taken not to caustically injure surrounding organs. The abdominal
cavity was then thoroughly washed with sterile saline to remove the residual CaCl 2, the
cavity closed, subcutaneously sutured and stapled, and the rats allowed to recover. After
28 days in rehabilitation, the animals were humanely euthanized by CO 2 asphyxiation.
The expanded infrarenal abdominal aortae were then excised and processed for isolation
of SMCs. The abdominal aortae were photographed before surgery and at 28 days to
compare the changes in aortic diameter.

Detailed histological analysis and MMP

release/activity within these expansions confirmed they were representative of early-stage
AAAs, as observed in our earlier report 19.
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To verify medial disruption and thinning, and calcific deposition within the aortic
wall of CaCl2-treated animals, standard hemotoxylin and eosin staining (H & E; for
nuclear and intracellular and extracellular protein visualization), modified Verhoff Van
Gieson staining (VVG; for elastin visualization; ScyTek Laboratories, Logan, UT), Von
Kossa staining (for calcific depostion; ScyTek Laboratories, Logan, UT), and scanning
electron microscopy (SEM; for aortic cross-section ultrastructural visualization) were
conducted on no treatment control and CaCl2-treated aortae (n = 3 animals/ group).
Aortae from respective animals harvested at 28 days post-op (or at a time-matched stage
for un-operated control animals) were rinsed in sterile saline, embedded in optimum
cutting temperature (OCT) medium, and stored at -20 °C until cryosectioning. Sections
(5µm) were processed for histology or SEM. Standard histological protocols were
followed. For SEM, samples were fixed in 2% v/v gluteraldehyde in phosphate buffer,
rinsed in phosphate buffer, DI water, then dehydrated in graded ethanol and finally
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min). The histological and SEM
samples were imaged on an Olympus BX41 (Olympus, Center Valley, PA) and a Hitachi
SEM TM1000 (Hitachi Technologies, Pleasanton, CA), respectively, and are shown in
Figure 4.1.

4.2.2 Isolation and culture of aRASMC and aHASMC
Expanded aortae isolated from adult, male Sprague Dawely rats (n = 3) subject to
caustic aortal injury with CaCl2 were opened lengthwise, and the intima was scraped off
gently with a scalpel blade.

The medial layer was dissected from the underlying
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adventitia, chopped into ~ 0.5 mm-long sections, and washed twice with warm
phosphate-buffered saline (PBS). The tissue slices were then pooled, enzymatically
degraded in DMEM-F12 (Invitrogen, Grand Island, NY) containing 125 U/mg
collagenase (Worthington, Biochemicals Lakewood, NJ) and 3 U/mg elastase
(Worthington Biochemicals) for 30 min at 37C, centrifuged (1400 RPM; 5 min), and
cultured in T-75 flasks with DMEM-F12 containing 10% v/v (PAA Laboratories,
Etobicoke, Ontario) fetal bovine serum over 15 days. Primary aneurysmal rat aortic
SMCs (aRASMCs) derived by outgrowth from these tissue explants were cultured for up
to 2 weeks, and the cells passaged when confluence was attained. Passage 3 SMCs were
then seeded onto 6-well tissue culture plates (growth area of 9.6 cm2) at a seeding density
of 2 × 104 cells/well and cultured in DMEM-F12 medium containing 10% v/v FBS and
1% v/v penstrep (South Logan, UT). The total volume of medium per well was 5 mL.
Waste human AAA tissue, generated during open AAA repair (Figure 4.3B),
was procured with IRB approval at the Medical University of South Carolina (HR#
18387, 07/2008). The tissue source was a 6 cm diameter AAA from a 62 year old male
patient with hypertension, coronary disease, and hyperlipidemia. The tissue was collected
from the anterior wall of the aneurysm near the origin of the inferior mesenteric artery; it
had significant thrombus formation. After explanting the aneurysmal tissue, the AAA
was successfully repaired in a standard fashion. To isolate primary aHASMCs, the 4 x 1cm-sized aortic tissue explant was opened lengthwise, the intima scraped with a scalpel
blade, the medial layer dissected from the adventitia, then chopped it into ~ 0.5 mm-long
sections. Subsequently, the pieces were rinsed with sterile phosphate buffered saline
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(PBS), pooled, and enzymatically degraded in DMEM-F12 medium (Invitrogen)
containing 357 U/mg collagenase (Worthington Biochemicals) and 4.5 U/mg elastase
(Worthington Biochemicals) over 45 min, at 37 C. The digestate was centrifuged (1400
RPM; 5 min) and the tissue segments then re-constituted, and cultured for up to 6 weeks
in 6-well plates with minimal volumes of DMEM-F12 medium containing 10% v/v FBS
(PAA Laboratories). Primary aneurysmal human aortic SMCs (aHASMCs), derived by
outgrowth from these tissue explants, were cultured until confluence was attained, and
then passaged. Passage 3 aHASMCs were then seeded onto 6-well tissue culture plates
(growth area of 9.6 cm2) at a density of 2 Χ 104 cells/well and cultured in DMEM-F12
supplemented with 5% v/v FBS, 1% v/v penstrep, 5 μg/ml human insulin (Sigma, St.
Louis, MO), 2 ng/ml of human recombinant fibroblast growth factor (huFGF) (Peprotech,
Rocky Hill, NJ), and 0.5 ng/ml of human recombinant epidermal growth factor (huEGF)
(Assay Design, Ann Arbor, MI). Passage-matched healthy human aortic SMCs derived
from the tunica media of a healthy and fibrous plaque-free aorta of a 48 year old
Caucasian male (HASMCs; Cell Applications, San Diego, CA) were also cultured under
identical conditions.

4.2.3 Experimental design and time points
Passage 3 aRASMCs, aHASMCs, and healthy HASMCs were cultured in media
supplemented with elastogenic factors (0-20 μg/ml HA-o and 0-10 ng/ml TGF-β) within
6-well plates (2 × 104 cells/9.6 cm2) for 21 days, over which time the cells deposited a
robust matrix. Spent medium aliquots were removed from each well, at the time of each,
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twice-weekly medium change, were pooled with previously removed aliquots, frozen at –
20˚C, then biochemically assayed together with their corresponding cell layers when
harvested at 21 days of culture.

4.2.4 DNA assay for cell proliferation
The DNA contents of each group of cell cultures were compared to determine the
impact of the factors and factor doses on SMC proliferation. For analysis, the cell layers
were harvested at 21 days of culture, resuspended in NaCl-Pi buffer, sonicated on ice,
and their respective DNA contents quantified using a fluorometric assay described by
Labarca and Paigen202. Cell counts were then calculated assuming 6 pg of DNA/cell202.

4.2.5 Immunoflourescence detection of SMC phenotypic markers
Immunofluorescence techniques were used to visualize contractile and synthetic
phenotypic markers of both human and rat aortic SMCs. SMCs were cultured in sterile,
2-well Permanox® chamber slides (4.2 cm2/ well; Nalge Nunc International, Rochester,
NY) under identical experimental conditions as described for cultures intended for
biochemical analysis, though the cell seeding density and treatment doses were adjusted,
to account for the reduced substrate surface area and cell number, respectively. Cell
layers were fixed with acetone for 10 minutes at -20 °C and blocked with 5% v/v goat
serum (30 min). α smooth muscle actin, SM22α, calponin, and caldesmon (contractile
phenotype markers), and thrombospondin and osteopontin (synthetic phenotype markers)
were then detected with polyclonal antibodies against rat antigens (1:100 v/v; Abcam,
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Cambridge, MA), which show cross-reactivity with human antigens, and visualized with
FITC-conjugated IgG secondary antibodies (1:1000 v/v; Chemicon, Temecula, CA). The
cell layers were cover-slipped with Vectashield mounting medium containing the nuclear
dye 4',6-diamidino-2-phenylindole (DAPI; Vector Laboratories, Burlingame, CA), which
labeled the cell nuclei.

4.2.6 Flow cytometry
Flow cytometry analysis of the SMCs (Passage 4) was performed. Cells were
trypsinized, centrifuged (1500 RPM; 10 min), reconstituted at 1 Χ 106 cells per sample,
fixed with 4% w/v paraformaldehyde in PBS (37 °C; 10 min), washed, then
permeabilized with 0.1% v/v Triton X-100 in PBS for 1 min. The immunoflourescence
detection of SMC phenotypic markers was conducted with the antibodies outlined above.
The samples were blocked (30 min; 4 °C), then incubated with primary antibodies (30
min; 4 °C), followed by a FITC-conjugated secondary antibody (20 min; 4 °C; in the
dark). After labeling, cells were resuspended in 0.5 ml of PBS and kept at 4 °C protected
from light until analysis. Cytometric analysis was performed using a Becton Dickinson
FACSCalibur Analytical Flow Cytometer and data were processed using Cell Quest Pro
5.2 (BD Biosciences, Franklin Lakes, NJ).

4.2.7 Fastin assay for elastin
The Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY)
was used to quantify the total amount of elastin deposited within cell layers (matrix
elastin), and that released into the culture medium as a soluble precursor (tropoelastin).
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For each treatment group, tropoelastin in the spent medium was collected and pooled
over the culture period and frozen at -20 ˚C. To isolate matrix elastin following either 21
days the cell layers were trypsinized, then scraped off, re-suspended in NaCl/Pi buffer,
and centrifuged (2500 RPM, 10 min). The cell pellet was digested with 0.1 N NaOH (98
˚C, 1 h), and centrifuged to yield a less crosslinked, alkali-soluble supernatant fraction
(soluble elastin), and a mature, highly crosslinked, insoluble pellet (insoluble elastin).
Since the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was
converted to a soluble form prior to quantification. To do this, the insoluble elastin pellet
was dried, solubilized with 0.25 M oxalic acid (95 ˚C, 1 h), and the pooled digests then
centrifuge-filtered (3000 RPM, 10 min) in microcentrifuge tubes fitted with low
molecular weight (10 kDa) cut-off membranes (Millipore, Bedford, MA). All three
elastin fractions (tropoelastin, and soluble and insoluble matrix elastin) were quantified
using the Fastin assay.

4.2.8 Von Kossa staining
Van Kossa staining was used to visualize calcific deposition by the aneurysmal
SMCs. SMCs were cultured in sterile, 2-well Permanox® chamber slides (Nalge Nunc
International, Rochester, NY) under identical experimental conditions as described for
cultures meant for biochemical analysis, though the cell seeding density and treatment
doses were adjusted, to account for reduced the substrate surface area and cell number,
respectively. After 21 days of culture, SMCs were incubated with 1% w/v silver nitrate
solution and placed under UV light (λ= 254 nm; 20 min). After several changes of
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distilled water, the un-reacted silver was removed by rinsing cells with 5% w/v sodium
thiosulfate for 5 min, then PBS. The slides were counterstained with hematoxylin. The
appearance of black stained masses in the cell layers confirmed the presence of calcium
phosphate deposits.

4.2.9 Gel zymography
Matrix metalloprotease (MMP) activity was detected from the cell culture
medium by gelatin zymography methods described elsewhere19. Briefly, aliquots of
culture medium were assayed for protein content using the BCA assay, and all lanes were
loaded in multiplicate with equal amounts of protein. A pre-stained molecular weight
standard (BioRad, Hercules, CA) and MMP-2 and 9 standards (Anaspec, San Jose, CA)
were loaded alongside. After development, staining, and destaining, bands from the
various MMP-2 and 9 isoforms appeared on a dark background of stained gelatin and
were measured using ImageJ software (NIH, Bethesda, MD), and quantified as relative
density units (RDU).

4.2.10 MMP array
To assess the MMPs and tissue inhibitors of MMPs (TIMPs) released by
aHASMCs as compared to aHASMCs treated with an optimal dose of elastogenic
factors, an MMP array was used. Proteins from factor-supplemented and non-factor
supplemented aHASMC cultures were extracted in a RIPA buffer (Thermo Scientific,
Waltham, MA), centrifuged (2500 RPM, 5 min), and the supernatant analyzed using an
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ELISA-based MMP antibody array (RayBiotech, Norcross GA). The array identified
MMPs-1, 2, 3, 9, 10, 13 and tissue inhibitors of MMPs (TIMPs)-1, 2, 4. The
manufacturer‟s protocol was followed and the array was imaged on the UVP EC3
BioImaging System (Upland, CA). An MMP array is not commercially available for rat
tissues/ cells, and was thus not conducted for those cell types.

4.2.11 SEM of elastic matrix
Scanning electron microscopy (SEM) was used to visualize elastic matrix
architecture. Spent medium was removed from atop cell layers after 21 days of culture.
The cell layers were rinsed with PBS, and fixed with 4% w/v paraformaldehyde in 0.1 M
phosphate buffer (4 ˚C, 15 min). After fixation, the cell layers were rinsed several times
with 0.1M phosphate buffer, then submersed in 25% w/v KOH (60 ˚C, 5 min) to remove
cellular and ECM debris and yield relatively pure, matrix elastin structures. Following a
phosphate buffer rinse, the isolated elastic structures were then treated with 1% w/v
tannic acid (1 h) and stained with osmium tetroxide (1 h), then dehydrated successively in
graded ethanol (70-100% v/v; 1 min each) and finally hexamethyldisilazane (Sigma
Aldrich, St. Louis, MO) (3 min), under a fume hood. The samples were finally mounted
on aluminum stubs and imaged using a Hitachi SEM TM1000 (Hitachi Technologies,
Pleasanton, CA).
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4.2.12 TEM of elastic matrix
Transmission electron microscopy (TEM) was used to characterize the
ultrastructure of the elastic matrix. At 21 days post seeding, all control and test groups
were fixed with 2% w/v cacodylate glutaraldehyde (12 h), post-fixed in 1% w/v osmium
tetroxide (1 h), dehydrated in a graded ethanol series (50-100% v/v), embedded in Epon
812 resin, sectioned, placed on copper grids, stained with uranyl acetate and lead citrate,
and visualized on a Hitachi TEM H7600T (High Technologies, Pleasanton, CA).

4.2.13 Statistical analysis
The experimental data (n = 3/case) was analyzed using Student‟s t-test. Statistical
significance was deemed for p < 0.05. Asterisks in figures denote statistical significance
(p < 0.05) for each group compared with controls (cells in medium alone).

4.3 Results

4.3.1 Aneurysm progression and SMC phenotype
An ~45% local increase in rat aortic diameter representing early aneurysm
expansion, was attained over a 28 day period following peri-adventitial CaCl2 exposure,
agreeing with our prior observations19.

Detailed histological analysis demonstrated

significant medial thinning, elastic matrix disruption, matrix calcification, and
involvement of inflammatory cells in the etiology of the expansion (Figure 4.1), similar
to our previous publication19. aRASMCs derived from CaCl2-injured aortae appeared to
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comprise a mixed cellular population with a significant number amongst them exhibiting
decreased volume/ spreading. Expression of α-actin, SM-22, caldesmon, and calponin
was reduced compared to healthy RASMCs, as illustrated in Figures 4.2A and 4.2B
suggesting a loss of contractile phenotype. The aRASMCs also exhibited increased
expression of osteopontin, a marker indicative of a switch to a synthetic phenotype,
which SMCs typically express in response to injury.

Figure 4.1 Representative SEM (50 X and 500 X magnification) and histological
micrographs (VVG, H&E, and Von Kossa; 20 X magnification) of CaCl2-treated aortae
(B) as compared to control NaCl-treated aortae (A).
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Figure 4.2 (A) Immunofluorescence images of RASMC and aRASMC phenotypic
marker expression. (B) Flow cytometry data of RASMC and aRASMC phenotypic
marker expression (total intensity of marker expression per 100 cells). (C) aRASMC
count following 21 days of culture with or without HA-o and TGF-β factor
supplementation (n = 3/case). * indicates P < 0.05. § indicates p < 0.05 as compared to
other specified conditions.

aHASMCs derived from atherosclerotic human AAA (Figure 4.3A) tissue
initially appeared less spread and more spindle-shaped relative to healthy human aortic
SMCs (Figure 3B), although no differences were noted at confluence. Compared to
healthy HASMCs, aHASMCs exhibited decreased SM22, caldesmon, and calponin
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expression indicating a loss of contractile phenotype and increased expression of
osteopontin suggesting assumption of a synthetic phenotype, as illustrated in Figures
4.3C and 4.3D.

Figure 4.3 (A) Phase contrast images of primary HASMCs 1 and 21 days post seeding.
(B) Phase contrast images of primary aHASMCs 1, 4 14, 21, and 28 days post seeding.
(C) Immunofluorescence images of HASMC and aHASMC phenotypic marker
expression. (D) Flow cytometry data of HASMC and aHASMC phenotypic marker
expression (total intensity of marker expression per 100 cells). (E) aHASMC count

106

following 21 days of culture with or without HA-o and TGF- factor supplementation (n
= 3/case). * indicates p < 0.05.

4.3.2 aRASMC and aHASMC proliferation
The aRASMC count following culture with variable doses of TGF-and-is
shown inFigure 4.2C. Over 21 days of culture, non-supplemented control aRASMCs
proliferated 2.5-fold relative to healthy RASMCs19. Addition of TGF- and HA-o had no
significant effects on aRASMC proliferation except at a dose of 2 µg/ml HA-o and 10
ng/ml TGF- which increased proliferation was noted (p = 0.002). At higher doses of
HA-o (20 µg/ml), attenuation of cell proliferationwas observedwith increasing TGF-
dose; there was significant decrease in cell count as compared to the control at the highest
provided TGF-dose (10 ng/ml TGF- p = 0.01) and a significant difference between
the cell counts at lowest and highest TGF-doses (1 and 10 ng/ml TGF-p = 0.023).
Figure 4.3E shows the count of aHASMCs cultured with variable doses of TGFand-over 21 days. Addition of TGF- and HA-o to aHASMC cultures again,
had no statistically significant effects on cell proliferation.

4.3.3 Matrix synthesis
As shown in Figure 4.4A, most dose combinations of HA-o and TGF-had no
effect on tropoelastin production by aRASMCs; at the highest dose of 20 µg/ml HA-o
and 10 ng/ml TGF-a significant increase in tropoelastin production by aRASMCs was
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seen (p = 0.043). Matrix elastin synthesis at this provided dose was also increased, but
was not deemed significant from a statistical standpoint. As seen in Figures 4.4A and
4.4B, when HA-o and TGF- were provided to aRASMCs at a moderate dose of 2 µg/ml
HA-o and 10 ng/ml TGF-, no increase in tropoelastin production over controls was
measured, though a significant increase in matrix elastin (including both highly crosslinked, alkali-insoluble structural elastin and an alkali-soluble fraction) was observed,
relative to control cultures (p = 0.016). The matrix yield (percentage of total elastin in
the matrix form, normalized to DNA) increased significantly from 1.39% (control) to
3.39% (2 µg/ml HA-o and 10 ng/ml TGF- p = 0.032).
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Figure 4.4 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and
matrix elastin (B) produced by aRASMCs. Data shown are normalized to cellular DNA
content at 21 days of culture (n = 3/case). * indicates P < 0.05; § indicates p < 0.05 as
compared to other specified conditions. (C-F) Tropoelastin and matrix elastin production
trends (based on mean values) associated with increased in HA-o or TGF-.

Figure 4.5 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and
matrix elastin (B) produced by aHASMCs. Data shown are normalized to cellular DNA
content at 21 days of culture (n = 3/case). * indicates p < 0.05: § indicates p < 0.05 as
compared to other specified conditions. (C-F) Tropoelastin and matrix elastin production
trends (based on mean values) associated with increased in HA-o or TGF-.
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There were significant increases in tropoelastin production by aHASMCs (Figure
4.5A) at doses of 2 µg/ml HA-o and 5 ng/ml TGF-and higher, in general, relative to
control cultures (p < 0.01 in all cases). At these higher dose combinations, a significant
increase in matrix elastin production was observed, relative to unsupplemented aHASMC
cultures (Figure 4.5B; p < 0.02 in all cases). The matrix yield enhanced from 0.19%
(control) to 0.31% (2 µg/ml HA-o and 5 ng/ml TGF- p = 0.039).

4.3.4 Ultrastructure of matrix elastin
Figures 4.6 (low magnification) and 4.7 (high magnification) are representative
transmission electron micrographs (TEM) of aRASMC layers following 21 days of
culture in the absence and presence of elastogenic factors. Similar to that previously
observed in healthy cultures of RASMCs, untreated control aRASMCs deposited
aggregating clumps of amorphous elastin protein that were overall sparse and rather
localized within the cell layers (panel A). When TGF-1 and HA-o together were
provided to these cultures, mature elastin fiber formation was favored, with the matrix
containing numerous fully-formed bundles (100-200 nm in diameter) of aggregating
fibrils (panel B). Fibrillin (immunogold particle-stained) appeared as darkly stained
nodules, and was located at the periphery of aggregating elastin fiber bundles, signifying
normal elastic fiber assembly.
In the case of human SMC cultures, the rather slow proliferation of healthy
HASMCs deterred their retention as an intact cell layer when subject to processing for
TEM. In the absence of control cell layers for evaluating factor-treated cell layers, these
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results have been omitted from this manuscript; comparison has instead been made using
SEM alone.

Figure 4.6 Representative TEM images of 21-day old aRASMC cultures with (B) or
without (A) HA-o and TGF- factor supplementation (7300 X magnification; scale bar =
2 µm). Black arrows indicate elastic matrix.

Figure 4.7 Representative TEM images of 21-day old aRASMC cultures with (B) or
without (A) HA-o and TGF- factor supplementation (30,000 X magnification; scale bar
= 500 nm). White arrows indicate fibrillar elastic structures.
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Representative scanning electron micrographs of elastic matrices isolated from 21
day cultures of treated and no-additive control rat and human aneurysmal SMCs are
shown (Figures 4.8 and 4.9, respectively). Enhanced cellular deposition of crosslinked
elastic fibers relative to control cultures was observed.

Figure 4.8 Representative SEM images of elastic matrix produced by 21-day old
aRASMC cultures with (B) or without (A) HA-o and TGF- factor supplementation
(1,000X magnification; scale bar = 20 µm). White arrows indicate fibrillar elastic
structures.

Figure 4.9 Representative SEM images of elastic matrix produced by 21-day old
aHASMC cultures with or without HA-o and TGF- factor supplementation (1,000X
magnification; scale bar = 20 µm). White arrows indicate fibrillar elastic structures.
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4. 3.5 Von Kossa staining
Calcific deposits were minimal or absent in all of the culture groups (aRASMC,
aRASMC +factors, aHASMCs, aHASMCs +factors) following 21 days of culture
indicating there was no/ minimal calcific deposition due to uptake of Ca2+ from culture
medium or the exogenous supplementation TGF-β.

4.3.6 Proteolytic enzyme activity
We previously showed a significant increase in MMP-2 and 9 activity in untreated
aRASMC cultures relative to healthy RASMC cultures (1.67-fold and 2.07-fold,
respectively; p = 0.03 and 0.01)19, confirming their activated phenotype. As shown in
Figure 4.10 gelatin zymography run in triplicate on spent medium samples derived from
aRASMC cultures supplemented with factors (2 μg/ml HA-o, 10 ng/ml TGF-β) revealed
decreased MMP-2 activity (22% decrease in MMP-2) and MMP-9 activity (4% decrease
in MMP-9) as compared to untreated control aRASMCs.

Figure 4.10 (A) Gel zymography analysis revealed the activity of MMP-2 and MMP-9
(numerous isoforms/ many bands) within aRASMC cultures treated with or without HA113

o and TGF- factor supplementation. (B) Data are shown normalized to the respective
values observed in non-supplemented aRASMC controls (n = 3/case). The factor dose
assessed was 2 µg/ml HA-o and 10 ng/ml TGF-

Figure 4.11 Gel zymography (C) revealed the activity of MMP-2 and MMP-9
(numerous isoforms/ many bands) released by aHASMCs as compared to HASMCs (A)
and the activity of MMP-2 and MMP-9 within aHASMC cultures treated with or without
HA-o and TGF- factor supplementation (B). Data are shown normalized to the
respective controls (n = 3/case). (D) MMP array revealed MMPs (MMPs-1, 2, 3, 9, 10,
and 13) and TIMPs (TIMPs- 1,2,4) released by aHASMC cultures with or without HA-o
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and TGF- factor supplementation. The factor dose assessed was 2 µg/ml HA-o and 5
ng/ml TGF-

4.4 Discussion
The CaCl2-injury model is frequently used for accelerated study of human AAA
pathology. The model has been shown to induce several characteristics of human AAAs,
such as medial layer disruption, inflammation, matrix calcification, thrombus
formation18, and enhanced MMP activity at the site of application

190, 192

significant and progressive local aortic dilation within 4 weeks200.

associated with
Despite the

similarities human AAAs, in the context of investigating elastic matrix regeneration and
induction of the same by human AAA-derived SMCs, the utility of the CaCl2-injury
model in rats remains unproven. From the standpoint of assessing the efficacy of our
elastin regenerative factors for AAA treatment in animal models of disease, it is vital to
ascertain that observations with the surrogate model/cell type parallel observations in
humans. Therefore, in this study we compared the elastogenic potential of cultured SMCs
from CaCl2-induced model of rat AAAs (aRASMCs) and from a biopsied atherosclerotic
human AAA tissue (aHASMCs) to evaluate the rodent disease cell culture model as an
appropriate surrogate.
In this study, at 4 weeks post-injury, CaCl2-treated rat abdominal aortae generated
many of the characteristic findings typical of human AAAs, such as medial elastic matrix
disruption, medial thinning, calcification, increased MMP activity, and an approximate
45% increase in aortic diameter, which is within the range reported by others
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.

Although, we refer to these dilatations of the aortic wall as induced-AAAs throughout
this paper, we acknowledge that they may be different pathological processes.
Differences in phenotype between healthy and aneurysmal vascular SMCs have
been reported by others

201

. As found in those studies, we also observed that aRASMCs

derived from CaCl2-injured aortae exhibited decreased volume/spreading and SM22,
caldesmon, and calponin expression as compared to healthy RASMCs (Figures 4.2A and
4.2B). SM22, a protein found extensively in adult SMCs, is implicated in restricting
phenotypic changes from a contractile to a synthetic phenotype

203

; it is homologous to

calponin and can be functionally compensated by calponin in maintenance of SMC
homeostasis

204-205

. Caldesmon plays a key role in SMC contraction by binding to acto-

myosin contractile units like actin, tropomyosin, myosin and calmodulin
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and may

have a regulatory role in the contractile apparatus; it has been reported to inhibit the
Mg2+-ATP-ase activity and hence inhibit smooth muscle contractility
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. Calponin binds

with actin light chains depending on the presence of Ca2+ thereby regulating the
contractile apparatus of SMC‟s

208-209

; due to this binding, it has also shown to inhibit

actin-activated Mg2+-ATP-ase activity in-vitro

210

. Together, a decrease in expression of

these markers signifies a loss of contractile SMC phenotype. In addition, the aRASMCs
also exhibited increased expression of osteopontin, a multi-functional pro-inflammatory
cytokine implicated with vascular disease and enhanced inflammatory response
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;

osteopontin has been shown to induce chemotaxis of macrophages and monocytes, which
stimulates calcification
deterioration

213

212

and enhances MMP activity, thereby promoting vascular wall

. In tandem with these alterations phenotypic marker expression, the
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aRASMCs exhibited enhanced MMP and elastase activity over healthy control RASMCs,
suggesting an activated phenotype19.
A comparison of the effects of the factors on aRASMCs and aHASMCs revealed
that HA-o and TGF-β1 together had only a limited impact on proliferation of either of
these cell types, which in general proliferated more rapidly than their healthy
counterparts. In aRASMC cultures, unlike in healthy RASMC cultures, low dose
combinations of HA-o (< 2 μg/ml) and TGF-β (< 5 ng/ml) together had no effect on
tropoelastin and matrix elastin production. This agrees well with our prior findings that
diseased SMCs require higher doses of these factors for elastogenic stimulation. Also
apparent from our results, are that HA-o and TGF-β1 in general, appear to more
sensitively influence the elastin crosslinking/ matrix assembly machinery than cellular
tropoelastin synthesis, which is increased only at the highest dose combination. At the
factor doses assessed in this study, effects of TGF-β on tropoelastin production by
aRASMCs were dependent on the concentration of HA-o. At low HA-o doses (2 μg/ml),
increased doses of TGF-β (1-10 ng/ml) decreased tropoelastin production, whereas at
high HA-o doses (20 μg/ml), increased doses of TGF-β increased tropoelastin production
(Figure 4.4D). For a given dose of HA-o to aRASMCs, increased doses of TGF-β
resulted in an increase in matrix elastin production (Figure 4F). At the higher doses of
TGF-β, there was minimal effect of HA-o on matrix elastin production (see convergence
of trend curves in Figure 4.4F). These trends are also clearly apparent in Figure 4.4E,
where dose increases in HA-o most significantly enhance elastic matrix synthesis at the
lowest TGF-β dose and least at the highest tested TGF-β dose. The results with
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aRASMCs suggest that (a) the predominant effects of HA-o lie in the enhancement of
elastic matrix deposition rather than improvement of tropoelastin production, which
corroborates inferences from our prior studies

214-215

, (b) the effects of HA-o on matrix

elastin production are most pronounced at lower tested TGF-β doses, indicating that at
the highest tested TGF-β dose, TGF-β effects dominate over that due to HA-o and (c)
increase in tropoelastin and matrix elastin synthesis with increasing TGF-β dose are more
pronounced at higher HA-o doses.
Similar to aRASMCs, cultured aHASMCs demonstrated a loss of contractile
phenotype relative to healthy HASMCs, but exhibited a marginal increase in expression
of markers typical of injured/activated SMCs (e.g., osteopontin; Figures 4.3C and 4.3D).
These cells were also similar to aRASMCs in that they proliferated much faster than their
healthy counterparts and that exposure to HA-o and TGF-β at any tested dose
combination did not impact cell proliferation. Overall, these results show that SMCs
obtained by passaging primary cell isolates from both CaCl2-injury generated rat AAAs
and human AAAs maintain an activated phenotype in culture and demonstrate
morphological and phenotypic similarities.
The aHASMCs showed similarities to aRASMCs in their matrix synthesis
responses to the provided factors, specifically in that tropoelastin and matrix elastin
synthesis was only enhanced at the higher dose combinations, and no effects were seen at
the lowest doses. However, two important differences are worthy of notice. The first is
that the minimal dose(s) for significant elastogenic up-regulation, particularly for
tropoelastin, of aHASMCs (2 µg/ml HA-o; 5 ng/ml TGF-β) is far lower than that
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determined for aRASMCs (20 µg/ml HA-o; 10 ng/ml TGF-β). The second is that at the
respective doses that induce maximal elastogenicity, the increases in tropoelastin and
matrix elastin was far greater in the aHASMC cultures (5.08-fold increase in tropoelastin/
DNA vs. 8.4 -fold increase in matrix elastin/ DNA at 2 µg/ml HA-o; 5 ng/ml TGF-β)
than for aRASMCs (16% decrease in tropoelastin vs. 2.15-fold increase in matrix elastin
at 2 µg/ml HA-o; 10 ng/ml TGF-β). Both these observations strongly suggest that the
intracellular signaling mechanisms that form the basis for downstream outcomes of
increased elastin precursor and matrix synthesis in aHASMCs are more sensitive to cell
interaction with HA-o and TGF-β than in the case of aRASMCs. This is suggested from
the trend curves which show elastin synthesis to have much stronger HA-o dose
dependency in aHASMC cultures (at a given TGF-β dose) than in aRASMC cultures,
especially at the lowest TGF-β doses (Figures 4.5C and 4.5E). It is also noteworthy that
at the lowest HA-o dose, TGF-β effects on elastic matrix deposition dominate, as deemed
from the classic biphasic TGF-β-dose response, with an initial increase in tropo/ matrix
synthesis with TGF-β dose, and a sharp decrease when TGF-β dose is increased still
further; such a biphasic response to TGF-β was not observed in aRASMC cultures, at
least within the tested dose range (Figures 4.5D and 4.5F). Our results also suggest that
the provided factors encourage elastic fiber organization in aHASMC cultures similar to
aRASMC cultures, in a manner similar to that observed in healthy cells (Figures 4.8 and
4.9).
At the factor dose combinations deemed most elastogenic, absolute elastic matrix
amounts in aRASMC and aHASMC cultures were 149% and 57% of the elastic matrix
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amounts generated by their respective healthy cultures (with no factor supplementation),
respectively. This reveals that although elastic matrix yield is enhanced significantly, that
additional elastogenic stimulation of human aneurysmal cells, particularly, may be
necessary to coax the elastogenic capacity to level at least that of healthy SMCs. There is
a strong potential for increasing matrix elastin further. Future studies to address this
challenge may incorporate combination therapies that would increase elastin crosslinking
into mature matrix (e.g., exogenous supplementation of lysyl oxidase (LOX) to initiate
covalent crosslinking of elastin precursors
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or copper nanoparticles to increase LOX-

mediated elastin crosslinking machinery to enhance matrix yield and maturation, as we
have previously demonstrated 217-218).
Similar to aRASMCs, which we showed in a prior publication to demonstrate
enhanced MMP-2 and 9 activity relative to healthy RASMCs
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, cultured aHASMCs

exhibited higher activity of elastolytic MMP-2 (but not MMP-9) relative to healthy
HASMCs confirming their activated phenotype. However, HA-o and TGF-β factors,
provided at the „most effective‟ doses identified for the respective cell types, had very
different effects on MMP activity in aRASMC and aHASMC cultures; the factors
attenuated MMP-2 (minimal change in MMP-9) activity in aRASMC cultures (Figure
10), but enhanced the same in aHASMC cultures (Figures 4.11B and 4.11C), although in
the latter the factors induced an across-the-board decrease in concentration of elastogenic
(MMP-2 and 9) and other MMPs relative to non-supplemented aHASMC cultures
(Figures 4.11D and 4.11E).
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4.5 Conclusions
1. The peri-adventitial CaCl2-injury model of AAAs exhibits the pathological
characteristics of human AAAs, including similarities in terms of decreased
contractile activity, enhanced proliferation, and reduced elastogenic capacity (relative
to healthy SMCs) when isolated and expanded in culture, the model differs from
human AAAs in cellular responses to elastogenic stimulation.

2. aRASMCs appear to be less sensitive to TGF-β and HA-o relative to aHASMCs in
the context of elastin regenerative responses, though trends are maintained. At the
respective doses that induced maximal elastogenicity, the increases in tropoelastin
and matrix elastin was far greater in the aHASMC cultures (5-fold increase in
tropoelastin/ DNA vs. 8-fold increase in matrix elastin/ DNA at 2 µg/ml HA-o; 5
ng/ml TGF-β) than for aRASMCs (16% decrease in tropoelastin vs. 2-fold increase in
matrix elastin at 2 µg/ml HA-o; 10 ng/ml TGF-β).

3.

Concurrent delivery of factors attenuated elastolytic MMP-2 activity in aRASMCs
(as shown previously). Interestingly, no significant decrease was seen in aHASMC
cultures, yet an overall decrease in MMP and TIMP expression was seen with factor
supplementation.

4.

Differences in cell responses may likely be due to differences in the stage in
maturation of the AAAs studied, with the CaCl2-injury induced aortal expansion
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barely qualifying as an aneurysm and the human AAA at pre-rupture stage. We also
acknowledge that aHASMCs were isolated from AAA tissue from a single patient,
and thus may not adequately represent phenotypic diversity of aHASMCs.

5. Further study of SMCs from stage-matched CaCl2-injury generated aortal expansions
and human AAAs will be necessary to more rigorously evaluate their basal and
induced elastogenic responses.

6. The CaCl2-injury model of AAAs exhibits distinctive short-comings as a surrogate in
the context of elastin regeneration within human AAAs; alternate models, such as an
elastase-perfusion model of AAAs, require similar investigation as to their suitability
for this role.
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CHAPTER FIVE
EVALUATIION OF ADVANCED RAT AAA- DERIVED SMCS FOR
ELASTOGENIC POTENTIAL
5.1 Introduction
In the previous chapter, we presented our observations on the dose-specific effects
of the factors (0-20 μg/ml HA-o and 0-10 ng/ml TGF-β) on elastogenesis by SMCs
derived from CaCl2-induced rat aortal expansions (aRASMCs)
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, which are

representative of early stage inflammatory human AAAs; we showed aRASMCs to
maintain a diseased/activated phenotype in culture and that they are amenable to
elastogenic stimulation, though much greater factor doses were required for these
diseased cell types than that by healthy RASMCs. However, it is also important to
recognize that AAAs are frequently diagnosed at relatively advanced stages of maturation
when matrix deterioration is severe. From the standpoint of a clinically applicable
paradigm for AAA regression, we must assess elastogenic up-regulation of SMCs derived
from late-stage AAAs (>100% diameter expansion). This is the subject of the present
study.

5.2 Materials and methods

5.2.1 Induction of aortal injury via elastase perfusion
All animal studies were approved by the IACUC at the Medical University of SC
and conformed to AVM stipulations for humane care of animals. Adult male Sprague-
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Dawley rats (250-300 g in weight) were acclimatized for one-week before surgery. The
rats were placed under general anesthesia (2-4% v/v isoflurane) and the infrarenal
abdominal aortae surgically exposed, and injured via elastase perfusion, using a
published method adapted for our purposes
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. The posterior lumbar aortic branches

and the inferior mesenteric arteries were ligated with 9-0 suture (Surgical Specialties
Corp., Reading, PA) if they were within the area of interest.

The aortae were

circumferentially dissected at the proximal and distal ends to allow placement of vascular
clamps (Fine Science Tools, Foster City, CA) and distal silk ties. The aortic diameters
were measured using an eyepiece micrometer fitted on a stereoscope (Olympus SZ61,
Olympus, Center Valley, PA). The proximal and distal microclips placed at the renal
junctions and iliac junctions, and small aortotomies made using the tip of a 271/2-guage
needle. PE-10 catheters (Scientific Commodities Inc., Lake Havasu City, AZ) were
inserted into the vessel lumen and the distal silk ties tightened to hold these intraluminal
catheters in place.

The aortae were slowly perfused with elastase (20 U/ml; 25 min)

until the aortal section between the clamps ballooned to 200% of the original diameter as
measured by the eyepiece micrometer. Following perfusion, the distal ties were released,
the catheter tubing removed, the aortotomies closed with 9-0 suture, and the proximal and
distal clamps removed (Figure 5.1). Following confirmation of re-perfusion to the lower
limbs, and collection of post-perfusion measurements, the intestines were replaced and
the incision sites closed in two layers with 4-0 Vicryl suture and 4-0 Ethilon suture
(Ethicon, New Brunswick, NJ).

The rats were then placed on a heat pad until they

became alert, indicating recovery from anesthesia, at which time, 80 µl of Buprenex®
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analgesic (0.03 mg/ml; Buprenorphine) was injected subcutaneously. The animals were
monitored for a few days with administration of Buprenex every 12 hours if necessary.
The aneurysmal aorta was harvested at 14 days post-op.

Figure 5.1 Elastase perfusion (20 U/ml; 25 min) procedural images. (A) Abdominal aorta
prepared for catheterization with clamps on the proximal and distal aorta and a silk tie in
place, yet loose, to secure the catheter upon placement. (B) Abdominal aorta with a PE10 catheter introduced in the lumen. (C) Secured catheter and perfused aorta. (D) Closure
and repurfusion of the aorta.
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5.2.2 Histological and biochemical characterization of aortal expansions
Diameter expansion measurements were conducted on aortae pre- and postperfusion and 14 days post-op (n = 12) from photographs taken at the respective time
points and analyzed via Image J software (NIH, Bethesda, MD). Histological and
biochemical analysis of these expansions was performed. Standard hemotoxylin and
eosin staining (H & E; for nuclear and intracellular and extracellular protein
visualization), modified Verhoff Van Gieson staining (VVG; for elastin visualization;
ScyTek Laboratories, Logan, UT), and scanning electron microscopy (SEM; for
ultrastructural visualization aortic cross-sections) were conducted on untreated control
aortae, sham (saline-perfused) aortae, and elastase-perfused aortae (n = 3 animals/ group).
Aortae from respective animals were harvested 14 days post-op (or at a time-matched
stage for un-operated control animals), rinsed in sterile saline, embedded in optimum
cutting temperature (OCT) medium, and stored at -20 °C until cryosectioning. Sections
(5µm) were processed for histology or SEM. Standard histological protocols were
followed. For SEM, samples were fixed in 2% v/v gluteraldehyde in phosphate buffer,
rinsed in phosphate buffer, DI water, then dehydrated in graded ethanol and finally
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min), under a fume hood. The
histological and SEM samples were imaged on an Olympus BX41 (Olympus, Center
Valley, PA) and a Hitachi SEM TM1000 (Hitachi Technologies, Pleasanton, CA),
respectively.
MMP activity within elastase-perfused aortae was assessed by gelatin
zymography methods 19 and compared to healthy rat aortae (n = 3/ group). Briefly, aortic
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tissue was homogenized in RIPA buffer and then assayed for protein content using the
BCA assay (Thermo Scientific, Waltham, MA). All lanes were loaded in multiplicate
with 25µg of protein in each lane. A pre-stained molecular weight standard (Invitrogen,
Grand Island, NY) was loaded alongside. After development, staining, and destaining,
densities of MMP-2 and 9 bands on a dark background of stained gelatin were quantified
using ImageJ software (NIH, Bethesda, MD), and reported as relative density units
(RDU).

5.2.3 Isolation and culture of EaRASMC
Expanded abdominal aortae segments from adult, male Sprague Dawely rats (n =
3), 14 days post perfusion with elastase, were opened lengthwise and the intima scraped
gently with a scalpel blade.

The medial layer was dissected from the underlying

adventia, chopped into ~ 0.5 mm-long sections, and washed twice with warm phosphatebuffered saline (PBS). The tissue slices were then pooled, enzymatically degraded in
DMEM-F12 (Invitrogen, Grand Island, NY) containing 125 U/mg collagenase
(Worthington, Biochemicals Lakewood, NJ) and 3 U/mg elastase (Worthington
Biochemicals) for 30 min at 37 C, centrifuged (400 g; 5 min), and cultured in T-75
flasks with DMEM-F12 containing 10% v/v fetal bovine serum (PAA Laboratories,
Etobicoke, Ontario) over 15 days. Primary aneurysmal rat aortic SMCs (EaRASMCs)
derived by outgrowth from these tissue explants were cultured over 2 weeks, and the cells
passaged when confluence was attained. For experiments, passage 2 SMCs were seeded
onto 6-well tissue culture plates (Area = 10 cm2) at a seeding density of 2 × 104 cells/well
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and cultured in DMEM-F12 medium containing 10% v/v FBS and 1% v/v Penstrep
(South Logan, UT). The total volume of medium added per well was 5 mL.

5.2.4 Experimental design and time points
Passage 3 EaRASMCs were cultured in medium containing supplemented factors
(0, 0.2, and 20 μg/ml HA-o and 1, 5, and 10 ng/ml TGF-β; n = 6/ condition) within 6-well
plates (2 × 104 cells/ 9.6 cm2) for 21 days, over which time the cells deposited a robust
matrix. Spent medium aliquots were removed from each well, at the time of each, twiceweekly medium change, pooled with previously removed aliquots, frozen at –20 ˚C, then
biochemically assayed together with their corresponding cell layers when harvested at 21
days of culture.

5.2.5 DNA assay for cell proliferation
The DNA contents of the cell cultures groups were compared to determine the
impact of the factors and factor doses on SMC proliferation. For analysis, the cell layers
were harvested at 21 days of culture, resuspended in NaCl-Pi buffer, sonicated on ice,
and their respective DNA contents quantified using a fluorometric assay described by
Labarca and Paigen202. Actual cell counts were then calculated assuming 6 pg of
DNA/cell202.
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5.2.6 Immunoflourescence detection of SMC phenotypic markers
Immunofluorescence techniques were used to visualize SMC contractile and
synthetic phenotypic markers. RASMCs and EaRASMCs (n = 3/marker/cell type) were
cultured in sterile, 2-well Permanox® chamber slides (Nalge Nunc International,
Rochester, NY) under identical experimental conditions as described for cultures
intended for biochemical analysis, though the cell seeding density and treatment doses
were adjusted, to account for the reduced substrate surface area and cell number,
respectively. Cell layers were fixed with acetone for 10 minutes at -20 °C and blocked
with 5% v/v goat serum (30 min). α smooth muscle actin, SM22α, calponin, and
caldesmon (contractile phenotype markers), and thrombospondin and osteopontin
(synthetic phenotype markers) were then detected with polyclonal antibodies against rat
antigens (1:100 v/v; Abcam, Cambridge, MA), which show cross-reactivity with human
antigens and visualized with FITC-conjugated IgG secondary antibodies (1:1000 v/v;
Chemicon, Temecula, CA). The cell layers were cover-slipped with Vectashield
mounting medium containing the nuclear dye 4',6-diamidino-2-phenylindole (DAPI;
Vector Laboratories, Burlingame, CA), which labeled the cell nuclei.

5.2.7 Flow cytometry
Flow cytometry analysis of the SMCs (Passage 4) was performed. Cells were
trypsinized, centrifuged (1500 RPM; 10 min), reconstituted at 1 Χ 106 cells per sample,
fixed with 4% w/v paraformaldehyde in PBS (37 °C; 10 min), washed, then
permeabilized with 0.1% Triton X-100 in PBS for 1 min. The immunoflourescence
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detection of SMC phenotypic markers was conducted with the antibodies outlined above.
The samples were incubated with primary antibodies (30 min; 4 °C), followed by a FITCconjugated secondary antibody (20 min; 4 °C; dark). After labeling, cells were
resuspended in 0.5 ml of PBS and kept at 4 °C protected from light until analysis.
Cytometric analysis was done using a Becton Dickinson FACSCalibur Analytical Flow
Cytometer and data were processed using Cell Quest Pro 5.2 (BD Biosciences, Franklin
Lakes, NJ).

5.2.8 Fastin assay for elastin
A Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY)
was used to quantify the total amount of elastin deposited within cell layers (matrix
elastin), and that released into the culture medium as a soluble precursor (tropoelastin).
For each treatment group, tropoelastin in the spent medium was collected and pooled
over the culture period and frozen at -20 ˚C. To isolate matrix elastin following either 21
days the cell layers were trypsinized, then scraped off, re-suspended in NaCl/ Pi buffer,
and centrifuged (2500 RPM, 10 min). The cell pellet was digested with 0.1 N NaOH (98
˚C, 1 h), and centrifuged to yield a less crosslinked, alkali-soluble supernatant fraction
(soluble elastin), and a mature, highly crosslinked, insoluble pellet (insoluble elastin).
Since the Fastin assay quantifies only soluble α-elastin, the insoluble elastin was first
converted to a soluble form prior to quantification. To do this, the insoluble elastin pellet
was dried, solubilized with 0.25 M oxalic acid (95 ˚C, 1 h), and the pooled digests then
centrifuge-filtered (3000 RPM, 10 min) in microcentrifuge tubes fitted with low
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molecular weight (10 kDa) cut-off membranes (Millipore, Bedford, MA). All three
elastin fractions (tropoelastin, and soluble and insoluble matrix elastin) were quantified
using the Fastin assay.

5.2.9 Von Kossa staining
Van Kossa staining was used to visualize calcific deposition by the aneurysmal
SMCs. SMCs (n = 2/ condition) were cultured in sterile, 2-well Permanox® chamber
slides (Nalge Nunc International, Rochester, NY) under identical experimental conditions
as described for cultures meant for biochemical analysis, though the cell seeding density
and treatment doses were adjusted to account for reduced the substrate surface area and
cell number, respectively. After 21 days of culture, the SMCs were incubated with 1%
w/v silver nitrate solution and placed under UV light (λ = 254 nm; 20 min). After several
changes of distilled water, the un-reacted silver was removed by rinsing cells with 5%
w/v sodium thiosulfate for 5 min, then PBS.

The slides were counterstained with

hematoxylin. The appearance of black stained masses in the cell layers confirmed the
presence of calcium phosphate deposits.

5.2.10 Gel zymography
Activity of MMPs-2 and 9 were detected in the culture medium by gelatin
zymography methods. Briefly, aliquots of culture medium were assayed for protein
content using the BCA assay, and all lanes were loaded in multiplicate with equal
amounts of protein in each lane. A pre-stained molecular weight standard (BioRad,
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Hercules, CA) and MMP-2 and 9 standards (Anaspec, San Jose, CA) were loaded
alongside. After development, staining, and destaining, densities of MMP-2 and 9 bands
on a dark background of stained gelatin were quantified using ImageJ software (NIH,
Bethesda, MD), and reported as relative density units (RDU).

5.2.11 TEM of elastic matrix
Transmission electron microscopy (TEM) was used to characterize the
ultrastructure of the elastic matrix. At the 21 days post seeding, all control and test
groups outlined in Table 1 were fixed with 2% w/v cacodylate glutaraldehyde (12 h),
post-fixed in 1% w/v osmium tetroxide (1 h), dehydrated in a graded ethanol series (50100% v/v), embedded in Epon 812 resin, sectioned, placed on copper grids, stained with
uranyl acetate and lead citrate, and visualized on a Hitachi TEM H7600T (High
Technologies, Pleasanton, CA).

5.2.12 Statistical analysis
The biochemical data were analyzed using Student‟s t-test.

Statistical

significance was deemed for p < 0.05. Asterisks in figures denote statistical significance
(p < 0.05) for each group compared with controls (cells in medium alone).

5.2.13 DNA microarray
To assess differences in gene expression patterns between healthy, untreated
RASMCs, elastase perfusion-derived EaRASMCs, and EaRASMCs cultured with
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elastogenic factor supplements (2 µg/ml HA-o and 5 ng/ml TGF-β), DNA microarray
analysis was conducted using an adaptation of a published method
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. Primary, passage

3 SMCs (derived from 3 different animals/ culture condition and passaged separately)
were cultured for 7 days under the conditions specified above. Total RNA was prepared
from cell layer samples by RLT buffer extraction followed by purification using RNeasy
columns (Qiagen, Valencia, CA). Quality and purity of the RNA preparations were
assessed by spectrophotometric determination of the ratio of absorbance at 260/280 nm
and by quantification of 28S:18S ribosomal RNA ratios using a Bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA).
Synthesis of double-stranded cDNA, in vitro transcription of biotin-labeled cRNA
targets, and fragmentation of target cRNA were performed as outlined by Affymetrix
protocols (Affymetrix, Santa Clara, CA). Fragmented cRNA samples were hybridized
overnight at 45 °C to Affymetrix Rat Expression 230 2.0 GeneChips. Post-hybridization
washing and phycoerythrin-streptavidin staining and fluorescence scanning were
performed using Affymetrix instrumentation in accordance with manufacturer protocols.
Gene hybridization intensities were normalized using Robust Multichip Average
implemented with Affymetrix Expression Console. Normalized hybridization values
were compared using dChip 2009 software or the Significance Analysis of Microarray
Addin for Microsoft Excel. Genes differentially expressed in response to elastase
perfusion injury or supplementation of HA-o and TGF-β factors were identified using
both statistical and fold change thresholds. Gene functional categories were assigned
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following review of gene ontology annotations as well as functional information
available through NCBI Entrez Gene.

5.3 Results

5.3.1 Aneurysm progression and SMC phenotype
A local increase in rat aortic diameter (~122%), typical of a late-stage aneurysmal
expansion, was induced over a 14 day period following elastase-perfusion (Figure 5.2AD). SEM and histological assessment (H & E and VVG) of the elastase-perfused aortae
revealed a collapsed lumen and disruption in the elastic medial layer of the vessel wall
compared to the no treatment control and the treatment sham (saline perfusion) (Figure
5.3A).

Assessment of sham-treated aortae revealed minimal elastic matrix degradation

relative to elastase-perfused aortae, yet mild disruption and disorganization of the elastic
structures was observed relative to healthy, control aortae (Figure 5.3A). These results
were typical of those observed by other groups who have studied this well-established
model 20, 113, 222.
Morphologically, EaRASMCs derived from elastase perfusion-injured aortae
appeared represent a mixed population and in general appearing smaller and less spread
than healthy RASMCs. Phenotypic analysis using immunofluorescence revealed the
EaRASMCs to exhibit decreased α-actin, caldesmon, and calponin expression as
compared to healthy RASMCs, as illustrated in Figure 5.4A, suggesting a loss of
contractile phenotype. The EaRASMCs also exibited increased expression of
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osteopontin. Flow cytometry analysis (total intensity of marker expression per 100 cells;
Figure 5.4B) indicated that there was a decrease in α-actin, caldesmon, and calponin
contractile marker expression as compared to healthy RASMCs; there was no notable
difference in SM22, osteopontin, and thrombospondin expression as compared to
RASMCs.

Figure 5.2 (A) Representative images of an aorta pre-perfusion, (B) elastase-perfused,
and (C) post-perfusion. A vascular clip is pictured as a scale marker. (D) Aortic diameter
measurements.

5.3.2 EaRASMC proliferation
Figure 5.4C shows the count of EaRASMCs cultured with different dose
combinations of TGF-and-. EaRASMCs proliferated more rapidly relative to
healthy RASMCs, with the cell number at 21 days post-seeding 2.8- fold that of healthy
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RASMCs. Addition of TGF- and HA-o to EaRASMC cultures significantly decreased
cell proliferation, with maximum attenuation observed for doses of 20 µg/ml HA-o and
10 ng/ml TGF- (75% of untreated control EaRASMCsp = 0.0001).

Figure 5.3 (A) Representative SEM (1000 X magnification) and histological
micrographs (VVG and H&E; 2 X and 20 X magnification) of elastase-perfused aortae as
compared to control and sham aortae. Black arrows indicate intact, healthy elastic media;
white arrows indicate disrupted elastic media. (B) Gel zymography analysis revealed the
MMP-2 activity increased within elastase-perfused aortae.
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Figure 5.4 (A) Immunofluorescence images of RASMC and EaRASMC phenotypic
marker expression. (B) Flow cytometry data of RASMC and EaRASMC phenotypic
marker expression (total intensity of marker expression per 100 cells). (C) EaRASMC
count following 21 days of culture with or without HA-o and TGF- factor
supplementation (n = 3/case). * indicates P < 0.05.
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Figure 5.5 Effects of HA-o and TGF- factor supplementation on tropoelastin (A) and
matrix elastin (B) produced by EaRASMC. Data shown are normalized to cellular DNA
content at 21 days of culture (n = 3/case). * indicates P < 0.05. (C-F) Tropoelastin and
matrix elastin production trends (based on mean values) associated with increased in HAo or TGF-.

5.3.3 Matrix synthesis
As shown in Figure 5.5A, at the high dose combination of 20 µg/ml HA-o and 10
ng/ml TGF-a significant increase in tropoelastin production by EaRASMCs was seen
(1.89-fold increase; p = 0.05), which translated into increased matrix elastin formation
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(1.49-fold increase; p = 0.006). At moderate doses of 2 µg/ml HA-o and 5 ng/ml TGF2 µg/ml HA-o and 10 ng/ml TGF- and 20 µg/ml HA-o and 1 ng/ml TGF- there was
no significant increase in tropoelastin, yet there was an increase in elastin crosslinked into
the matrix form. As shown in Figure 5.5B, when HA-o and TGF- were provided to
aRASMCs at an optimal dose (least amount supplement needed for greatest elastogenic
benefit) determined as 2 µg/ml HA-o and 5 ng/ml TGF-, a significant increase in matrix
elastin (including both highly cross-linked, alkali-insoluble structural elastin and an
alkali-soluble fraction) was observed, relative to control cultures (1.40-fold increase; p =
0.049). At this optimal elastogenic dose, EaRASMC cultures produced 112% of the
absolute matrix elastin of that produced by healthy RASMCs (with no factor
supplementation).

5.3.4 Ultrastructure of matrix elastin
A

B

Figure 5.6 TEM of elastic fibers produced by EaRASMCs with (B) and without (A)
factor supplementation (10,000 X magnification).
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5.3.5 Von Kossa staining
In all culture groups, calcium deposits were absent or minimal indicating there
was no/ minimal calcific deposition due to uptake of Ca2+ from culture medium or the
exogenous supplementation TGF-β.

5.3.6 Production of proteolytic enzymes
Gelatin zymography run in triplicate on homogenized aortic tissue and spent
medium samples, respectfully, revealed that the MMP activity was increased (9 %
increase in relative density units) in tissues that underwent elastase perfusion as
compared to untreated control aortae (Figure 5.3B). MMP activity of cells derived from
these elastase-perfused aortae was minimally affected by the addition of the factors
(Figure 5.7).

Figure 5.7 (A) Gel zymography analysis revealed the activity of MMP-2 and MMP-9
within aRASMC cultures treated with or without HA-o and TGF- factor
supplementation. (B) Data are shown normalized to the respective values observed in
non-supplemented EaRASMC controls (n = 3/case).
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5.3.7 DNA microarray
Differential gene expression was measured using DNA microarray and
preliminary analysis was conducted. Differential gene expression of EaRASMCs relative
to healthy RASMCs was noted; Figure 5.8A is a heat map of these differentially
expressed genes (criteria of p < 0.05 for unpaired Student‟s t-test and a fold change > 2)
with red representing up-regulation and green representing down-regulation. Further
assessing the effects of HA-o and TGF-on gene expression (with the same criteria), we
found a small set of genes that returned to „healthy levels‟ following treatment of factors
(Figure 5.8B). A gene of interest from that subset was pro-collagen type VI, which was
down-regulated in EaRASMCs relative to RASMCs and returned to healthy levels in
EaRASMCs with factor supplementation.
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* Indicate genes (probe sets) on
the microarray that did not have
an assigned identity but which
were subsequently conditionally
identified based on homology
searches against the mouse
genome.

Figure 5.8 Differential gene expression as measured by DNA microarray. (A)
Differentially expressed genes in elastase-perfusion-derived EaRASMCs relative to
healthy RASMCs (p < 0.05 for unpaired Student‟s t-test and fold change > 2). (B) Gene
expression that returned to „healthy‟ levels following 7 days of culture with factors (2
µg/ml HA-o and 5 ng/ml TGF-). Shown is a subset of genes differentially expressed
between treatment groups as defined by Significance Analysis of Microarrays, multiclass
analysis, with delta adjusted for false discovery rate > 5%.

We utilized gene ontology functional categories (AmiGO
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) for analysis of

differential gene expression. The AmiGO functional group search terms of interest to us
included smooth muscle cell, extracellular matrix, apoptosis, inflammation, matrixmetalloproteases, and TGF-β. The criterion we implemented was a fold change > 1.5; the
output is represented in Appendix A. There are numerous genes of interest to further
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investigate; here, we will highlight only a few. Of note, bone morphogenic protein-4
(BMP-4) expression was decreased in EaRASMCs relative to RASMCs and HA-o and
TGF-appeared to have no effect on that expression level. Interestingly, elastin
expression was decreased in EaRASMCs relative to RASMCs and the factors seemed to
suppress this further. On a promising note, tissue inhibitor of MMP (TIMP)-3 expression
was increased and MMP-12 expression was decreased in EaRASMCs that received
factors.

5.4 Discussion
We previously showed that healthy RASMCs215 and peri-adventitial CaCl2derived aneurysmal RASMCs, representing early-stage aneurysmal cells, can be
elastogenically stimulated in vitro with our HA-o and TGF-factorsThe relevance of
this study lies in the fact that we seek to evaluate the elastogenic inductibility of cells
isolated from AAA models that exhibit severely-degraded, late stage AAA matrix
environment.
In the current study, at 2 weeks post-injury, elastase-perfused rat abdominal
aortae generated many of the outcomes typical of human AAAs, such as medial elastic
matrix disruption, increased MMP activity, and an approximate 120% increase in aortic
diameter, similar to more advanced human AAAs. SMCs isolated from the abdominal
aortic expansions can be propagated in culture, therefore limitations due to tissue
procurement do not restrict rigorous evaluation of parameters that influence cell
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phenotype and matrix regenerative potential. Our in vitro model is thus valuable for study
of biochemical regulation of cell phenotype by supplemented biomolecules.
In this elastase-perfusion AAA model, we see increases in the activity of
elastolytic MMPs in intact elastase-perfused aortae compared to untreated aortae (Figure
3), and in cultures of EaRASMCs relative to healthy RASMCs, indicating that elastase
injury induces an activated phenotype. Morphologically, we found EaRASMCs exhibited
decreased volume/ spreading as compared to healthy RASMCs. Phenotypic analysis
using immunofluorescence and flow cytometry revealed a significant number of
EaRASMCs exhibited decreased α-actin, caldesmon, and calponin expression as
compared to healthy RASMCs. Caldesmin plays a key role in SMC contraction by
binding to acto-myosin contractile units like actin, tropomyosin, myosin and
calmodulin206 and may have a regulatory role in the contractile apparatus; it has been
reported to inhibit the Mg2+-ATP-ase activity and hence inhibit smooth muscle
contractility207. Calponin binds with actin light chains depending on the presence of Ca2+
thereby regulating the contractile apparatus of SMC‟s

208-209

; due to this binding, it has

also shown to inhibit actin-activated Mg2+-ATP-ase activity in-vitro210. Together, these
suggest a loss of contractile phenotype. In addition, the aRASMCs also exhibited an
increased expression of osteopontin, a multifunctional pro-inflammatory cytokine
implicated with vascular disease and enhanced inflammatory response

211

; osteopontin

has been shown to induce chemotaxis of macrophages and monocytes, which stimulates
calcification
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deterioration

213

and enhances MMP activity, thereby promoting vascular wall

. In tandem with these phenotypic marker alterations, the aRASMCs
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exhibited enhanced MMP and elastase activity over healthy control RASMCs, suggesting
an activated phenotype

19

. However, Von Kossa staining showed no visible matrix

calcification in either the elastase-perfused aortal segments or in cultures of isolated
EaRASMCs, indicating that the treatment did not induce a significant osteogenic
phenotype amongst the EaRASMCs.
EaRASMCs in general proliferated much faster than that of healthy RASMCs. A
comparison of the effects of the factors on EaRASMCs revealed that HA-o and TGF-
suppressed cell proliferation significantly, relative to non-additive, control EaRASMCs.
In EaRASMC cultures, unlike in healthy RASMC cultures, low dose combinations of
HA-o (< 20 μg/ml) and TGF-β (< 10 ng/ml) together had no effect on tropoelastin
production. This agrees well with our prior findings that diseased SMCs require higher
doses of these factors for elastogenic stimulation. Also apparent from our results, are that
HA-o and TGF-β1 in general, appear to more sensitively influence the elastin
crosslinking/ matrix assembly machinery than cellular tropoelastin synthesis, which is
increased only at the highest dose combination. Also, observations from this study
suggest that the predominant effects of HA-o lie in the enhancement of elastic matrix
deposition, which corroborates inferences from our prior studies

214-215

and increases in

tropoelastin and matrix elastin synthesis with increasing TGF-β dose are more
pronounced at higher HA-o doses.
We saw attenuated MMP-2 (minimal change in MMP-9) activity in EaRASMC
cultures that received the maximum factor dose tested (20 μg/ml HA-o and 10 ng/ml
TGF-β). Interestingly, we did not see this decrease in MMP activity from the moderate
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factor dose of 2 μg/ml HA-o and 5 ng/ml TGF-β, at which dose combination we did see
comparable matrix elastin production. This may signify the necessity to utilize higher
factor doses to maximize elastic matrix stability.
At the transcriptional level, DNA microarray provided a plethora of valuable
information that deserves a thorough ongoing investigation. Our preliminary observations
from this data are multi-fold. First, elastase perfusion appears to result in differential gene
expression of EaRASMCs relative to RASMCs in culture (passage 3; Figure 5.8A). It is
promising this differential expression is maintained ex-vivo and suggests that cells
derived from an AAA maintain an altered gene expression in vitro. At this time, we have
not further investigated the differentially expressed genes between the EaRASMCs
relative to RASMCs; we have instead focused our initial efforts on understanding the
effects of HA-o and TGF-β1 on EaRASMCs. Of interest, bone BMP-4 expression was
decreased in EaRASMCs relative to RASMCs and HA-o and TGF-appeared to have no
effect on that expression level. This supports our observations that there were no calcific
deposits found within the elastase-perfused aortae or the derived EaRASMC cultures.
Interestingly, elastin (tropoelastin) expression was decreased in EaRASMCs relative to
RASMCs and the factors seemed to suppress this further. This suggests that increases in
matrix elastin are caused by post-transcriptional events such as tropoelastin packaging,
transport, and assembly into mature fibers in EaRASMC cultures. This contrasts the
previously observed 1.5-fold increase in elastin mRNA expression observed by factor
supplemented healthy RASMCs relative to untreated RASMCs

215

. These results agree

well with the fact that we observed an 8-fold increase in tropoelastin production by
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RASMCs 215 and no significant increase in tropoelastin production by EaRASMC (at the
2 μg/ml HA-o and 5 ng/ml TGF-β tested on cells prior to microarray analysis). Also, of
note is that aHASMC cultures had a 5-fold increase in tropoelastin in response to the
factors (Chapter 4), whereas EaRASMC had 1.9-fold increase. One possibility is that the
factors influence aneurysmal SMCs differently than they do healthy cells, particularly at
the transcriptional level, though there may be similarities in their manner of influencing
post-transcriptional cellular mechanisms leading to tropoelastin release and extracellular
processes of elastic matrix assembly. The second is that despite the broad etiological and
pathological similarities between the elastase perfusion model of rat AAAs and human
AAAs, it appears that there exist critical differences in the manner in which elastin gene
transcription and protein synthesis, and possibly less so, elastic matrix assembly are
impacted by the factors. A final note on differential expression of genes pertains to the
observed decrease in MMP-12 and increase in TIMP-3 expression in EaRASMCs that
received factors. This observation points to the possibility that the factors are „protecting‟
the elastic matrix from enzymatic breakdown. This data is extremely interesting, yet the
design of future experiments to further assess the mechanistic role of HA-o and TGF-β1
on elastin matrix formation in AAA models is necessary.

5.5 Conclusions
1.

The elastase perfusion-injury model exhibits pathological characteristics similar to
human AAAs, such as medial elastic matrix disruption, increased MMP activity,
and ~120% increase in aortic diameter, similar to more advanced human AAAs.
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2.

EaRASMC phenotypic analysis revealed a significant number of EaRASMCs
exhibited decreased contractile phenotypic marker expression and enhanced MMP
activity relative to healthy RASMCs, suggesting an activated phenotype.
EaRASMCs in general proliferated much faster than that of healthy RASMCs and
HA-o and TGF- suppressed cell proliferation relative to control EaRASMCs

3.

EaRASMCs were sensitive to TGF-β and HA-o in the context of elastic matrix
regenerative responses (at an optimal dose of 2 μg/ml HA-o and 5 ng/ml TGF-β).
Tropo- and matrix elastin production was increased (at factor doses ≥ 2 μg/ml HA-o
and 5 ng/ml TGF-β) and elastolytic MMP-2 activity was attenuated (at a factor dose
of 20 μg/ml HA-o and 10 ng/ml TGF-β).

4.

There was significant differential gene expression of EaRASMC relative to
RASMCs, indicating the AAA-derived cells maintain altered gene expression in
vitro, even at passage 3. Differential gene expression as a result of supplanted HAo and TGF-was observed and further assessment of functional groups is
necessary.

5.

The elastase perfusion-injury model of AAAs may be suitable as a surrogate in the
context of elastin regeneration within advanced human AAAs, yet a shortcoming is
the unparalleled increases in tropoelastin production by aHASMCs in response to
factor supplementation.

148

CHAPTER SIX
IMPACT OF PRE-EXISTING ELASTIC MATRIX ON INDUCED
REGENERATIVE REPAIR BY RASMCS

6.1 Introduction
The results presented in Chapters 3-5 demonstrate the utility of HA-o and TGF-β1
for matrix engineering elastic tissue constructs within elastin-compromised tissues (e.g.,
peri-adventitial CaCl2 and elastase perfusion-derived experimental AAAs). Yet, it is not
known as to how the severity of proteolytic elastic matrix degradation alone and hence
quality/ content of the pre-existing elastic matrix, would impact subsequent basal- and
induced- cellular elastin regenerative outcomes. This is relevant since cell phenotype and
remodeling of the ECM are influenced by the biochemical and biomechanical stimuli
cells perceive from their microenvironments. In fact, numerous parameters such as the
etiology of an aneurysm, size and location, proximity to site of injury, stage in
development, and inflammatory cell and thrombus involvement can impact proteolytic
activity and generate temporal- or location- specific variability in cell phenotype and
matrix degradation properties within aneurysms

110-112

. In the current study, these

individual parameters will be studied step-wise in a cell culture model of porcine
pancreatic elastase (PPE)-injured aortal SMCs. This model has been previously shown to
degrade intact elastic structures, and reduce elastin content in cell cultures to mimic the
diseased state

224

. Though simplistic, this cell culture model is advantageous because it

isolates the effects of individual parameters (e.g., inflammatory cells, thrombus-derived
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cellular factors, etc.) on elastin degradation and cell phenotype, including their basal- and
induced- elastic matrix synthesis responses.

6.2 Materials and methods

6.2.1 Cell Isolation and culture
Aortae were harvested from adult Sprague-Dawley rats. All animal protocols
were approved by the Institutional Animal Care and Use Committee at Clemson
University. Aortae were opened lengthwise and the intima scraped gently with a scalpel
blade. The medial layer was dissected out from the underlying adventia, and was then
chopped into ~ 0.5 mm-long sections, rinsed with sterile phosphate buffered saline
(PBS), pooled, then enzymatically degraded in DMEM-F12 medium (Thermo Scientific,
Logan, UT) containing 357 U/mg collagenase (Worthington Biochemicals, Lakewood,
NJ) and 4.5 U/mg elastase (Worthington Biochemicals, Lakewood, NJ) for 45 min at 37
C. The digestate was centrifuged at 400 g for 5 min, the tissue segments then
reconstituted and cultured in 6-well plastic plates with minimal volumes of DMEM-F12
medium containing 10% v/v fetal bovine serum (PAA, Etobicoke, Ontario) over 4-6
weeks. Primary rat aortic SMCs (RASMCs), derived by outgrowth from these tissue
explants, were cultured until confluence and passaged. Low passage (2-8) RASMCs
were then seeded onto 6-well tissue culture plates (area = 10 cm2) at a density of 3 × 104
cells/well and cultured in DMEM-F12 medium containing 10% v/v FBS and 1% v/v
Penstrep (Thermo Scientific, Logan, UT) for time periods designated in Table 1.
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6.2.2 Experimental design and time points
Table 6.1 summarizes the experimental cases, and corresponding conditions of
culture and treatments. Briefly, RASMCs (Passage 2-8) were cultured within 6-well
plates (3 × 104 cells/10 cm2) for 21 days, over which time the cells deposited a robust
matrix. Select wells (n = 3/case) were then incubated for 45 min with 2 mL of porcine
pancreatic elastase (PPE) (Worthington Biochemicals, Lakewood, NJ), prepared at doses
of 0.15 U/ml (PPE15) and 0.75 U/ml (PPE75) respectively, to proteolytically degrade the
elastin matrix to different degrees of severity. Cultures designated as injury controls (No
PPE) instead received PPE-free medium. One set of cultures (n = 3/treatment) was
harvested before, and after proteolytic injury to assess the effects of proteolytic injury on
cell viability and elastin matrix amounts. Other cell layers (n = 3/case) were cultured for a
further 21 days with or without factors (0.2 μg/ml of HA-o, 1 ng/ml of TGF-β1; see
below) with medium changes performed twice weekly. In this study, the effects of these
factors alone were not assessed due to our previous findings with healthy cells that the
factors, delivered individually at the present doses, had limited effect, and were much
more effective when delivered together225. Spent medium aliquots removed from each
well, at the time of each medium change, were pooled and frozen, and biochemically
assayed together with their corresponding cell layers when harvested 42 days postseeding.
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Group Name
No PPE_21 day
No PPE_42 day
No PPE_42 day_+factors
PPE15_21day
PPE75_21day
PPE15_42 day
PPE75_42 day
PPE15_42 day_+factors
PPE75_42 day_+factors

Culture Period
21 day
21 day
21 day
21 day
21 day
21 day + 21day
21 day + 21day
21 day + 21day
21 day + 21day

Enzymatic Treatment
Media Supplements
HA-o & TGF-β1
0.15 U/ml PPE
0.75 U/ml PPE
0.15 U/ml PPE
0.75 U/ml PPE
0.15 U/ml PPE
HA-o & TGF-β1
0.75 U/ml PPE
HA-o & TGF-β1

Table 6.1 Experimental groups with corresponding treatments and conditions of culture.
RASMCs were cultured within 6-well plates for 21 days, over which time the cells
deposited a mature elastic matrix. Select wells (n = 3/case) were then incubated for 45
min with 2 mL of PPE, prepared at doses of 0.15 U/ml (PPE15) and 0.75 U/ml (PPE75)
respectively, to proteolytically degrade the elastin matrix to different degrees of severity.
Cultures designated as injury controls (No PPE) instead received PPE-free medium. One
set of cultures (n = 3/treatment) was harvested before, and after proteolytic injury to
assess the effects of proteolytic injury on cell viability and elastin matrix amounts. Other
cell layers (n = 3/case) were cultured for a further 21 days with or without factors (0.2
μg/ml of HA-o, 1 ng/ml of TGF-β) with medium changes performed twice weekly.

HA-o mixtures used in this study contained ~ 75 ± 15% w/w of HA 4-mers
(tetramers), with 6-mers and 8-mers forming the balance, and were prepared using our
priviously-described protocols based on digestion of HMW HA (>1 MDa; Genzyme
Biosurgery, Cambridge, MA), with testicular hyaluronidase (20 mg hyaluronidase, 40 U
enzyme/mg; Worthington Biochemicals, Lakewood, NJ) for 20 min at 37 C
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181

. HA-o

and TGF-β (Peprotech, Rock Hill, NJ) dissolved in serum-free DMEM-F12 medium,
were syringe-filtered and supplemented to DMEM-F12 culture medium containing 10%
v/v FBS and 1% v/v Penstrep. Final serum levels were normalized to 10% for all culture
groups, so the TGF-β content in the serum would not be a confounding factor. The
presence of FBS was deemed necessary since these poorly elastogenic cell types, produce
even less elastic matrix, at the threshold of detection, when cultured in the absence of
FBS. A 5 mL-volume of medium was added to each well. As with the above cultures,
spent medium from each of these wells was also changed twice weekly. The spent
medium collected from each well was pooled with prior collected aliquots from the
respective wells and stored frozen at –20 ˚C until biochemical analysis was performed.

5.2.3 Immunoflourescence detection of SMC markers
Immunofluorescence techniques were used to confirm the isolated cells as SMCs.
RASMCs were cultured in sterile, 2-well glass chamber slides (Nalge Nunc International,
Naperville, IL) at a low cell density overnight.

They were fixed with 4 % w/v

paraformaldehyde for 10 minutes (4 °C), and detected with polyclonal rabbit antibodies
for SM22α and α smooth muscle actin (Abcam, Cambridge, UK), and visualized with
FITC-conjugated goat anti-rabbit IgG secondary antibodies (Chemicon, Temecula, CA).
Cell nuclei were visualized with Vectashield hard-set mounting medium with DAPI
(Vector Laboratories, Switzerland).
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6.2.4 DNA assay for cell proliferation
The DNA content of the RASMC cultures listed in Table 6.1 were compared to
determine the impact of PPE and the elastogenic factors on cell viability and
proliferation. Select cell layers were harvested at 21 days (before and after PPE injury)
and 42 days of culture, sonicated, and their respective DNA contents quantified using a
fluorometric assay described by Labarca and Paigen202. Actual cell counts were then
calculated assuming 6 pg of DNA/cell202.

6.2.5 Immunoflourescence detection of elastic matrix
Immunofluorescence techniques were used to visualize and confirm PPE-induced
elastic matrix loss within treated cell layers. RASMCs were cultured in sterile, 2-well
glass chamber slides (Nalge Nunc International, Naperville, IL) under identical
experimental conditions as described for cultures meant for biochemical analysis, though
the seeding density and treatment doses were adjusted proportionally to the substrate
surface area and the cell number respectively. At 21 days post-seeding, when the cell
layers were either treated with PPE75 or were untreated with PPE, they were fixed with 4
% w/v paraformaldehyde for 10 minutes (4 °C), and elastin and fibrillin in the matrix
then detected with polyclonal mouse antibodies (courtesy of Dr. Robert Mecham, St.
Louis, Missouri), and visualized with FITC-conjugated donkey anti-mouse IgG
secondary antibodies (Abcam, Cambridge, UK). Cell nuclei were visualized with the
nuclear stain DRAQ5 (Biostatus Limited, Leicestershire, UK).
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6.2.6 Fastin assay for elastin
A Fastin assay (Accurate Scientific and Chemical Corporation, Westbury, NY)
was used to quantify the total amount of elastin deposited within cell layers (matrix
elastin), and that released into the culture medium as a soluble precursor (tropoelastin).
For each treatment group, tropoelastin in the spent medium was collected and pooled
over the culture period and frozen at -20 ˚C. The spent medium fractions collected from
individual wells were pooled separately for the pre- and post-injury phases of cell culture.
To isolate matrix elastin following either 21 days, or 42 days of culture, the cell layers
were trypsinized, scraped, re-suspended in NaCl/Pi buffer, and centrifuged (2500 rpm, 10
min). The cell pellet was digested with 0.1 N NaOH (98 ˚C, 1 h), and centrifuged to yield
a less crosslinked, alkali-soluble supernatant fraction (soluble elastin), and a mature,
highly crosslinked, insoluble pellet (insoluble elastin). Since the Fastin assay quantifies
only soluble α-elastin, the insoluble elastin was first converted to a soluble form prior to
quantification. To do this, the insoluble elastin pellet was dried, solubilized with 0.25 M
oxalic acid (95 ˚C, 1 h), and the pooled digests then centrifuge-filtered (3000 RPM, 10
min) in microcentrifuge tubes fitted with low molecular weight (10 kDa) cut-off
membranes (Millipore, Bedford, MA). All three elastin fractions (tropoelastin and soluble
and insoluble matrix elastin) were quantified using the Fastin assay. Between each of the
cases, the ratios of matrix elastin (soluble + insoluble elastin) to total elastin (tropoelastin
+ matrix elastin), and the ratios of the soluble and insoluble fractions of matrix elastin
were compared to gauge efficiency of crosslinking into a structural elastin matrix, and the
extent of maturation of the matrix elastin respectively.
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6.2.7 SEM analysis of elastic matrix
Scanning electron microscopy (SEM) was used to visualize proteolytic
degradation of elastin matrix by PPE and its subsequent regeneration, under basal and
induced conditions. Spent medium was removed from atop cell layers after 21 or 42 days
of culture. The cell layers were rinsed with PBS, and fixed with 4% w/v
paraformaldehyde in 0.1 M phosphate buffer (4˚C, 15 min). After fixation, the cell layer
was rinsed several times with 0.1M phosphate buffer, then submersed in 25% w/v KOH
(60 ˚C, 5 min) to remove cellular and ECM debris and yield relatively pure, matrix
elastin structures. Following a phosphate buffer rinse, the isolated elastic structures were
then treated with 1% w/v tannic acid (1 h) and stained with 1% w/v osmium tetroxide (1
h). The osmium tetroxide was used as an alternative to sputter coating in order to create a
high electron emission without the need for a metal coating. The samples were
dehydrated successively in graded ethanol (70-100% v/v 1 min each) and finally
hexamethyldisilazane (Sigma Aldrich, St. Louis, MO) (3 min), under a fume hood. The
samples were finally mounted on aluminum stubs and imaged using a Hitachi SEM
TM1000 (Hitachi Technologies, Pleasanton, CA).

6.2.8 LOX enzyme activity assay
Frozen aliquots of spent culture medium, pooled over the respective periods of
culture (21 and 42 days) were assayed for the elastin crosslinking enzyme, lysyl oxidase
(LOX), using a fluorometric assay (Amplex® Red Assay, Molecular Probes, Eugene,
OR) based on measurement of H2O2 released when LOX oxidatively deaminates alkyl
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monoamines and diamines

226

. The fluorescence intensities were measured at λexcitation =

560 nm and λemission = 590 nm.

6.2.9 Assay for elastase activity
Elastase activity following proteolytic injury of the cell cultures was assayed
using an EnzChek® Elastase Assay kit (Molecular Probes, Eugene, OR). Aliquots (50
L) of spent medium (collected and pooled over the 21 or 42 days, after injury or
recovery) were mixed with diluted bovine neck ligament elastin, incubated for 30 min at
37 ºC, and the fluorescence intensity measured at λexcitation = 485 nm and λemission = 510
nm. One unit of elastase was defined as the amount of porcine pancreatic elastase
required to solubilize 1 mg of elastin at pH 8.8 and 37 ºC.

6.2.10 Gel zymography for MMP-2, 9 activity
Proteins from spent medium fractions collected from control and test cultures (at
21 days post-seeding, and between 21 and 42 days post-seeding with and without PPEtreatment at 21 days) and from cell layers themselves (before and after PPE-treatment at
21 days of culture) were extracted in a RIPA buffer, dialyzed, and analyzed by gelatin
zymography using 4 μg of protein per lane (as per BCA assay) as described previously227.
Intensity of the MMP bands were quantified and expressed as relative density units
(RDUs) normalized to protein content, prior to comparison between cases.
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6.2.11 Statistical analysis
Although non-parametric tests (e.g., Mann-Whitney Test) are less powerful than
parametric tests based on Gaussian distribution, especially for smaller sample sizes, they
are still recommended for analyzing biologic data since these data typically do not follow
Gaussian (bell-shaped) distribution. Accordingly, we used non-parametric methods for
statistical analysis in the current study. The Kruskal-Wallis test was initially used to
broadly assess differences between cell layers with or without proteolytic degradation
and cell layers with or without the exogenous supplementation of TGF-β and HA-o.
Subsequently, more detailed, pair-wise analysis between specific groups was conducted
using the Mann-Whitney (Rank-Sum) test. Assumptions were that the data was
representative, observations were independent, and the matrix elastin distributions were
identical except for a shift in location. Statistical significance was deemed for p ≤ 0.1.
This level of significance is different than the typical α = 0.05, representing a 5% type I
error rate, because the current sample size of n = 3/case, selected in consideration of the
large number of test cases, long-culture times, and high cost of analysis, is inadequate to
demonstrate significance with greater than 90% confidence level. Further analysis on the
most promising results from this study will be subsequently conducted at a higher
confidence level (i.e., 95%).
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6.3 Results

6.3.1 Experimental design and time points
The cells harvested from rat aortae expressed SM22α and α smooth muscle actin
confirming their identity as SMCs (Figure 6.1A). At 21 days of culture prior to PPEtreatment, the cells were confluent and exhibited a spindle-like phenotype. The cell layers
were elastolyzed with two different strengths of PPE (0.15 U/ml: PPE15 and 0.75 U/ml:
PPE75; 45 min) to degrade the elastin matrix to different levels of severity. Following
incubation with PPE, the majority of the cells in both sets of cultures remained viable and
spindle-shaped, with a small number of rounded cells (Figures 5.1B and C).

6.3.2 DNA assay for cell proliferation
A fluorometric DNA assay was used to quantify cell proliferation of each of the
three replicate cell layers from each treatment group listed in Table 6.1. In the PPEuntreated group, cell layers cultured for 42 days (with and without factors) contained a
slightly lower number of cells relative to 21 day cultures (p = 0.001 and 0.00004 for 42
day and 42 day + factors vs. 21 day cultures; Figure 6.2). There were no significant
differences in cell proliferation between cell layers cultured for 42 days with HA-o and
TGF- β factors and those that were not (p-value = 0.8). Additionally, there were no
differences in cell proliferation between No PPE, PPE15, and PPE75-treated groups
(Kruskal- Wallis, p-value = 0.4).
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Figure 6.1 Immunofluorescence (IF) of SMC markers (SM22α and α smooth muscle
actin) was used to confirm isolated cells from rat aortae as SMCs (A). A count of these
RASMC was conducted after 21 days of culture following variable PPE injury (B) and
the elastic matrix degradation after treatment with PPE was validated with IF and
scanning electron microscopy (SEM) (C). Representative 21day RASMC cultures with
no PPE injury and severe PPE injury (PPE 75) are shown. Scale Bars: (A) 150 µm (B)
150 µm for IF; 30 µm for SEM.
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6.3.3 Immunofluorescence detection of elastic matrix
Figure 6.1C illustrates the decreased elastin content found in cell layers treated
with PPE75 as compared to controls. With cell numbers both before and after PPE
treatment at 21 days of culture appeared constant (Figures 6.1B, C), the elastic matrix
was significantly decreased after PPE75 treatment.

Figure 6.2 Cell proliferation ratios of RASMC culture groups as described in Table 1.
Data shown represent mean ± SD of cell count determined by DNA content of cell layers
after 21 and 42 days of culture, normalized to 21 day control cultures that received no
PPE treatment or elastogenic additives (n = 3/case). * indicates significance (p ≤ 0.05).

6.3.4 Elastin production
Prior to PPE-treatment at 21 days of culture, all cell layers contained similar cell
numbers (Figure 1B) and produced similar amounts of tropoelastin (Figure 5.3).
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Similarly, regardless of whether they were treated with PPE or not, cell layers also
synthesized similar amounts of tropoelastin in the time period between 21 and 42 days of
culture, leading to very similar totals when measured at 42 days (Figure 6.3). Culture of
cell layers (with or without PPE injury) for a further 21 days in presence of HA-o and
TGF-β, did not enhance tropoelastin synthesis relative to the corresponding cell layers
cultured without any factors (Figure 6.3). Matrix elastin content was also identical in all
cultures prior to PPE-treatment. Incubation with PPE (PPE15 and PPE75) at 21 days of
culture was found to cause a significant reduction in matrix elastin content relative to
untreated control cultures (Kruskal-Wallis, p-value = 0.002); matrix elastin content in cell
layers treated with 0.15 U/ml of PPE (PPE15) was 74 ± 9% of that in non-injured cell
layers, while that treated with 0.75 U/ml of PPE was only 31 ± 13% (Mann- Whitney, p =
0.1 vs. non-injured cell layers for both cases) (Figure 6.4).
In the PPE-untreated cultures, at 21 days, approximately 88% of the total elastin
in the cell layer was crosslinked into an alkali-insoluble form (Table 6.2). This proportion
was maintained over longer-term culture, both in presence and absence of TGF-β and HA
factors. In cell layers that were only moderately proteolyzed (PPE15), the fraction of
matrix elastin in the alkali-insoluble form was initially no different than in PPE-untreated
cell layers, though the value gradually decreased to approximately 71% following 21
days of post-injury culture in the absence of any stimulating factors (Table 6.2).
Differently, however, in those PPE-treated cell layers that were cultured with factors, the
fraction of matrix elastin in the alkali-insoluble form, as analyzed at 42 days of total
culture, was again similar to that measured in 21-day-old, PPE-untreated cultures. In cell
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layers subject to more severe proteolysis (PPE 75), such injury to elastic matrix caused an
immediate reduction in to the absolute content of fractional alkali-insoluble elastin.
Regardless of further culture with HA-o and TGF-β factors, the maturation levels of the
elastic matrix as exhibited within cell layers prior to PPE treatment, was not reinstated.

Figure 6.3 Tropoelastin measured from each individual sample outlined in Table 5.1 are
shown. The mean and standard deviation are compared for each case (n = 3/case). There
are no statistically significant differences.
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Figure 6.4 Matrix elastin data measured from each sample outlined in Table 6.1 are
shown (A). The mean and standard deviation are compared for each case (n = 3/case). *
indicates significance (p ≤ 0.1). Representative scanning electron micrographs of
RASMC cultures following PPE15 and PPE75 injury and supplementation with factors
are shown (B). Regeneration of elastic fiber networks is confirmed with the addition of
HA-o and TGF-β.

Broad statistical comparison of matrix elastin amounts between 21 day cultures
and 42 day cultures (culture with or without added factors, and either following PPEtreatment at 21 days or not), indicated significant differences (Kruskal-Wallis, p = 0.04).
More specifically, in PPE-untreated cell layers, cumulative accumulation of elastin
matrix over 42 days of culture in the absence of added factors, was no different than that
at 21 days, though in the presence of TGF-β and HA-o factors, matrix elastin content
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increased by a further 23% (p = 0.1 for 42 day + factors vs. 21 day, no PPE group).
Culture of PPE-treated cell layers for a further 21 days without any supplemented factors
failed to enhance elastic matrix amounts (Figure 6.4). However, when instead cultured
with TGF-β and HA-o factors, elastic matrix amounts in PPE15 and PPE75-injured cell
layers was increased by 58 ± 20% and 100 ± 0%, respectively. In the PPE15 group,
induction of injured cells with the supplemented factors enhanced cumulative matrix
elastin amounts to levels beyond that measured in 21 day-old cell layers prior to PPEtreatment, just as was observed for the no PPE-treatment group (p-value = 0.1 vs. no PPE
treatment, 21 day cultures in both cases) (Figure 6.4).

No PPE

PPE15

PPE 75

Total Matrix Elastin (Ave μg/sample)
Insoluble Elastin Soluble Elastin Total Matrix Elastin Insol/Total Matrix
230.3
32.4
262.7
0.88
21d
200.9
35.1
236.0
0.85
42d
285.4
38.4
323.8
0.88
42d + factors
167.9
26.3
194.2
0.86
21d
79.9
33.2
113.1
0.71
42d
259.1
49.3
308.4
0.84
42d + factors
60.6
21.6
82.2
0.74
21d
69.1
27.5
96.6
0.72
42d
126.5
37.7
164.2
0.77
42d + factors

Table 6.2 Basal and induced elastic matrix synthesis. Shown are cumulative, mean
amounts of alkali-soluble and insoluble matrix elastin per well (n = 3/group), quantified
in RASMC cultures either prior to or following PPE-treatment at 21 days post-seeding,
and following culture of these cell layers for 21 more days (i.e., 42 days post-seeding), in
the presence or absence of TGF-β (1 ng/ml) and HA-o (0.2 μg/ml) factors. Yield of
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alkali-insoluble matrix elastin, i.e., insoluble elastin /total matrix elastin is indicative of
the efficiency of crosslinking and hence, matrix maturation.

5.3.5 SEM analysis of elastic matrix
Figure 6.1C shows representative scanning electron micrographs of elastic
matrices isolated from 42 day cultures of RASMCs prior to and following proteolytic
degradation with PPE75. These images show that elastic matrix structures are severely
degraded upon treatment with PPE. Figure 6.5A shows elastic fibers deposited by
RASMCs over 21 days of post PPE-injury culture in the absence of HA-o and TGF-β1
factors; elastic matrices in cell layers that were not PPE-injured at 21 days (A, B)
contained more crosslinked, elastic matrix structures than cell layers treated with PPE15
(C, D) or PPE75 (E, F). Figure 6.5B shows scanning electron micrographs of elastic
fibers deposited by RASMCs over 21 days of post PPE-injury culture (C, D for PPE15
and E, F for PPE75), in the presence of HA-o and TGF-β1 factors. A comparison of
panels in Figures 6.5A and 6.5B indicates that culture of RASMCs with HA-o and TGFβ1 factors, following injury with PPE15 (panels C, D) and PPE75 (panels (E, F)
enhanced cellular deposition of crosslinked elastic fibers relative to culture without the
factors.

6.3.6 LOX enzyme activity
There was no difference in LOX activities between the different treatment groups.
On average, the LOX activity was (1 ± 0.24) x 10-4 U/ml.
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Figure 6.5 For SEM, the cell layers were incubated with KOH to digests away nonelastin ECM and cellular components. (A) Scanning electron micrographs of elastic
fibers deposited by RASMCs over 21 days following proteolytic injury in the absence of
elastogenic factors (42 days of culture, overall). Few highly-crosslinked elastic fibers
remained after KOH digestion in PPE-injured cultures. (B) Micrographs of elastic fibers
deposited by RASMCs over 21 days following proteolytic injury (42 days of culture,
overall), in the presence of HA oligomer and TGF-β supplements. Relative to cell layers
that did not receive the HA-o and TGF-β supplements during post-injury culture (see
images in Figure 6.5A), these supplements enhanced cellular deposition of mature,
crosslinked fibers that could survive KOH digestion. Black arrows and white arrows
indicate elastic fibers and undigested cell debris, respectfully. Magnification: 1000 Χ (A,
C, E), 2500 Χ (B, D, F). Scale Bars: 100 µm (A, C, E) and 30 µm (B, D, F).
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6.3.7 Elastolytic activity
As shown in Figure 6.6A, there was no difference in endogenous elastase activity
in cultures representative of each of the tested groups. Gel zymography (Figure 6.6B)
also indicated that the activities of MMPs 2, 9 measured in spent medium fractions
collected from 21 day-old cell layers, before and after PPE-treatment were similar.
Further, activities of MMPs 2, and 9 measured in the pooled spent medium aliquots
collected from PPE-treated cell layers over 21 days of culture in the presence and absence
of elastogenic factors, were no different from that measured immediately following PPEtreatment. No error bars are present on Figure 6.6B because the data was collected from a
single gel with n = 1/ condition. This gel served as a secondary confirmation of the data
collected with the elastase assay, therefore was not completed in triplicate.

B

Figure 6.6 Endogenous elastolytic activity was measured using an elastase activity assay
(n = 3/condition) (A) and gel zymography (n = 1/ condition) (B) for all treatment groups.

6.4 Discussion
A gradient of proteolytic enzymes and matrix proteins has been shown to exist
within AAAs as a function of distance from the rupture site110-112. In such cases, vascular
SMC behavior can be modulated by their binding to the ECM via specific integrin
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receptors; the impacted behavioral patterns can include their own synthesis and
organization of matrix proteins, responsiveness to growth factors and cytokines, altered
Ca2+ ion uptake to possibly promote matrix calcification228, and importantly the type and
extent of matrix (e.g., collagen, elastin)- degrading enzymatic activity they exhibit. Thus,
establishing the utility of elastogenic protocols, and the need for their customization is
contingent on understanding of inter-relationships between extracellular matrix
content/quality, and cell phenotype, and hence the nature of basal and induced
elastogenic responses. This study seeks to explore these aspects.
Established aneurysmal tissues represent disease outcomes and thus do not allow
us to distinguish between disease causes and secondary degenerative changes, and to
isolate the standalone impact of individual factors that influence inherent or induced
matrix repair and/or regeneration. Small animal models of AAAs also rely on artificial
hemodynamic manipulations that influence cellular behavior

229

. Such in vivo models

also render it difficult to distinguish the effects of matrix content and quality/extent of
degradation on one hand, and matrix architecture, and the incidence and extent of matrix
debridement by inflammatory cells recruited to the site of tissue/matrix injury on
subsequent elastic matrix regeneration or repair. In vitro cell culture models, such as one
previously described by Thompson et al. 230, may be usefully adopted to circumvent these
problems. Such models have been previously studied to understand progression of elastic
fiber injury by elastases and inherent cellular mechanisms for repair of degraded elastic
fibers. They have never been adapted to the study of elastin regenerative processes, either
inherent or induced, which we propose here. In mimicking the progressive changes in
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existing ECM and assessing the subsequent matrix repair and regeneration, such models,
though simplistic, are superior to ones based on culture of aneurysmal cells, which
represent a terminal outcome of a disease.
In the present study, we have sought to specifically investigate the impact of
elastic matrix degeneration, independent of leukocyte debridement, on its subsequent
repair possible via regeneration of new elastin, and if/how this phenomenon may by
stimulated by exposure to factors we have deemed „elastogenic‟ based on prior study of
effects on healthy and AAA derived SMCs. While it may exhibit minimal, non-specific
proteolytic activity, PPE was selected for this study, since it specifically targets and
rapidly degrades elastic matrix structures, unlike post-inflammatory cell-mediated matrix
degradation that gradually, and simultaneously degrades elastin, collagen, and other ECM
structures due to the collective action of multiple matrix metalloproteases (MMPs)
exhibiting diverse substrate specificities.
Mature RASMC layers were incubated with two different concentrations of PPE.
The lack of change in cell counts before and after enzyme treatment attested to the lack of
any immediate deleterious effects on the SMCs; yet, DNA analysis at 21 days post-PPEtreatment (42 days post-seeding) showed the cell numbers to have nearly halved. One
possibility is that the PPE-treatment had no short-term (i.e., 45 minutes) effect on the
cells, yet triggered degenerative effects that compromised their viability in long-term
culture. However, the occurrence of a similar decrease in cell number in control cultures
that were not treated with PPE, eliminated this hypothesis. Rather, a likely explanation
for the decrease in cell number is competition of cells for life-sustaining resources, as the
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already-confluent cell layers at 21 days, further proliferated to form multi-layers with the
cells in the interior possibly succumbing to limitations to diffusional supply of essential
nutrients/ gases.
Identical tropoelastin amounts synthesized in all (test and control) cell layers prior
to PPE-treatment suggested deposition of identical elastin matrix amounts as well,
although this was only measured in one set of cell layers (n = 3) that was harvested at 21
days of culture, and prior to PPE-treatment. With this assumption as a basis, we deemed
PPE-treatment to induce an enzyme dose-dependent decrease in elastic matrix amounts,
particularly of insoluble matrix elastin relative to non-treated cultures, as confirmed via
biochemical assays and electron microscopy (Figures 5.1, 5.4, and 5.5). Elastase activity
and gel zymography analysis for MMP activities performed on medium aliquots drawn
from the PPE-treated cultures (both doses) following 1 hr of recovery after PPE treatment
and after 21 days (i.e., 42 days post-seeding) did not indicate any increase in values
beyond that measured in non-treated cultures (Figure 5.6). This suggests that PPEtreatment likely does not result in sustained injury to cells, beyond the actual 45 minute
period of incubation of the PPE with the cell layers. These results lend credence to our
above explanation that decreased cell number in long-term culture post-PPE treatment is
not due to any sustained effects of the treatment, but rather due to nutritional limitations.
However, the lack of any measured increase in elastase activities in the culture medium
removed from cell layers as early as 1 hr after PPE-treatment, relative to control cultures,
was unexpected. To assess this further, an independent set of experiments was performed,
wherein confluent RASMC cultures were treated with the higher dose of PPE (PPE75),
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and following 1 hour of recovery, the cellular, rather than the medium fraction was
analyzed using gel zymography. These results (not shown) again indicated no differences
in activities of the MMPs-2, and 9 between PPE-treated and –untreated cell layers.
Collectively, these results suggest that PPE-treatment at the present doses/duration is
effective from the standpoint of inflicting elastic matrix damage, but does not
significantly activate cells, to be able to quantify temporal increases in activities of
elastolytic MMPs.
Although tropoelastin production by PPE-untreated (control) cell layers between
21 and 42 days of culture was less than that in the first 21 days of culture, the lack of
elastic matrix accumulation during the same period could be possibly attributed to either
(a) a decrease in LOX-mediated crosslinking activity or of LOX protein itself, (b)
sustained elastolysis due to PPE, MMP release by cells, or (c) spatial limitations for
matrix deposition, imposed by high cellularity and already dense matrix in cell layers at
42 days of culture. Since elastase and LOX activity assays showed no change in cell
layers at 42 days of culture relative to cell layers at 21 days of culture, the lack of any
significant accumulations of elastic matrix between 21 and 42 days of culture may be
purely due to a contact inhibition of the SMCs within the super-confluent and dense cell
layers. Although, we did not specifically quantify other mature elastic fiber proteins such
as fibrillin and microfibril-associated glycoprotein (MAGP) it is quite possible that
cellular synthesis of these and other proteins critical to elastic fiber formation could have
also been inhibited when cell layers attained super-confluence. This will be elucidated in
a follow-up study.
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In light of the multi-fold increases in tropo- and matrix elastin production that we
previously showed TGF-β and HA-o to induce in healthy cells225, here, 21 day culture of
PPE-untreated (control) cultures with these very factors only modestly improved matrix
elastin production (23%), and had no effect on tropoelastin synthesis. We believe that this
muted effect is due to our high cell count, due to which factor doses on a per cell basis
were rendered very low. Although the cell seeding densities in both our earlier and
current studies was almost identical (3 × 104/10 cm2), in this study, the factors were not
provided to the cell layers immediately, but only after 21 days of culture, and by which
time the cell counts had exponentially increased. Thus, effectively, the TGF-β and HA
oligomer doses on a per cell basis were orders of magnitude lower than that provided in
the prior study. It is thus likely that providing greater doses of HA-o and TGF-β on a per
cell basis, to be equivalent to that provided in our prior study (0.2 μg/ mL per 40,000
cells and 1 ng/mL per 40,000 cells; 5 mL per well) would much more dramatically
enhance tropo-and matrix elastin production in the control cell layers in this study also.
Our biochemical analysis clearly demonstrated that in absence of any provided
factors, proteolytically-injured cell layers were incapable of regenerating the lost elastin
matrix, though they continued to produce tropoelastin. As SEM analysis indicated, PPEtreatment resulted in etching of elastic fibers (see degenerated fibers vs. intact fibers in
Figure 1C), their fragmentation and sometimes complete degeneration, particularly at the
higher PPE dose. Prior studies have emphasized the importance of intact elastic fibers to
the process of tropoelastin nucleation, crosslinking, and fiber formation

87

, and the

importance of glycosaminoglycans such as HA in facilitating the process of tropoelastin
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coacervation

6-10, 70, 82, 91

. Thus the reduced presence of intact fibers in PPE-treated cell

layers, could likely have deterred further elastin matrix deposition. Perhaps for the same
reason, we observed elastic matrix accumulation in PPE-treated cell layers cultured with
HA-o and TGF-β factors. Likely, the provided HA-o interacted with cell surface
receptors (Toll like Receptor 4 (TLR-4) for HA 4mers and CD44 for larger oligomers) to
localize at the cell layer and further coacervate tropoelastin precursors through opposite
charge interactions and facilitate their lateral aggregation and crosslinking with lysyl
oxidase, to for mature fiber structures. Though likely muted in its effects, due to the low
HA-o dose/cell (~0.2 μg/2 × 106 cells), it is clear that HA-o do benefit elastin matrix,
specifically fiber formation (compare Figures 5A and 5B), in a manner that mimics our
prior observations, though those outcomes were more significant. As we noted in a prior
publication

225

, TGF-β likely interacts with cells independently via TGF-β receptors to

elicit enhanced elastin synthesis, through changes to intracellular signaling pathways that,
due to synergy between them and HA-o, likely show some degree of commonality. TGFβ may also enhance LOX production/activity to benefit tropoelastin crosslinking into a
matrix. The lack of any perceivable increase in LOX activities in cell layers, post culture
with TGF-β, and the absence of any significant increase in tropoelastin production over
non-additive cultures may be again due to the low provided dose on a per cell basis.
Our results indicate that the provided elastogenic factors induce greater percent
increase in elastic matrix synthesis within cell layers that are subject to more severe
proteolytic injury. This could be due to a less dense matrix in the more severely
proteolyzed cultures, which permits greater access of the elastogenic factors to the cells
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in the interior of the cell multi-layer. Although cell counts immediately after PPEtreatment were similar in both PPE15 and PPE75-treated cell layers, cell numbers after an
additional 21 days of culture ended up slightly lower in the latter case. It is thus possible
that the somewhat lower cell numbers in PPE75-treated cell layers resulted in higher
effective factor doses on a per cell basis, and accounted for the greater percent increase in
matrix elastin relative to PPE15-treated cultures. Nevertheless, the provided dose of
elastogenic factors was deemed insufficient to restore elastic matrix amounts to preinjury levels within the more severely proteolyzed cell layers. These results suggest that
the greater the severity of elastic matrix injury, the greater the dose of elastogenic factors
that must be provided to induce complete recovery of lost elastic matrix. Fractional
content of alkali-insoluble elastin in the matrix showed immediate and substantial
(PPE75), or gradual and mild (PPE15) decreases from that in PPE-untreated (control) cell
layers. In the absence of any added growth factors, there was no recovery after even 21
days of culture. As mentioned before, likely, more severe the PPE-injury, the greater the
deterioration and removal of existing elastic matrix structure, and more afflicted the
subsequent process of tropoelastin coacervation and crosslinking. The fact that the HA-o
and TGF-β factors are able to restore fractional content of insoluble matrix elastin in
PPE15 but not PPE75-treated cultures clearly demonstrates the vital involvement of the
HA-o and TGF-β in the tropoelastin crosslinking process, and yet inadequacy of these
factors (at the current doses) in overcoming the effects of severe elastic matrix injury.
The study thus illustrates the importance of customizing factor doses to the severity of
elastic matrix deterioration.
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6.5 Conclusions
1. In vitro elastase (PPE) treatment to established RASMC cultures with robust matrices
induced an enzyme dose-dependent decrease in elastic matrix amounts, particularly of
insoluble matrix elastin relative to non-treated RASMC cultures.

2. The ability of cell layers to self-repair and regenerate elastic matrices following their
proteolytic damage was limited, particularly when elastic matrix injury is severe.

3. HA-o and TGF-β together can elastogenically stimulate RASMCs in elastic matrixdegraded cultures to restore both elastic matrix amounts and elastic fiber deposition to
levels of accumulation observed in healthy cultures.

4. Doses of the elastogenic factors must be enhanced and optimized based on the
severity of elastic matrix damage. These studies suggest that with early clinical
diagnosis of AAAs and therefore moderate elastic matrix degeneration in the vessel
wall, delivery of these elastogenic factors may be an appropriate therapeutic option.
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CHAPTER SEVEN
HYDROGEL-COATED GRAFT SYSTEM FOR DELIVERY
OF ELASTOGENIC FACTORS

7.1 Introduction
Endovascular aneurysm repair (EVAR) involves the deployment of a stent-graft
within the lumen of an aneurysmal aorta using a balloon catheter and guide wire. The
stent-graft is designed to isolate the aneurysm sac while providing a conduit for normal
blood flow. The first successful EVAR for abdominal aortic aneurysm repair was
reported in 1991 231. This technique is currently used as a relatively safe and less invasive
alternative to open surgical repair, that yields acceptable clinical results 232. The skeleton
of the stent graft is usually Elgiloy®, Algiloy®, or Nitinol®, while the graft material is
typically Dacron™ (polyethylene terephthalate or PET) or poly(tetrafluoroethylene)
(PTFE).
Though EVAR has numerous benefits (reduced blood loss and complications
(such as cardiac events, congestive heart failure, respiratory failure, myocardial
infarction, limb ischemia, post-op bleeding, graft thrombus, wound infection) during
surgery or following surgery and decreased duration of hospital stay and recovery time)
over open repair, a number of late (>1 year post-implantation) problems occur, which
may require secondary interventions. Endoleaks, which occur when the stent-grafts fail to
completely exclude blood flow to the aneurysm sac, are the most common cause of
secondary intervention

233

, with a typical incidence of 10-50% 234. Endoleaks can lead to
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further distension of the aorta and the eventual rupture of the vessel wall. To ensure
optimum fixation of the device, most devices use barbs, hooks, and radial force applied
during deployment at the proximal and distal ends of the stent. Although the currently
marketed stent graft designs address the issue of fixation, endoleak still remains one of
the main causes of device failure 234.
One hypothetical way of reducing endoleak is to induce local, cell-mediated
regeneration of elastic matrix-rich vascular tissue. A strategy of incorporating elastogenic
factors (e.g., HA-o and TGF-β as discussed in previous chapters) into currently applied
EVAR systems to deliver them to aneurysmal tissue for the purpose of regenerating an
elastic matrix is thus attractive. Theoretically, the ability of this a newly regenerated
elastic matrix to restore native elastic mechanics to the treated vessel segment would
encourage sustained intimate contact of the expanded stent graft with the vessel wall,
eliminating the occurrence of endoleak. This strategy broadly resembles that published by
Kajimoto et al. who examined the efficiency of stent-grafts with a basic fibroblast growth
factor delivery system in the canine thoracic aortic aneurysm model with endoleaks
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.

The current study will provide preliminary data as to the feasibility of coating
hyaluronan-based hydrogel systems (with loaded elastogenic factors) on ePTFE graft
material for sustained release of the elastogenic factors at the site of AAA.
Aeos™ ePTFE (Zeus, Orangeburg, SC) is used as the graft material in this study;
it is micro-porous, biocompatible, implantable, flexible, hydrophobic, has a high linear
strength, excellent radial expansion, and has been shown to allow endothelialization
236

235-

. Extracel-HP™ hydrogel (Glycosan Biosystems, Salt Lake City, UT) is used as the
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delivery vehicle for factors, in the form of a graft coating; it contains thiol-modified HA
and thiol-modified gelatin chemically crosslinked with polyethylene glycol diacrylate and
small amounts of thiolated heparin which can ionically bind a wide variety of growth
factors to allow slow release

237-238

. Specifically, the manufacturers have shown with 0.2

ng/μl of TGF-β1 incorporated within their hydrogel releases 31.6% of this amount over 7
days and 41.5% over 21 days 179.
In this study, we loaded different concentrations of TGF-β1 into the Extracel-HP™
gels at variable doses, evenly coated the formulations on the ePTFE graft surface,
dehydrated these gel coatings into a thin film (to demonstrate the feasibility of packaging
and storage for clinical applications), and assessed the factor release rate over a 2 week
period. Although this body of work is too premature in development to be able to
evaluate induced elastic matrix regeneration within AAAs, it will serve as a proof-ofconcept that currently used grafts for EVAR can be modified to deliver elastogenic
factors, for interaction with/ uptake by endogenous SMCs. This study will serve as a first
step toward demonstrating that growth factor delivery in this manner can evoke
elastogenic responses from SMCs within intact aneurysms, ultimately leading to elastic
matrix repair and AAA regression.
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7.2 Methods

7.2.1 Surface modification of ePTFE graft
Since ePTFE is highly hydrophobic and inert, we functionalized our ePTFE graft
(Aeos™ ePTFE; Zeus, Orangeburg, SC) surface by introducing reactive amines by NH3plasma treatment. Plasma treatment was performed at the lab of our collaborator, Dr.
Marian McCord at NCSU. Flattened ePTFE grafts (2 mm diameter, 2 cm in length, and
0-50 µm pore diameter) were ultrasonically cleaned with acetone and methanol. They
were vacuum-dried and treated with a helium/ forming gas (H2, N2) mixture (base
pressure: 2.67 Pa, He gas and forming gas flow rates: 10, 0.3-4 l/ min; < 12 min) while
vertically oriented within a Pyrex glass plasma reactor so as to treat both exterior sides of
the flattened graft.

7.2.2 XPS validation of amine functionalization on ePTFE
X-ray photoelectron spectroscopy (XPS) was used to determine the efficacy of the
plasma treatment (to introduce amine groups on the surface of the ePTFE). Using this
technique, we compared the elemental composition and chemical structure characteristics
of the plasma-treated and untreated ePTFE. Samples were analyzed using an Axis 165
XPS system (Kratos, Chestnut Ridge, NY) with a monochromatic aluminum target x-ray
source (15 kV and 10 mA). Samples were analyzed at a pressure of 1 X 10-9 torr and
temperature of 23 ºC with a takeoff angle close to 0º. Scans between 1200 eV and 0 eV
were performed and the resulting spectra were referenced to the substrate C 1s peak.
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Higher resolution spectra were also generated to monitor the formation of functional
groups upon plasma treatment.

7.2.3 Loading factors into the hydrogel
Under sterile conditions, the ePTFE graft material was cut into rectangles (6.3
mm x 66.7 mm) and individually placed, with the plasma-treated side up, in the wells of a
24 well plate. Hydrogel films for coating ePTFE were prepared with thiolated derivatives
of GAGs (HA) and gelatin (Gtn). Michael addition between these thiolated derivatives
and diacrylate PEG at neutral to slightly basic pH was used to crosslink the hydrogel
(Figure 7.1). HA-o & TGF-β (reconstituted in 50 µl PBS at the different concentrations
listed in Table 7.1) was added to a mixture of Heprasil (carboxymethyl hyaluronic acidthiopropanoyl hydrazide with heparin-thiopropanoyl hydrazide (CHMA-S with HPDTPH) & Gelin-S (carboxymethyl gelatin-DTPH (Gtn-DTPH); Extracel-HP™ Hydrogel
Kit, Glycosan Biosystems, Salt Lake City, Utah; 2 µl/ 3 samples; n = 3 samples/
condition) before crosslinking with Extralink (poly(ethylene glycol) diacrylate (PEGDA);
25 µl/ 3 samples, yielding a total of 150 µl/ 3 samples).

Figure 7.1 Chemical structure of crosslinked HA-DTPH 238.
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Group ID
A
B
C
D

TGF-β (ug/ sample)
Control
0.025
0.125
0.25

Dose Equivalent (ng/ ml)
0
1
5
10

Table 7.1 TGF-β1 concentrations of each hydrogel test group (n = 3/ group). The doses
correspond to the dose equivalent of the total TGF-β delivered to previously assessed
healthy and aneurysmal SMC cultures over 21 days for elastogenic regeneration (0, 1, 5,
10 ng/ml TGF-β; Chapters 4 and 5). The TGF-β release from the hydrogels was
quantified at 1, 3, 7, and 14 days.

7.2.4 Hydrogel coating on ePTFE
The respective Extracel-HP™ hydrogel formulations (Table 7.1) were carefully
pipetted onto the surface of the ePTFE (50 µl/ 420 mm2 sample; n = 3 samples/ group)
and allowed to air-dry overnight in a standard cell culture hood, to create a thin film.

7.2.5 SEM confirmation of hydrogel coating on ePTFE
Scanning electron microscopy of the ePTFE surface before and after hydrogel
coating was conducted to confirm uniform coating with the hydrogel and the absence of
the hydrogel delaminating upon drying. The dried samples were mounted on aluminum
stubs and imaged using a tabletop Hitachi SEM TM1000 (Hitachi Technologies,
Pleasanton, CA), which is capable of direct stereoscopic observation of the surface
topography of non-conductive samples.
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7.2.6 Factor release
Following re-hydration (5 min in phosphate buffered saline; PBS) of the hydrogel
on the ePTFE samples, 1 ml of PBS was added to each sample well. The samples were
stored at 37 °C and the PBS supernatants were replaced at 1, 3, 7, and 14 days; the
removed PBS aliquots were stored at -20 °C until analysis. The TGF-β released from the
hydrogel was measured using the TGF-β Emax® ImmunoAssay System (Promega,
Madison, WI), which measures biologically active TGF-β. A 96-well place was coated
with TGF-β coat mAb (Promega) in coating buffer (1:1000 v/v; 100 µl/ well; Biolegend,
San Diego, CA) and incubated overnight at 4 °C. The plate was then returned to RT and
excess coating buffer removed. Wells were blocked with TGF block buffer (35 min at 37
°C; Promega) and vigorously washed with TBST wash buffer (Millipore, Billerica, MA).
Standards were prepared and samples were added to wells (90 min; 500 RPM shaking at
RT). 50 µl of diluted anti-TGF-β1 pAb was added to each well (2 hr; 500 RPM shaking
at RT) followed by TBST washes. 100µl of HRP conjugate (Promega) was added to each
well (2 hr; 500 RPM shaking at RT) followed by TBST washes. 100 µl of TMB One
Solution was added to each well (15 min; RT; Promega) and the reaction stopped by
adding 100 μl of 1 N HCL. Finally, the absorbance was read at 450 nm.
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7.3 Results

7.3.1 XPS of surface amine groups
As illustrated in Table 7.2, XPS spectra show that gas plasma treatment of ePTFE
introduces reactive amine/amide groups on the surface (compare increased N and O
concentrations in cases 3 or 6 over case 1). There was a significant increase in % C, O, N
in XPS spectra of HA-coated gas-plasma-treated ePTFE (7, 8) over non-coated and HAcoated unmodified ePTFE (1, 2). Yet, treatment parameters need to be optimized to
maximize surface functionalization of reactive functional groups.

Table 7.2 XPS analysis of untreated and plasma-treated ePTFE with and without
incubation with HA.
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7.3.2 Hydrogel coating on ePTFE
The Extracel-HP™ hydrogel formulations with loaded factors (Table 7.1) were
coated on plasma-treated Aeos™ ePTFE samples, dehydrated overnight, then rehydrated
prior to assessment of factor release (Figure 7.2). The films appeared slightly crystalline
upon dehydration, yet rehydrated fully to an even coating (with no cracks visible).

Figure 7.2 (A) Aeos™ ePTFE alone (following plasma treatment); (B) ePTFE with
Extracel-HP™ Hydrogel film; (C) Initial rehydration (30 sec) of hydrogel; (D) Complete
rehydration (5 min) of hydrogel coating on ePTFE.

7.3.3 SEM of hydrogel coating on graft
The ePTFE was analyzed via scanning electron microscopy (SEM) before and
after hydrogel coating. As illustrated in Figure 7.3, the ePTFE had an intermodal
diameter of 0-50 μm. Upon coating with the hydrogel film, the hydrogel filled the ePTFE
surface pores and there was a distinct film interface between the non-coated and
hydrogel-coated ePTFE. No cracks or delamination was seen.
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7.3.4 Sustained TGF-β release
Slow TGF-β release was measured using the TGF-β Emax® ImmunoAssay System.
As demonstrated in Figure 7.4, over 14 days there was steady release of TGF-β beginning
at 1 day post incubation; only 0.04% w/w (of the total TGF-β released over the 14 days)
was released over 1 day, 13.8% w/w over 3 days, and 48.4% w/w over 7 days. The total
active TGF-β released over the 14 days (1377 ± 93.7 pg/ sample), represented only a
small fraction of the theoretical TGF-β loading amounts into the hydrogels (0.025, 0.125,
and 0.25 µg/ sample). Thus, TGF-β release kinetics, at least at over the initial 14 days,
does not appear to be dictated by TGF-β loading amount.
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Figure 7.3 SEM images of (A) ePTFE prior to hydrogel coating and (B) following
hydrogel coating and dehydration. White arrows indicate the interface between uncoated
and coated ePTFE.
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Figure 7.4 TGF-β (active) release over 14 days as measured by TGF-β Emax®
ImmunoAssay System. Data points and error bars are based upon values measured from
all the hydrogel formulations listed in Table 7.1.

7.4 Discussion
In this study, we examined the efficiency of Aeos™ ePTFE graft materials coated
with a factor-releasing hydrogel, Extracel-HP™. This study served as an in vitro
assessment of hydrogel-coated graft delivery of our elastogenic factors, which can later
be applied to endovascular delivery in vivo at the site of AAA for elastin regeneration,
elimination of endoleak, AAA growth senescence, and possibly even AAA regression. It
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provides a preliminary assessment of feasibility of endovascular elastogenic factor
localized and sustained delivery to a diseased vessel segment.
As mentioned previously, PTFE is a common EVAR graft material. AeosTM
ePTFE is micro-porous, biocompatible, implantable, flexible, hydrophobic, and has a
high linear strength, excellent radial expansion, and has been shown to allow
endothelialization

235-236

. This material was chosen due to these ideal characteristics. A

graft diameter of 2 mm was selected for study to facilitate future translation of this
technology for study of therapeutic regression of AAAs, in rats, where the abdominal
aorta typically measures ~2 mm in diameter. The graft material was made up of a number
of solid ePTFE nodes inter-connected by a matrix of thin fibrils with 0-50 µm spacing
between the nodes (IND) to eliminate passage of red blood cells through the graft. Due to
the hydrophobicity of ePTFE, chemical modification of the graft surface was conducted
to render it more reactive for adherence of the hydrogel coating. The results show that we
effectively introduced reactive amines on the outer surface of the ePTFE (by NH3-plasma
treatment), that could potentially bind to –COOH groups on the modified HA and thus
bind the hydrogel coating.
The Extracel-HP™ hydrogel allowed for effective incorporation of TGF-β and its
sustained release over a 14 day period in vitro (Figure 7.4). The hydrogel formulations
assessed were loaded with TGF-β amounts (0, 0.025, 0.125, and 0.25 µg/ sample) that
represented equivalents of the TGF-β doses tested in Chapters 4 and 5 for elastogenic
inductibility of aneurysmal SMCs in vitro (0, 1, 5, 10 ng/ml TGF-β, 5ml media/ well, 5
media changes over 21 days of culture). In this tested range of TGF-β loading amounts,
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we did not see a any dependence of kinetics of TGF-β (active-form) release from the
hydrogels on TGF-β loading amounts, at least over 14 days of incubation in a nonenzymatic aqueous medium. This suggests increasing the loaded TGF-β amounts in the
hydrogels may only serve to prolong the duration of factor release. It is important to
acknowledge that in the in vivo environment enzymatic degradation in addition to
hydrolytic degradation is likely to occur more rapidly, therefore releasing the TGF-β at a
more rapidly. It is also important to note that the -β Emax® ImmunoAssay System only
measures active TGF-β, so for future analysis it may be important to activate TGF-β
(using an acid treatment procedure) prior to quantification to be sure to quantify both the
active and inactive TGF-β released from the hydrogel.
There is evidence that hyaluronan oligomers (HA-o) could be similarly released
from the hydrogel due to hydrolytic and enzymatic degradation in vivo. Studies have
shown that Extracel-HP™ is naturally degraded in vivo by endogenous hyaluronidases
and collagenases produced by cells to form hyaluronan fragments
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. Degradation/

resorption time in vivo depends heavily on the water content of the implanted ExtracelHP™
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with standard Extracel-HP™ formulations persisting in vivo for up to 4 weeks,

and lyophilized sponges of the same material lasting as long as 8 weeks

239-240

.

Degradation times and therefore HA-o and TGF-β release can be altered based upon
experimental requirements by controlling crosslinking within the hydrogels, which can in
turn impact their water content.
Additional work is necessary for demonstration of cellular uptake/interaction and
functional response to the factors released by the Extracel-HP™-coated Aeos™ ePTFE
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graft materials. An in vitro experiment wherein factor delivery to EaRASMCs (elastaseperfusion derived AAA SMCs) from Extracel-HP™-coated grafts would be a first step
toward demonstrating elastogenic inductibility of these cell types. The hydrogel-coated
graft could be mounted in cell culture wells to allow immersion in the culture medium
without direct contact with the EaRASMCs. The elastic matrix deposition by the cells
could be biochemically quantified and ultrastructurally assessed after 3 weeks of culture
to validate the efficacy of factors delivered in this manner for elastogenic induction.
There is a concern that the size of the hyaluronan degradation products from
Extracel-HP™ may adversely influence the cellular response, with larger, non-oligomeric
size fragments eliciting undesirable outcomes (e.g., inflammation). However, in prior
studies, we have shown that non-oligomeric HA fragments do not impact tropoelastin
synthesis and cellular proliferation, but in fact may improve elastic matrix deposition
through coacervating tropoelastin by opposite charge interactions (a mostly physical
effect) to facilitate efficient crosslinking into matrix structures
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. Future studies will

thus need to evaluate the effects of these degradation products in the context of aneurysm
repair, particularly from the standpoint of potentially inciting inflammatory responses.
The modes of hydrogel degradation are discussed further below.
Non-enzymatic hydrolysis and enzymatic hydrolysis (mainly resulting from
MMPs, including collagensases, hyaluronidases, and chondroitinases) contribute to the
degradation of Extracel-HP™. Figure 7.5A illustrates the non-enzymatic degradation of
the HA-Gtn-based hydrogel, which interestingly is approximately four times longer than
the predicted half-life for ester bond hydrolysis
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241

. Figure 7.5B shows the in vitro

hyaluronidase (bovine testicular hyaluronidase) and collagenase (from Clostridium
histolyticum) degradation of the hydrogel. These data suggest that the hydrogel is quite
stable against hydrolytic degradation, yet degrades in an activity-dependent manner in an
enzymatic environment. These characteristics can be taken advantage of in the future
modification of this gel-based system for delivery of elastogenic factors in vivo. The
factor-hydrogel formulations can be altered to take into account the enzymatic activity of
the endogenous AAA environment. For example, increasing the hydrogel crosslinking
could be useful to reduce the degradation rate in a highly enzymatic AAA environment.

Figure 7.5 (A) Nonenzymatic degradation in vitro of hydrogels: (a) 50:50 HA-Gtn
hydrogel. Open circles indicate wet weights; open triangles indicate dry weights
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. (B)

Enzymatic degradation in vitro of 50:50 HA-Gtn hydrogel in DMEM medium containing
different concentrations of hyaluronandase plus collagenase. Open diamonds: no
enzymes; open squares: 50 U/mL each enzyme; open triangles: 100 U/mL each enzyme;
open circles: 150 U/mL each enzyme 239.
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Another consideration is the mechanical forces seen by this delivery system in
vivo; the modified EVAR system must have excellent fixation and the hydrogel-coating
must be sustained for weeks to allow for appropriate delivery of elastogenic factors.
Other groups have conducted numerical modeling of aneurysms and stent grafts using
finite element analysis and computational fluid dynamics to evaluate the stresses on the
aneurysm wall 242-243 and flow patterns and drag forces around stent grafts 244. Figure 7.6
illustrates the wall stress in an aneurysm prior to and following EVAR treatment.
Following EVAR, the highest stresses are seen at the sites of anstomoses, therefore,
fixation approaches (high deployment pressure, hooks, or barbs) are extremely important
to ensure the hydrogel coating of the stent are not eliminated due to the high pressures.

Figure 7.6 (A) A computer-generated image illustrating a modular bifurcated graft. The
main component comprises a body and one limb, introduced from the left femoral artery
in this case (curved arrows). There is a short limb in the main component on the side
opposite to that of introduction (straight arrow). An extension limb (open arrows) is
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docked with this short limb to complete the bifurcated device 245. (B) Von Mises stress of
Pre-op, Post-op and Follow-up AAA models at time of maximum wall stress. Pre-op
model (left), Post-op model (center), and Follow-up model (right) showing peak wall
stress. Stresses are normalized to the pre-operative peak stress. The peak stress on the
aneurysm sac region is indicated by the black triangle 246.

Finally, an important consideration for the proposed mode of elastogenic factor
delivery is intraluminal thrombus that would limit diffusion of the elastogenic factors to
medial SMCs. It has been reported that in fact ~75% of all AAAs have intralunimal
thrombus
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. In this context, elastogenic factor delivery would not be recommended for

those AAAs with a thick thrombus. Alternatively, for thrombus-rich AAAs, other local
delivery techniques could potentially be utilized. The Angiotensin II (Ang II) infusion
AAA model may be useful to test additional delivery modes because the model yields
thrombus formation in combination with aortic wall ECM degradation and expansion.

7.5 Conclusions
1.

This study provides a preliminary assessment of the feasibility of localized,
endovascular elastogenic factor delivery to an aneurysmal vessel segment. It serves
as a preliminary in vitro assessment of hydrogel-coated graft delivery of our
elastogenic factors, which can later be applied to endovascular delivery in vivo at
the site of AAA for elastin regeneration, elimination of endoleak, inhibition of
AAA growth, and possibly even AAA regression.
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2.

The Extracel-HP™ hydrogel attachment to Aeos™ ePTFE graft and sustained TGF-β
delivery over weeks is promising, yet much further work addressing functional
efficacy is necessary.
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CHAPTER EIGHT
OVERALL CONCLUSIONS FROM THIS PROJECT AND FUTURE DIRECTIONS

8.1 Overall conclusions
The objectives of this project were to (a) assess the utility of the extracellular
matrix-derived factors, hyaluronan oligomers (HA-o) and TGF-β1 (elastogenic factors),
to stimulate aneurysmal SMCs (from CaCl2-injury and elastase-perfusion AAA models)
to regenerate biologically and ultrastructurally faithful mimics of native vascular elastin
networks, (b) identify a working range of effective elastogenic factor doses, which may
serve as a basis for model-independent prediction of in vivo delivery doses, (c)
demonstrate that clinical translation of this elastogenic induction approach is feasible, (d)
predict if and how basal and induced elastic matrix repair and new elastic matrix
regeneration by activated vascular SMCs depends on their location within AAAs, and (e)
provide preliminary studies toward developing a strategy for localized delivery of
elastogenic factors within intact AAAs, and demonstrate the feasibility of sustained
release of these factors.
Here, we will summarize the conclusions we have drawn from this project as a
whole towards the above outlined objectives.

The CaCl2-treatment and elastase

intralumenal perfusion models were successful in inducing expansions in the abdominal
aorta of rats (~45% and ~120% diameter increase within 28 days and 14 days,
respectively). Specifically, the CaCl2-injury model of AAAs exhibited pathological
parallels to human AAAs, including medial layer disruption, inflammation, matrix
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calcification, and enhanced MMP activity and CaCl2-injury-derived SMCs (aRASMCs)
had similarities to aneurysmal human SMCs (aHASMCs) in terms of decreased
contractile activity, enhanced proliferation, increase elastolytic activity, and reduced
elastogenic capacity (relative to healthy SMCs). Compared to healthy RASMC cultures,
aRASMCs proliferated less and produced less collagen, tropoelastin, and matrix elastin.
The protein synthesis within these aRASMC cultures was not up-regulated by adding
either HA-o or TGF-β alone. Yet, concurrent delivery of the factors resulted in slight
suppression of proliferation, significant increases in lysyl oxidase (LOX), desmosine,
collagen, tropo- and matrix elastin, and reduced calcification and MMP activity in
aRASMC cultures, which was not achieved by the presence of either factor alone.
The CaCl2-injury model differed from human AAAs in cellular responses to
elastogenic stimulation; aRASMCs appeared to be less sensitive to TGF-β and HA-o in
the context of elastin regenerative responses relative to aHASMCs, though trends were
maintained. Factors attenuated elastolytic MMP-2 activity in aRASMCs; interestingly,
no significant decrease was seen in aHASMC cultures, yet an overall decrease in MMP
and TIMP expression was seen with factor supplementation. The differences in cell
responses to factors may likely be due to differences in the stage of maturation of the
AAAs studied. Therefore, the CaCl2-injury model of AAAs may not be the most
appropriate as a surrogate in the context of elastin regeneration within human AAAs,
since the majority of AAAs are diagnosed at a late-stage.
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The elastase perfusion-injury model induced pathological characteristics similar
to human AAAs, such as medial elastic matrix disruption, increased MMP activity, and
~120% increase in aortic diameter, similar to more advanced human AAAs. EaRASMC
phenotypic analysis revealed a significant number of EaRASMCs exhibited decreased
contractile markers relative to healthy control RASMCs, suggesting an activated
phenotype. There was significant differential gene expression of EaRASMC relative to
RASMCs, supporting that the AAA-derived cells maintain altered gene expression in
vitro (even at passage 3). The EaRASMCs proliferated much faster than healthy
RASMCs and HA-o and TGF- suppressed cell proliferation significantly, relative to
control EaRASMCs. EaRASMCs were sensitive to TGF-β and HA-o in the context of
elastic matrix regenerative responses and elastolytic MMP-2 activity was attenuated. In
support of these findings, differential gene expression (e.g., MMP, TIMP) as a result of
supplemented HA-o and TGF-was observed, yet further assessment of functional gene
groups is necessary. Overall, the elastase perfusion-injury model of AAAs may be
suitable as a surrogate in the context of elastin regeneration within advanced human
AAAs, yet a shortcoming is the unparalleled increases in tropoelastin production by
aHASMCs in response to factor supplementation.
Table 8.1 shows the biochemical data obtained from study of the SMCs derived
from the different AAA models. This compiled data illustrates our observations that
aRASMCs, EaRASMCs, and aHASMCs with factor supplementation produced absolute
amounts of tropoelastin quantities beyond that produced by healthy RASMCs and
HASMCs (Table 8.1B). Also, that aRASMCs and EaRASMCs with factor
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supplementation produced absolute amounts of matrix elastin quantities at or beyond
amounts produced by healthy RASMCs, while aHASMCs with factor supplementation
did not produce absolute amounts of matrix elastin to the level of healthy HASMCs,
although they did have a dramatic 8.5-fold increase in matrix elastin as normalized to
DNA and non-supplemented aHASMC control levels (Table 8.1C).

Table 8.1 Biochemical data collected from the AAA-derived SMC cultures as compared
to one another and their respective controls. (A) Cell sources and proliferation relative to
healthy SMCs. Maximum absolute tropoelastin (B) and matrix elastin (C) amounts
(average µg/ sample) produced by SMC layers and tropoelastin (B) and matrix elastin (C)
amounts normalized to DNA and non-supplemented AAA-derived SMC amounts.
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Figure 8.1 illustrates the effects of the factor doses on elastin production and
matrix formation. The same HA-o and TGF- doses appear to have more or less
exaggerated effects on tropoelastin production and matrix elastin crosslinking by the
AAA-derived SMCs from different models, with the most obvious difference being the
bi-modal effect of TGF-β at low HA-o doses on aHASMCs. This indicates to us that the
aHASMCs are more sensitive to the factors than the aRASMCs and EaRASMCs. At
higher (than tested) TGF-β doses, we would anticipate a similar characteristic bi-modal
response of the aRASMCs and EaRASMCs.
It was important to assess if the increase in elastin production by SMCs with
factor supplementation was accompanied by an increase in other proteins within these
SMC cultures. Table 8.2 illustrates the minimal differences in protein content (as
quantified using a BCA assay on spent medium from the cultures) indicating there is not
a dramatic influence on overall protein production by these SMCs due to factor
supplementation. Further study of SMCs from stage-matched elastase perfusion-injury
generated aortal expansions and human AAAs will be necessary to more rigorously
evaluate their basal and induced elastogenic responses.
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Figure 8.1 Trends of tropoelastin and matrix elastin production by AAA-derived SMCs
with the addition of elastogenic factors. Data points represent the mean elastin
quantities/sample (normalized to DNA) at a particular factor dose.
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Table 8.2 Protein amounts quantified (BCA assay) from spent medium samples of the
SMC layers listed (average µg/ sample ± standard deviation). No/minimal increases in
overall protein in spent medium was observed with the additional of factors.

The observations from our in vitro elastase-injury studies illustrated the ability of
cell layers to self-repair and regenerate elastic matrices following their proteolytic
damage is limited, particularly when elastic matrix injury is severe. Our results also
provide evidence that HA-o and TGF-β factors together can elastogenically stimulate
RASMCs in elastin-degraded cultures to restore both elastic matrix amounts and elastic
fiber deposition to levels of accumulation observed in healthy cultures. Doses of the
elastogenic factors must be enhanced and optimized based on the severity of elastic
matrix damage.
We conducted preliminary in vitro assessment of hydrogel-coated graft delivery
of our elastogenic factors, which can later be applied to endovascular delivery in vivo at
the site of AAA for elastin regeneration, elimination of endoleak, inhibition of AAA
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growth, and possibly even AAA regression. The Extracel-HP™ hydrogel attachment to
Aeos™ ePTFE graft and sustained TGF-β delivery over weeks is promising, yet much
further work addressing functional efficacy is necessary.

8.2 Future outlook
This thesis details the progress made regarding cell-mediated elastic matrix
regeneration toward regression of AAAs. Despite the many positive outcomes of the
project, there are still several issues that need to be addressed/ resolved. We have begun
to investigate the gene expression profiles of elastase perfusion AAA-derived cells
(EaRASMCs) and those that have been supplemented with HA-o and TGF-β factors,
relative to healthy RASMC; this has provided us with a great deal of information to
investigate the mechanism at work, yet extensive follow-up work is necessary. In
additional to gaining a mechanistic understanding of HA-o and TGF-β effects on elastic
matrix assembly, in vivo delivery of the factors and functional analysis in the complex
AAA environment is crucial. Suggestions for future study include:

1. Identification and quantification of specific genes and cell surface-receptors
modulated by HA-o and TGF-β1in elastic matrix assembly.

2. Design and fabrication of a customized bioreactor for long-term (6-8 week) in situ
aortae tissue culture to optimize factor formulations for hydrogel-graft delivery (and
other factor delivery modes).
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3. Hydrogel coating and deployment studies to address challenges of the hydrogel-graft
delivery modality.

4. Controlled, local delivery of these optimized elastogenic factors to elastase-perfused
AAA sites in vivo.

5. Mechanical testing of aorta burst strength following elastic matrix regeneration.

6. Assessment of the utility of these factors in other areas of matrix engineering, such as
wound healing.

203

APPENDICES

204

Appendix A
Functionally categorized differential gene expression:
effects of elastase perfusion and HA-o and TGF-β
Gene Symbol
Functional Group
SMC

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Il6

0.60

0.401626

1.21

0.76317

2.01

0.387412

Ptgs2

0.91

0.643641

1.79

0.05619

1.97

0.022163

Igfbp5

0.37

0.068968

0.64

0.30545

1.72

0.250517

Edn1

1.14

0.363659

1.71

0.01044

1.51

0.042894

Igfbp5

0.42

0.074371

0.64

0.31369

1.51

0.374809

Pdgfa

1.17

0.214759

1.69

0.01301

1.44

0.008892

Igfbp5

0.55

0.101609

0.76

0.4801

1.39

0.379792

Calcrl

1.29

0.516066

1.80

0.0839

1.39

0.429106

Plau

2.28

0.186726

3.10

0.11168

1.36

0.631705

Rcan1

0.53

0.006866

0.69

0.02226

1.29

0.092128

Aamp

1.21

0.56031

1.54

0.20896

1.27

0.271108

Plau

1.96

0.186801

2.41

0.08187

1.23

0.670651

Igfbp3

8.34

0.046284

10.20

0.02542

1.22

0.79115

Pdgfa

1.26

0.065877

1.53

0.00145

1.21

0.100302

Flt1

0.45

0.005677

0.54

0.02167

1.19

0.334386

Ang1

1.42

0.185657

1.71

0.06752

1.19

0.502653

Tgfbr2

1.39

0.5072

1.65

0.248

1.18

0.659857

Jun

1.37

0.022319

1.61

0.01379

1.18

0.048104

Flt1

0.45

0.030265

0.52

0.03798

1.17

0.235144

Fgfr2

1.37

0.388995

1.57

0.25503

1.15

0.461533

S1pr1

0.30

0.045423

0.34

0.01622

1.13

0.740314

Jun

1.45

0.017525

1.64

0.01306

1.13

0.155523

Plat

0.52

0.007598

0.56

0.00042

1.09

0.421657

Igfbp3

8.63

0.047674

9.38

0.01786

1.09

0.910991

Bmp4

0.34

0.191973

0.34

0.13864

1.01

0.987394

Wnt4

0.44

0.002765

0.44

0.00164

0.99

0.892201

Cdh13

0.52

0.053067

0.50

0.02814

0.95

0.844594

Cdh13

0.46

0.008636

0.37

0.00793

0.81

0.324185

Abcc4

0.70

0.02322

0.57

0.0047

0.81

0.073253

Cdh13

0.42

0.010185

0.34

0.00708

0.80

0.354974
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Gene Symbol
Functional Group
ECM

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Col11a1

0.99

0.92619

1.88

0.00532

1.89

0.006218

Col12a1

1.27

0.569232

2.27

0.03027

1.79

0.208378

Col12a1

1.21

0.536214

2.01

0.02334

1.67

0.178639

Col11a1

0.80

0.167469

1.33

0.13562

1.66

0.036941

Acan

2.03

0.181373

3.25

0.00834

1.60

0.327825

Acan

1.75

0.09966

2.01

0.02172

1.15

0.60649

Col24a1

0.52

0.10521

0.55

0.05511

1.06

0.858478

Col27a1

1.58

0.195917

1.61

0.17863

1.02

0.85531

Col4a5

0.59

0.000945

0.51

0.01079

0.86

0.254557

Col4a2

0.66

0.075698

0.57

0.04138

0.86

0.400526

Eln

0.71

0.7619

0.28

0.125

0.39

0.41874

Gene Symbol
Functional Group
Apoptosis

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Il1b

1.16

0.466254

3.32

0.08766

2.89

0.104409

Sod2

1.10

0.852202

2.43

0.09699

2.20

0.237827

Il6

0.60

0.401626

1.21

0.76317

2.01

0.387412

Ptgs2

0.91

0.643641

1.79

0.05619

1.97

0.022163

Tgfb2

0.63

0.1584

1.09

0.678

1.74

0.126365

Rarb

0.49

0.037748

0.79

0.2864

1.61

0.005104

Tcf7

2.66

0.030365

4.14

0.00891

1.56

0.233474

Sod2

1.07

0.837145

1.57

0.1281

1.46

0.331139

Slc2a3

1.49

0.381544

2.17

0.11957

1.45

0.29719

Rarg

1.14

0.74717

1.64

0.19031

1.43

0.324017

Sh3kbp1

1.41

0.234334

1.91

0.05178

1.35

0.334126

Cdkn1a

1.68

0.087314

2.27

0.03164

1.35

0.110026

Nuak2

1.24

0.19803

1.64

0.07311

1.32

0.208639

Dusp1

1.54

0.126132

1.97

0.06009

1.28

0.180143

Sh3kbp1

1.85

0.185964

2.38

0.05098

1.28

0.555288

Psen1

1.29

0.451495

1.65

0.19463

1.27

0.261339

Bcl2l1

1.22

0.317295

1.55

0.07276

1.26

0.162954

Fgfr1

1.46

0.377823

1.80

0.09336

1.23

0.631933

Igfbp3

8.34

0.046284

10.20

0.02542

1.22

0.79115

Dedd

2.51

0.008473

3.01

0.0036

1.20

0.365891

Jun

1.37

0.022319

1.61

0.01379

1.18

0.048104
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Aldh1a3

0.09

0.016994

0.10

0.02204

1.16

0.79035

Sphk1

1.61

0.102913

1.87

0.13006

1.16

0.671907

Cdkn1b

1.80

0.210276

2.06

0.13656

1.14

0.654001

Slc2a3

1.44

0.004452

1.65

0.01098

1.14

0.253205

Jun

1.45

0.017525

1.64

0.01306

1.13

0.155523

Il1rn

1.65

0.206985

1.83

0.25262

1.11

0.836328

Igfbp3

8.63

0.047674

9.38

0.01786

1.09

0.910991

Sgk1

1.43

0.250665

1.54

0.12924

1.07

0.824026

Pla2g4a

0.54

0.01162

0.57

0.01865

1.06

0.538588

Krt18

1.45

0.445778

1.51

0.25905

1.04

0.937859

Cx3cl1
Bdkrb2 ///
RGD1308470

0.46

0.035913

0.45

0.03149

0.97

0.90341

1.51

0.345011

1.46

0.25747

0.97

0.946584

Fosl1

1.56

0.057282

1.49

0.19673

0.97

0.892607

Scg2

0.55

0.436181

0.49

0.38369

0.90

0.900874

Casp12

0.54

0.026857

0.47

0.01923

0.88

0.404009

Arnt2

0.66

0.020512

0.57

0.00681

0.88

0.259162

Bcl11b

1.77

0.128676

1.55

0.19129

0.87

0.705116

Dedd

0.66

0.033757

0.55

0.01677

0.83

0.064734

Casp4

0.68

0.039668

0.56

0.00521

0.82

0.184381

Cd74

0.59

0.220776

0.45

0.05074

0.76

0.440143

Rbm5

0.79

0.643049

0.47

0.16589

0.60

0.24002

Rbm5

0.85

0.808848

0.49

0.25023

0.58

0.355954

Pabpn1

0.87

0.856259

0.44

0.23259

0.50

0.295728

Gene Symbol
Functional Group
Inflammatory

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Cxcl1

1.23

0.841887

6.23

0.03932

5.06

0.204318

Calca

5.43

0.070802

19.56

0.01789

3.61

0.1597

Il1a

1.15

0.595764

3.46

0.11739

3.01

0.135762

Il1b

1.16

0.466254

3.32

0.08766

2.89

0.104409

Il1a

1.51

0.251524

4.06

0.06718

2.69

0.11757

Ccl20

3.56

0.310902

9.51

0.05306

2.68

0.444948

Lbp

0.45

0.253799

1.21

0.71938

2.66

0.207958

Ccl11

9.71

0.142542

24.08

0.05125

2.48

0.509848

Calca

1.48

0.235877

3.34

0.09209

2.25

0.169999

Il6

0.60

0.401626

1.21

0.76317

2.01

0.387412

Ptgs2

0.91

0.643641

1.79

0.05619

1.97

0.022163

C3

3.03

0.187732

5.74

0.07868

1.89

0.484129

Cxcl2

1.04

0.549448

1.97

0.03092

1.89

0.045504
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Calca

1.00

0.98212

1.69

0.14741

1.69

0.140456

Bdkrb1

1.77

0.312226

2.95

0.13583

1.67

0.454037

LOC687992

1.21

0.30849

1.92

0.1843

1.59

0.295729

Olr1

0.79

0.250987

1.19

0.16532

1.51

0.089561

Ccl7

2.79

0.16366

4.23

0.02493

1.51

0.529097

Ccl2

1.28

0.61751

1.83

0.12531

1.41

0.527683

Tollip

1.13

0.745545

1.60

0.26364

1.41

0.159779

Bmp2

1.97

0.027986

2.77

0.01055

1.40

0.191856

F3

1.29

0.516002

1.80

0.09918

1.39

0.439078

Calcrl

1.29

0.516066

1.80

0.0839

1.39

0.429106

Fabp4

1.47

0.261607

2.00

0.12372

1.36

0.468983

Bmp2

1.78

0.062863

2.39

0.0251

1.35

0.305759

Masp1

3.53

0.038798

4.72

0.05446

1.34

0.610745

Tnfrsf1b

1.77

0.233661

2.36

0.14132

1.34

0.588102

Adora2b

1.65

0.320441

2.07

0.17654

1.26

0.680103

Il4ra

0.54

0.006689

0.65

0.13898

1.20

0.452939

Fcgr2b

1.42

0.185508

1.67

0.11147

1.16

0.582423

Sphk1

1.61

0.102913

1.87

0.13006

1.16

0.671907

Ptafr

1.56

0.111794

1.78

0.03452

1.13

0.602021

Masp1

3.84

0.026681

4.35

0.02817

1.13

0.766825

Serpina3n

0.09

0.015888

0.10

0.02046

1.12

0.267368

Il1rn

1.65

0.206985

1.83

0.25262

1.11

0.836328

Ccr1

1.75

0.147837

1.91

0.18291

1.09

0.842117

Igfbp4

1.45

0.415808

1.57

0.29398

1.08

0.880775

Pla2g4a

0.54

0.01162

0.57

0.01865

1.06

0.538588

Spp1

0.58

0.105861

0.60

0.01861

1.04

0.871083

Il17b

1.62

0.004118

1.59

0.00835

0.98

0.709508

Pdpn

3.32

0.093758

3.25

0.04055

0.98

0.973203

Cx3cl1

0.46

0.035913

0.45

0.03149

0.97

0.90341

Aif1l

1.52

0.032087

1.42

0.04783

0.94

0.644912

Ednra

0.56

0.136364

0.49

0.07152

0.87

0.673086

Ggt5

1.71

0.16035

1.47

0.24661

0.86

0.698545

Casp4

0.68

0.039668

0.56

0.00521

0.82

0.184381
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Gene Symbol
Functional Group
MMP

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Mmp3

1.30

0.393566

3.03

0.14918

2.31

0.221094

Timp3

0.98

0.8921

1.65

0.034

1.68

0.020215

Mmp13

1.00

0.987619

1.64

0.1646

1.64

0.176342

Timp3

1.10

0.5638

1.55

0.04

1.40

0.071918

Adam19

1.18

0.54488

1.57

0.09974

1.33

0.26884

Spg7

1.33

0.4387

1.69

0.20801

1.27

0.218382

Adam10

1.21

0.589963

1.53

0.1662

1.26

0.480745

Mmp15

1.47

0.325779

1.85

0.10088

1.26

0.485582

Mme

1.27

0.347804

1.53

0.10062

1.21

0.330783

Adamts9

0.31

0.160119

0.31

0.05271

0.97

0.96868

Mmp12

2.03

0.1526

1.61

0.136

0.80

0.575757

Mmp23

0.72

0.447467

0.54

0.16614

0.75

0.392478

LOC314655

0.66

0.204466

0.46

0.01977

0.70

0.254939

Bmp1

0.72

0.370985

0.45

0.05648

0.63

0.213692

Adam33

0.90

0.856548

0.48

0.21874

0.54

0.228588

Gene Symbol
Functional Group
TGF

Elastase vs Healthy

Elastase+Factors vs Control

Elastase+Factors vs Elastase

Fold change

Fold change

Fold change

P value

P value

P value

Tgfb2

0.63

0.158

1.09

0.678

1.74

0.126

Tnfaip6

1.79

0.049

2.87

0.011

1.60

0.118

Acan

2.03

0.181

3.25

0.008

1.60

0.328

Fos

0.55

0.005

0.84

0.153

1.54

0.024

Pdgfa

1.17

0.215

1.69

0.013

1.44

0.009

Ccl2

1.28

0.618

1.83

0.125

1.41

0.528

Hapln3

1.73

0.009

2.22

0.039

1.29

0.290

Bmpr2

1.42

0.025

1.74

0.006

1.22

0.076

Pdgfa

1.26

0.066

1.53

0.001

1.21

0.100

Tgfbr2

1.39

0.507

1.65

0.248

1.18

0.660

Jun

1.37

0.022

1.61

0.014

1.18

0.048

Acan

1.75

0.100

2.01

0.022

1.15

0.606

Jun

1.45

0.018

1.64

0.013

1.13

0.156

Vcan

1.62

0.329

1.83

0.012

1.12

0.796

Ltbp4

0.51

0.124

0.54

0.055

1.05

0.891

Vcan

1.54

0.216

1.55

0.020

1.00

0.993

Vcan

1.65

0.163

1.57

0.014

0.95

0.859

Pdgfrb

0.64

0.488

0.39

0.149

0.62

0.367

209

Appendix B
Differentially expressed genes: symbols and names
Gene Symbol

Gene Title

Aamp

angio-associated, migratory cell protein

Abcc4

ATP-binding cassette, sub-family C (CFTR/MRP), member 4

Acan

aggrecan

Adam10

ADAM metallopeptidase domain 10

Adam19

a disintegrin and metallopeptidase domain 19 (meltrin beta)

Adam33

ADAM metallopeptidase domain 33

Adamts9

a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 9

Adora2b

adenosine A2B receptor

Aif1l

allograft inflammatory factor 1-like

Aldh1a3

aldehyde dehydrogenase 1 family, member A3

Ang1

angiogenin, ribonuclease A family, member 1

Arnt2

aryl hydrocarbon receptor nuclear translocator 2

Bcl11b

B-cell CLL/lymphoma 11B (zinc finger protein)

Bcl2l1

Bcl2-like 1

Bdkrb1

bradykinin receptor B1

Bdkrb2 /// RGD1308470

bradykinin receptor B2 /// similar to RIKEN cDNA 4933433P14 gene

Bmp1

bone morphogenetic protein 1

Bmp2

bone morphogenetic protein 2

Bmp4

bone morphogenetic protein 4

Bmpr2

bone morphogenetic protein receptor, type II (serine/threonine kinase)

C3

complement component 3

Calca

calcitonin/calcitonin-related polypeptide, alpha

Calcrl

calcitonin receptor-like

Casp12

caspase 12

Casp4

caspase 4, apoptosis-related cysteine peptidase

Ccl11

chemokine (C-C motif) ligand 11

Ccl2

chemokine (C-C motif) ligand 2

Ccl20

chemokine (C-C motif) ligand 20

Ccl7

chemokine (C-C motif) ligand 7

Ccr1

chemokine (C-C motif) receptor 1

Cd74

Cd74 molecule, major histocompatibility complex, class II invariant chain

Cdh13

cadherin 13

Cdkn1a

cyclin-dependent kinase inhibitor 1A (p21, Cip1)

Cdkn1b

cyclin-dependent kinase inhibitor 1B

Col11a1

collagen, type XI, alpha 1

Col12a1

collagen, type XII, alpha 1
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Col24a1

collagen, type XXIV, alpha 1

Col27a1

Collagen, type XXVII, alpha 1

Col4a2

collagen, type IV, alpha 2

Col4a5

collagen, type IV, alpha 5

Cx3cl1

chemokine (C-X3-C motif) ligand 1

Cxcl1

chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha)

Cxcl2

chemokine (C-X-C motif) ligand 2

Dedd

Death effector domain-containing

Dusp1

dual specificity phosphatase 1

Edn1

endothelin 1

Ednra

endothelin receptor type A

Eln

elastin

F3

coagulation factor III (thromboplastin, tissue factor)

Fabp4

fatty acid binding protein 4, adipocyte

Fcgr2b

Fc fragment of IgG, low affinity IIb, receptor (CD32)

Fgfr1

Fibroblast growth factor receptor 1

Fgfr2

fibroblast growth factor receptor 2

Flt1

fms-related tyrosine kinase 1

Fos

FBJ osteosarcoma oncogene

Fosl1

fos-like antigen 1

Ggt5

gamma-glutamyltransferase 5

Hapln3

hyaluronan and proteoglycan link protein 3

Igfbp3

insulin-like growth factor binding protein 3

Igfbp4

insulin-like growth factor binding protein 4

Igfbp5

insulin-like growth factor binding protein 5

Il17b

interleukin 17B

Il1a

interleukin 1 alpha

Il1a

interleukin 1 alpha

Il1b

interleukin 1 beta

Il1rn

interleukin 1 receptor antagonist

Il1rn

interleukin 1 receptor antagonist

Il4ra

interleukin 4 receptor, alpha

Il6

interleukin 6

Jun

Jun oncogene

Krt18

keratin 18

Lbp

lipopolysaccharide binding protein

LOC314655

Similar to a disintegrin-like and metalloprotease with thrombospondin type 1 motif, 10

LOC687992

similar to Serum amyloid A-3 protein precursor

Ltbp4

latent transforming growth factor beta binding protein 4

Masp1

mannan-binding lectin serine peptidase 1
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Mme

membrane metallo endopeptidase

Mmp12

matrix metallopeptidase 12

Mmp13

matrix metallopeptidase 13

Mmp15

matrix metallopeptidase 15

Mmp23

matrix metallopeptidase 23

Mmp3

matrix metallopeptidase 3

Nuak2

NUAK family, SNF1-like kinase, 2

Olr1

oxidized low density lipoprotein (lectin-like) receptor 1

Pabpn1

poly(A) binding protein, nuclear 1

Pdgfa

platelet-derived growth factor alpha polypeptide

Pdgfrb

platelet derived growth factor receptor, beta polypeptide

Pdpn

podoplanin

Pla2g4a

phospholipase A2, group IVA (cytosolic, calcium-dependent)

Plat

plasminogen activator, tissue

Plau

plasminogen activator, urokinase

Psen1

presenilin 1

Ptafr

platelet-activating factor receptor

Ptgs2

prostaglandin-endoperoxide synthase 2

Rarb

retinoic acid receptor, beta

Rarg

retinoic acid receptor, gamma

Rbm5

RNA binding motif protein 5

Rcan1

regulator of calcineurin 1

S1pr1

sphingosine-1-phosphate receptor 1

Scg2

secretogranin II (chromogranin C)

Serpina3n

serine (or cysteine) peptidase inhibitor, clade A, member 3N

Sgk1

serum/glucocorticoid regulated kinase 1

Sh3kbp1

SH3-domain kinase binding protein 1

Slc2a3

Solute carrier family 2 (facilitated glucose transporter), member 3

Sod2

superoxide dismutase 2, mitochondrial

Spg7

spastic paraplegia 7 homolog (human)

Sphk1

sphingosine kinase 1

Spp1

secreted phosphoprotein 1

Tcf7

transcription factor 7, T-cell specific

Tgfb2

Transforming growth factor, beta 2

Timp3

TIMP metallopeptidase inhibitor 3

Tnfaip6

tumor necrosis factor alpha induced protein 6

Tnfrsf1b

tumor necrosis factor receptor superfamily, member 1b

Tollip

toll interacting protein

Vcan

versican

Wnt4

wingless-type MMTV integration site family, member 4
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